

Señora Jefe
DIVISIÓN DE NUEVAS CREACIONES
SUPERINTENDENCIA DE INDUSTRIA Y C
Bogotá, D.C.

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 05-121481 - 00003-0000

Fecha: 2007-05-07 16:08:55 Dep. 2020 NUECREACIONES
Tra. 11 PATENTEIYII Eve: 379 FASENACIONALI
Act. 538 PETICION Folios: 2

Re.: Expediente No. 05 121.481
Fase Nacional Solicitud de Patente PCT
a nombre de
PURDUE PHARMA L.P.
Código 011 - 379 - 538

En relación con la solicitud contenida en el Expediente de la referencia y, en particular, con la publicación del extracto de la misma en la Gaceta de la Propiedad Industrial No. 571 de 29 de Diciembre de 2006, por medio del presente escrito muy respetuosamente me permito solicitarle se sirva proceder a efectuar el **EXAMEN DE PATENTABILIDAD** de la solicitud aquí contenida.

Para tal efecto, acompaño el comprobante de pago por concepto de la tasa respectiva, Recibo No. 07, 35 - 533

De Usted Atentamente,

GERMAN CASTILLO GRAU
T.P. # 2978 del C.S.J.

230
R

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 05-121481-00003-0000

Fecha: 2007-05-07 16:08:55 Dep. 2020 NUECREACIONES
Tra. 11 PATENTEIYII Evs: 379 FASENACIONALII
Act. 538 PETICION Folios: 2

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800176089-2

RECIBO OFICIAL DE CAJA : 07 - 35,533
FECHA : MAYO 7 DE 2007

***** CONSIGNACION *****

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PGO	Vr. PAGO
CASTILLO GRAU Y ASOCIADOS	CONSIGNACION	BANCO POPULAR	050-00110-6	64176550	07/05/2007	1,328,000.00

***** CONCEPTO *****

CANT.	RENTISTICO	CONCEPTO	TOTAL CONCEPTO
1	50005-01-01	SOLICITUDES	
		114 PTC CAP-II EXAMEN DE PATENTIBILID	202,000.00
		TOTAL :	\$ 202,000.00

SON: DOSCIENTOS DOS MIL PESOS

RESPONSABLE : _____



Industria y Comercio

SUPERINTENDENCIA

**SOLICITUD
PATENTE DE INVENCION
PCT**

EXPEDIENTE N° **05-121080**

TITULO: DERIVADOS SUSTITUIDOS DEL PIRROL

CLASIFICACION INTERNACIONAL: _____

SOLICITANTE: RANBAXY LABORATORIES LIMITED

DOMICILIO: NUEVA DELHI, INDIA

APODERADO: DARIO CARDENAS NAVAS



BOGOTÁ, D.C. A61K 31/366, 31/40

COTD 207/00

16-02-06

17 folios

PETITORIO

Industria y Comercio
SUPERINTENDENCIA

SUPERINDUSTRIA Y COMERCIO
Radicación : 05121000 00000000 Folios: 275
Fecha (MM): 2005-11-29 17:50:47
Trámite : 011 PCT-PATENT 379 FASE NACI 411 PRESENTAC
Dependencia: 2020 DIVISION DE NUEVAS CREACIONES

FORMULARIO UNICO DE SOLICITUD DE PATENTE

PCT

ENTRADA EN FASE NACIONAL

2005-12-30

①

SOLICITUD DE:

☒

Patente de Invención

☐

Patente de Modelo de Utilidad

☐

Capítulo I

☒

Capítulo II

②

SOLICITANTE
(71)

Nombre: RANBAXY LABORATORIES LIMITED

Dirección: 19, Nehru Place 110 019 New Delhi, India

Nacionalidad o Domicilio: NUEVA DELHI, INDIA

Lugar de Constitución: NUEVA DELHI, INDIA

Teléfono: 3123600

Fax: 3122410

E-mail: general@cardenasycardenas.com

IDENTIFICACION

C.C.

☐

NIT

☐

C.E.

☐

Otro

☒

Cual

Número

③

REPRESENTANTE
O APODERADO

Nombre: DARIO CARDENAS NAVAS

Dirección: Carrera 7 No 71- 52 Torre B Piso 9

Teléfono: 3123600

Fax: 3122410

E-Mail: general@cardenasycardenas.com

IDENTIFICACION

C.C.

☒

NIT

☐

C.E.

☐

Otro

☐

Cual

Número 17.088.629 TP 1.250
C.S.J.

④

INVENTOR(ES)
(72)

Nombre:

1. Mohammad Salman
2. Jitendra Sattigeri
3. Yatendra Kumar
4. Ram Chander Aryan
5. Vikram Krishna Ramanathan
6. Anita Chugh

Dirección:

1. 12 Jackson Avenue, Princeton, NJ 08540, Estados Unidos de América
2. N-323, Vijay Rattan Vihar, Sector -15-II, Gurgaon-122 001, Haryana, India
3. U-26/5, Phase-III, DLF Qutab Enclave, Gurgaon-122 001, Haryana, India
4. 1066, Sector-A, Pocket-A, Vasant Kunj, New Delhi-110 070, India
5. C-103, Ambience Island Apartments, NH 8, Gurgaon- 122 001, Haryana, India
6. RA-36, Inderpuri, New Delhi-110 012, India

Nacionalidad:

1. HINDÚ
2. HINDÚ
3. HINDÚ
4. HINDÚ
5. HINDÚ
6. HINDÚ

⑤

PCT (88)

Solicitud Internacional No. PCT/ IB2004/001761

Fecha Mayo 28, 2004

Publicación Internacional No. WO 2004/106299AZ

Fecha Diciembre 9, 2004

⑥

Título(54):

DERIVADOS SUSTITUIDOS DEL PIRROL

⑦

Clasificación Internacional (51):

C07D

(8) Prioridad SI ☒ NO ☐	(33) País de Origen	(32) Fecha	(31) N° de Solicitud
	U.S.A.	Mayo 30, 2003	10/449,418


(9) Comprobante de Pago No.: 05-91,164 **Fecha** Noviembre 29, 2005

(10)

ANEXOS

- ☒ Comprobante de pago de la tasa de presentación de la solicitud.
- ☐ Documento que acredita la existencia y representación legal cuando el solicitante sea persona jurídica.
- ☐ Poderes, si fuere el caso.
- ☐ Documento de cesión del inventor al solicitante o a su causante.
- ☐ Declaraciones
- ☒ Copia de la solicitud internacional. (Resumen, descripción, reivindicaciones, dibujos)
- ☒ Traducción de la solicitud internacional al castellano. (Resumen, descripción, reivindicaciones, dibujos)
- ☒ Copia del examen preliminar internacional efectuado por la Autoridad Internacional de Examen Preliminar (IPEA).
- ☐ Traducción del examen preliminar internacional efectuado por la IPEA.
- ☐ De ser el caso, copia del contrato de acceso.
- ☐ De ser el caso, documento que acredite la licencia o autorización de uso de conocimientos tradicionales de las comunidades indígenas.
- ☐ De ser el caso, certificado de depósito del material biológico.
- ☐ Arte final 12x12.
- ☐ De ser el caso, información sobre otras solicitudes de patente o títulos obtenidos en el extranjero por el mismo titular o su causante, relacionadas parcial o totalmente con la invención de esta solicitud.
- ☐ De ser el caso, modificaciones efectuadas a la solicitud internacional.

11 FIGURA CARACTERISTICA




12

Solicito la Concesión de la patente,

NOMBRE: DARIO CARDENAS NAVAS

FIRMA:



C.C. 17.066.629 BTA TP. 1,250
C.S.J.

7

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

NIT : 800176089-2

SUPERINDUSTRIA Y COMERCIO
Radicacion : 05121000 00000000 Folios: 275
Fecha (MM): 2005-11/29 17:50:47
Tramite : 011 PET-PATENT 373 FASE NACI 411 PRESENTAC
Dependencia: 2020 DIVISION DE NUEVAS CREACIONES

RECIBO OFICIAL DE CAJA : 05 - 91,164
FECHA : NOVIEMBRE 29 DE 2005

***** CONSIGNACION *****

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PAGO	Vr. PAGO
CARDENAS Y CARDENAS P.I. CONSIGNACION		BANCO POPULAR	050-00110-6	36361150	29/11/2005	443,000.00

***** CONCEPTO *****

CANT. RENTISTICO	CONCEPTO	TOTAL CONCEPTO
1 50005-01-01 SOLICITUDES	1 TRAMITES DE SOL. DE PATENTE DE IN	443,000.00
	TOTAL :	443,000.00

SON: CUATROCIENTOS CUARENTA Y TRES MIL PESOS

RESPONSABLE : _____

CARDENAS & CAÑAS
ABOGADOS

RECIBO DE CAJA APLICADO AL EXPEDIENTE No. DERIVADOS SUSTITUIDOS DEL PIRROL

3

- Colombia -

POWER OF ATTORNEY

In the city of New Delhi on the 19th day of the month of October, one thousand nine hundred and ninety nine (1999) before me, _____ Notary Public, appeared _____ of age, and domiciled at _____, and stated:

FIRST: That he/she acts in his/her capacity of Company Secretary of **RANBAXY LABORATORIES LIMITED**, a company legally constituted and in existence in accordance with the laws of INDIA and domiciled at 19 Nehru Place, New Delhi, 110 019 India as evidenced in the By Laws, documents which I have examined.

SECOND: That in such capacity he/she grants hereby special, ample and sufficient Power of Attorney to DARIO CARDENAS-NAVAS and/or EDUARDO CARDENAS-CABALLERO and/or BERNARDO P. CARDENAS-MARTINEZ y/o JAMES VALDIRI-REYES and/or LUZ HELENA ADARVE-GOMEZ, registered lawyers of the firm CARDENAS & CARDENAS-LAWYERS, domiciled at Carrera 7 No. 71-52, Torre B, Piso 9 Bogotá, D.C., Colombia, to carry before the corresponding Colombian national Offices and authorities the proceedings to obtain trademarks, patents, utility models, Industrial drawings and designs, deposits of commercial names and enshins, as well as processing of renewals, assignments, change of name or domicile of the owner, waivers and licenses of the same for which purpose they are empowered to take before said authorities all necessary actions for the indicated purposes; to file applications, statements, claims, formulate descriptions, amendments, oppositions and appeals; pay all taxes and installments and make any other payments determined by law; to receive every document and values issuing the respective discharge; to fulfill any other requirements and take, in general, every measure that they shall deem opportune for the defense and protection of the Industrial Property of the company in the event of infringements, oppositions, proceedings for cancellation or annulment, Imposition of fines, passing the antecedents to the courts; they are empowered to appear as plaintiff or defendant before the competent judges, being entitled to transact, submit to arbitration, waive, receive, resign, withdraw, appeal and all other legal powers which may be necessary, and it is hereby declared ever since now valid and good whatever such attorneys do for its benefit, granting them also power to substitute this proxy and if necessary to revoke such substitutions.

THIRD: That for purposes of articles 597 and 543 of the Colombian code of Commerce the attorneys are empowered to receive service of notice and designate judicial and extrajudicial attorneys.

SIGNED RANBAXY LABORATORIES LTD. ON _____

BY Sean

Company Secretary
NOTARY PUBLIC (Signature)

(To be legalized up to the Colombian Consul)



ATTESTED

Pandora
Not. (India) Dy./Mr. Asst./Secretary/Adm. Officer
VMD Chamber of Commerce and Industry
New Delhi

ATTESTED



AUTHENTICATED
AFTER EXECUTION BEFORE ME

NOTARY

NEW DELHI (INDIA)

2 OCT 1999

The undersigned Notary Public certifies that Mr. S.K. PATANARI appeared before me and signed the preceding document; that I know him personally and I am certain that he has legal capacity to grant it; that he is COMPANY SECRETARY of RANBAXY LABORATORIES LIMITED and is consequently authorized to grant such document; that the named company exists and is organized under the laws of INDIA and is domiciled in 19, Nehru Place New Delhi 110 019 India and that the act for which this document is granted is included among those which constitute the corporate object of the named company.

I am certain of all these facts because I have examined the respective documents consisting of Power of Attorney executed by 7/5 Ranbaxy Laboratories Ltd all of which I hereby attest.

[Signature]
NOTARY PUBLIC (signature)


[Signature]
O. P. ABBOTT
NOTARY PUBLIC
Patials House Courts
Delhi (INDIA)

Issued and signed in



12 OCT 1999

Dated

(LEGALIZATION BY COLOMBIAN CONSUL IS REQUIRED)



ATTESTED
[Signature]
Addl. Secy./Sr. Asst./Secretary
640 Chamber of Commerce & Industry
New Delhi



99/170
REPRODUCCION OFICIAL No. 99/170
NIDA ASULIZA DE FIDELIDAD
INTERPRETE OFICIAL
99/170 No. 223 861 M.D. de INTERPRETE


4

16


RECEIVED
11/1/72

RECEIVED
11/1/72
(TO: JAGG) 10
(FROM: JAGG) 10
(DATE: 11/1/72)

11



RECEIVED
11/1/72
12 11/1/72



AZULEJO DE PORTUGAL

MARCA REGISTADA

(STATE EMBLEM)

OF INCORPORATION CONSEQUENT ON CHANGE OF NAME
THE REGISTRAR OF COMPANIES DELHI AND HARYANA

[Under the Companies Act, 1956 (1 of 1956)]

I hereby certify that,.....RANBAXY LABORATORIES PRIVATE LIMITED which was originally incorporated on SIXTEENTH day of ...JUNE, 1961, under the Companies Act, 1956 and under the name Lepetit Ranbaxy Laboratories Private Limited, having duly passed the necessary special resolution passed on 26-8-1973 in terms of Section 21/31 of Companies Act, 1956, the name of the said Company is this day changed to Ranbaxy Laboratories Limited and this certificate is issued pursuant to Section 23(1) of the said Act.

ASSTT. REGISTRAR OF COMPANIES
DELHI & HARYANA

TESTED PHOTO COPY
NOTARY U. T. BULL

OCT 1959

99/172

MINISTERIO DE RELACIONES
EXTERIORES

367151

CUYA FIRMA APARECE EN EL
DOCUMENTO DESEMPEÑA
LAS FUNCIONES INDICADAS


NO SE ASUME
RESPONSABILIDAD POR EL TEXTO

1999 OCT 19 A M: 56


JEFE DE LEGACION
SANTAFE DE BOGOTA D.C.

Maria Clara Betancur
Reduccion Oficial, No. 94/1992

SEDA ACREDITADA DE PROFORMA
INTERPRETE OFICIAL



Ministry of Foreign Relations
Bogota, Colombia
(KISMAN SWANSON)
Bogota, Colombia (KISMAN SWANSON)
Ministry of Foreign Relations
Bogota, Colombia



EXENTO DE IMPUESTO DE TIMBRE 2%
Y DERECHOS CONSULARES 1%

CONSULADO DE COLOMBIA

NEW DELHI

No. 1021/77

El suscrito Consul de Colombia CERTIFICA
que el señor... EL SEÑOR... S...
que autoriza el presente documento, que
aparece, en la fecha allí expresada, las
funciones de...
H...
y que la firma y sello que en el documento
aparece como suyos son los que usa y
corresponden en sus actos oficiales.
El consul no asume responsabilidad
alguna por el contenido del documento.

Maria Clara Betancur


MARIA CLARA BETANCUR
Embajadora of Colombia
Encargado de
Funciones Consulares

El suscrito CONSUL DE COLOMBIA es

CERTIFICA

1. Que tuvo a la vista las pruebas de que **RANBAXY LABORATORIES LIMITED** sociedad organizada y existente de conformidad con las leyes _____, domiciliada en _____ existe legalmente, y que actualmente ejerce su objeto social de acuerdo con las leyes del respectivo país.
2. Que el señor _____, quien firmó el documento que precede en su carácter de _____ de dicha compañía, está autorizado para representarla en este acto y otorgar el documento.

CONSUL



ATTESTED

Attest/Attest/Dy./Sr. Asst./Secretary/Adm. Officer
FED Chamber of Commerce and Industry
New York



ATTESTED TRUE COPY

[Signature]
**NOTARY PUBLIC
DELHI (INDIA)**

12 OCT 1999


X

(PRODUCTION ORIGINAL NO.
 BIDA ACQUISITA DE OPERAÇÕES
 INTERIORES 01... 1... 0-10
 99/110

(KIRAN SWAMY)
 (1999 0000)
 Chief Officer (A-1000)
 Senior Officer (A-10)
 New Delhi



058765
 1999



Consulado de Colombia
Nueva Delhi

No. 41/99

LA SUSCRITA EMBAJADORA ENCARGADA DE FUNCIONES CONSULARES ANTE LA EMBAJADA DE COLOMBIA EN NUEVA DELHI, INDIA, VISTOS LOS DOCUMENTOS PRESENTADOS POR LOS INTERESADOS

CERTIFICA:


QUE EL SEÑOR KISHAN SWARUP, FUNCIONARIO CONSULAR DEL MINISTERIO DE RELACIONES EXTERIORES DE INDIA, QUIEN AUTENTICO LA FIRMA DEL SEÑOR S.K. PATAWARI, FIRMANTE DEL PRESENTE PODER, EJERCIÓ EN LA FECHA LAS FUNCIONES INDICADAS Y SU FIRMA CORRESPONDE A LA REGISTRADA EN ESTE CONSULADO; QUE LA COMPAÑIA " RANBAXY LABORATORIES LIMITED" ESTA CONSTITUIDA DE ACUERDO CON LAS LEYES DE LA INDIA Y CUMPLE SU OBJETO CONFORME A LAS MISMAS. DOMICILIADA EN DELHI INDIA; QUE EL SEÑOR S.K. PATAWARI, EN SU CARACTER DE SECRETARIO DE LA COMPAÑIA Y REPRESENTANTE LEGAL DE LA EMPRESA MENCIONADA, ESTA FACULTADO PARA FIRMAR EL PRESENTE DOCUMENTO.

DADO EN NUEVA DELHI A LOS TRECE (12) DIAS DEL MES DE OCTUBRE DE MIL NOVECIENTOS NOVENTA Y NUEVE (1.999).



Maria Clara Betancur
MARIA CLARA BETANCUR
EMBAJADORA
Encargada de Funciones Consulares

PAGADO IMPUESTO DE TIMBRE
DERECHOS CONSULARES: US \$107.000
(Ciento Siete Dólares Americanos)



MINISTERIO DE RELACIONES
EXTERIORES
COLOMBIA
DOCUMENTO QUE SE PUEDE
LAS FUNCIONES INDICADAS

NO SE ASUME
RESPONSABILIDAD DEL TEXTO
Jefe de Legalizaciones
SANTAFE DE BOGOTÁ D.C.
2005 MAY 15

[Handwritten signature]

TRADUCCIÓN OFICIAL No.99/170 de un documento escrito en inglés, el cual para su identificación se sella con el sello del traductor al tiempo con la presente. Esta traducción ha sido preparada por Hilda Aguilera de Piedrahita traductora e intérprete oficial debidamente reconocida por el Ministerio de Relaciones Exteriores y autorizada por el Ministerio de Justicia y del Derecho, por resolución número 323 de 1980.

(Se traduce un Poder otorgado por la compañía RANBAXY LABORATORIES LIMITED, ante Notario Público de Nueva Delhi, India, y el respectivo certificado notarial (sociedad) todos escritos en inglés.)

PODER

COLOMBIA

En la ciudad de Nueva Delhi, el día 12 de Octubre de mil novecientos noventa y nueve (1999), ante mi,____, Notario Público, compareció _____ mayor de edad, y domiciliado en _____, y manifestó:

PRIMERO: Que obra en su calidad de Secretario de la Compañía RANBAXY LABORATORIES LIMITED, compañía legalmente constituida y existente de conformidad con las leyes de la India, y domiciliada en 19 Nehru Place, Nueva Delhi, 110 019 India, según lo evidencian sus estatutos, documentos que he examinado.

SEGUNDO: que en tal calidad otorga por el presente poder especial amplio y suficiente a DARÍO CÁRDENAS-NAVAS y/o EDUARDO CÁRDENAS CABALLERO, y/o BERNARDO P. CÁRDENAS-MARTÍNEZ, y/o JAMES VALDIRI-REYES y/o LUZ HELENA ADARVE-GOMEZ , abogados registrados de la firma

99/170
TRADUCCION OFICIAL No.
HILDA AGUILERA DE PIEDRAHITA
INTERPRETE OFICIAL
No. 323 del 80

7
4

CÁRDENAS & CÁRDENAS Abogados, domiciliada en la Carrera 7 No. 71-52, Torre B, Piso 9, Santafé de Bogotá D.C., Colombia para llevar a cabo ante las correspondientes Oficinas nacionales y autoridades colombianas los trámites para obtener marcas, patentes, modelos de utilidad, dibujos y diseños industriales, depósitos de nombres comerciales y enseñas así como para tramitar renovaciones, cesiones, cambios de nombre o domicilio del propietario, renunciaciones y licencias de los mismos para cuyo fin están facultados para realizar ante dichas autoridades todas las acciones necesarias para los fines indicados; para presentar solicitudes, declaraciones, reivindicaciones, formular descripciones, modificaciones, oposiciones, desistimientos y apelaciones; pagar todos los impuestos y cuotas y hacer cualesquiera otros pagos que la ley determine; recibir todos los documentos y valores con expedición del respectivo descargo; llenar cualesquiera otros requisitos y tomar en general todas las medidas que juzguen oportunas para la defensa y protección de la Propiedad Industrial de la compañía en el evento de infracciones, oposiciones, procesos de cancelación o anulación, imposición de multas, presentación de antecedentes ante las cortes; quedan facultados para comparecer en calidad de demandante o demandado ante los jueces competentes, tendrán derecho de transar, someterse a arbitraje, renunciar, recibir, desistir, apelar y todas las demás facultades legales que puedan requerirse, y por el presente se declara desde ahora válido y satisfactorio lo que dichos abogados hagan en nuestro beneficio, otorgándoles también poder para sustituir este poder y si fuere necesario para revocar tales sustituciones.

TERCERO: que para fines de los artículos 597 y 543 del Código Colombiano de

Comercio, los abogados están facultados para recibir notificaciones y para designar apoderados judiciales y extrajudiciales.

Suscrito en RANBAXY LABORATORIES LTD. El _____.

Por (Fdo.) S. K. Patwari Secretario de la Compañía

Notario Público (Firma)

(A ser legalizado ante el Cónsul Colombiano)

(SELLO A TINTA DE LA CÁMARA DE COMERCIO E INDUSTRIA)

(SELLO A TINTA DE RANBAXY LABORATORIES LTD.)

(SELLO A TINTA CERTIFICANDO POR PARTE DE LA CÁMARA DE COMERCIO E INDUSTRIA, NUEVA DELHI)

(SELLO NOTARIAL A TINTA O.P. ABBOT, NOTARIO, NUEVA DELHI, CERTIFICADO DE COPIA FIEL)

(SELLO NOTARIAL DE AUTENTICACIÓN DESPUES DE FIRMADO) 12 de Octubre, 1999



El suscrito Notario Público certifica que S.K. PATAWARI compareció ante mí y suscribió el documento que antecede; que lo conozco personalmente y estoy seguro de que tiene la facultad legal para otorgarlo; que es el Secretario de la Compañía de RANBAXY LABORATORIES LIMITED. y está en consecuencia autorizado para otorgar dicho documento; que la mencionada compañía existe y está constituida bajo las leyes de India, y su domicilio es 19 Nehru Place, Nueva Delhi, 110 019 India, y que el acto para el cual se otorga este documento está incluido entre los que constituyen el objeto social de dicha compañía.

Estoy seguro de estos hechos por haber examinado los respectivos documento de los cuales consta el poder firmado por Ranbaxy Laboratories Ltd., de todo lo cual doy fe.

11

99/170
REPRODUCCION DE LA COPIA ORIGINAL
DE LA NOTARIA
DE LA NOTARIA
DE LA NOTARIA

(Firmado), NOTARIO PUBLICO

Dado y firmado en

(SELLO NOTARIAL A TINTA O.P. ABBOT, NOTARIO, NUEVA DELHI) (Firmado)

12 de Octubre de 1999

(SELLO A TINTA DE RANBAXY LABORATORIES LTD.)

(Se requiere legalización por el Cónsul Colombiano)

(SELLO NOTARIAL A TINTA O.P. ABBOT, NOTARIO, NUEVA DELHI)

(SELLO A TINTA DE LA CÁMARA DE COMERCIO E INDUSTRIA)

(SELLO A TINTA CERTIFICANDO POR PARTE DE LA CÁMARA DE COMERCIO
E INDUSTRIA, NUEVA DELHI)

(SELLO NOTARIAL A TINTA O.P. ABBOT, NOTARIO, NUEVA DELHI,
CERTIFICADO DE COPIA FIEL)

(AL RESPALDO, FIRMA Y SELLO A TINTA DE KISHAN SWARUP,
FUNCIONARIO CONSULAR DEL MINISTERIO DE RELACIONES EXTERIORES
DE INDIA, QUIEN AUTENTICA LA FIRMA DE S. K. PATAWARI)



Co. No. 3479

(EMBLEMA ESTATAL)

CERTIFICADO RECIENTE DE CONSTITUCIÓN Y EXISTENCIA ORIGINADO
POR CAMBIO DE NOMBRE

EN LA OFICINA DEL REGISTRADOR DE COMPAÑÍAS, DELHI Y HARYANA

[Bajo la Ley de Compañías, 1956 (1 de 1956)]

BAJO EL ASUNTO DE Ranbaxy Laboratories Private Limited, Okhla, Nueva Delhi

Por el presente certifico que RANBAXY LABORATORIES PRIVATE LIMITED que
fue originalmente constituida el Dieciseis de Junio, 1961, bajo la Ley de

TRANSCRIPCION OFICIAL No. 99/99
SILVA ABULIZA DE PRIMA-VAL
INTERPRETE OFICIAL
CALLE 86, 229 DEL MUN. DE MONTICOR

Compañías, y bajo el nombre Lepetit Ranbaxy Laboratories Private Limited, habiendo debidamente tramitado la resolución especial presentada el 28-9-1973 en los términos de la Sección 21/31 de la Ley de Compañías, 1956, el nombre de dicha compañía es cambiada hoy a Ranbaxy Laboratories Limited y este certificado se expide de conformidad con las Sección 23(1) de dicha Ley.

Dado bajo mi firma en NUEVA DELHI hoy 27 de Septiembre de 1973 (Mil Novecientos Setenta y Tres).

(Sello Pre-Impreso del Registrador de Compañías, Nueva Delhi)

Por: Firmado

(Sello A tinta de la Cámara de Comercio e Industria, Nueva Delhi)

Sd/-

(R.K. Jain)


Registrador Asistente de Compañías

DELHI & HARYANA

(Sello de la Cámara de Comercio e Industria, Octubre 11, 1999)

(Sello Notarial a Tinta)

(Sello Notarial de Autenticidad, Firmado, Ilegible, Notario Público)



(FIRMA Y SELLO A TINTA DE KISHAN SWARUP, FUNCIONARIO CONSULAR DEL MINISTERIO DE RELACIONES EXTERIORES DE INDIA)

En español, certificado No. 1021/99 por el Consulado de Colombia en Nueva Delhi. Pagado el impuesto de Timbre y Derechos Consulares por valor de US\$22.00.

Legalización de la firma del Cónsul por el Jefe de Legalizaciones del Ministerio de Relaciones Exteriores, No. 367151 del 19 de Octubre de 1999.

En Español, Certificación No. 41/99 por la Embajadora Encargada de Funciones Consulares de Colombia en Nueva Delhi, de fecha 12 de Octubre de 1999.

Pagados el impuesto de timbre y derechos consulares por US\$107.00.

Legalización de la firma de la Embajadora Encargada de Funciones Consulares por el Jefe de Legalizaciones del Ministerio de Relaciones Exteriores, No. 166455 del 15 de Mayo del 2000.


ES TRADUCCIÓN FIEL Y COMPLETA de la cual se deja copia en los archivos de esta oficina para su confrontación y a la cual me remito.

Santafé de Bogotá, 16 de Mayo del 2000.

NO SE ASUME
RESPONSABILIDAD DEL TEXTO

2000 MAY 17 P 1:12

JEFE DE LEGALIZACIONES
SANTAFÉ DE BOGOTÁ D.C.



MINISTERIO DE RELACIONES
EXTERIORES

162791

CUYA FIRMA APARECE EN EL
DOCUMENTO DESEMPEÑA
LAS FUNCIONES INDICADAS

ASSIGNMENT OF RIGHTS, TITLE AND INTEREST IN INVENTION

This is an Assignment of the following rights, title and interest (check all that apply):

- ☒ United States of America rights, title and interest in the invention
☒ Indian rights, title and interest in the invention
☒ Foreign (non-Indian, non-United States) rights, title and interest in the invention
____ United States Patent Application Serial No. _____
____ Date of Execution: _____ Date of Filing: _____
____ United States Provisional Patent Application Serial No. _____
____ United States Patent No(s). _____
☒ International (PCT) Patent Application Serial No. PCT/IB2004/001761
____ Other (specify) _____

Title of the Invention:

SUBSTITUTED PYRROLE DERIVATIVES

Inventors (assignors)

Name	Address
Mohammad SALMAN	P-2/19, Phase - II DLF Qutab Enclave Gurgaon, Haryana 122001 India
Jitendra SATTIGERI	N-323, Vijay Rattan Vihar Sector 15-11 Gurgaon, Haryana 122001 India
Yatendra KUMAR	U-26/5, Phase - III DLF Qutab Enclave Gurgaon, Haryana 122001 India
Ram Chander ARYAN	1086, Sector - A, Pocket - A Vasant Kunj New Delhi, Delhi 110070 India
Vikram Krishna RAMANATHAN	C-103, Ambience Island Apartments, NH-8 Gurgaon, Haryana 122001 India
Anita CHUGH	RA-36, Inderpuri New Delhi, Delhi 110012 India

Assignee

Name	Address
Ranbaxy Laboratories Limited	19, Nehru Place New Delhi - 110019, India

Whereas, we, the above-identified Inventors, have invented certain new and useful improvements in the invention identified above and described in the above-identified patent application(s) and/or patent(s) (hereinafter referred to as "Invention");

And, whereas we desire to assign our above-identified rights, title and interest in the invention to the above-identified Assignee;

Now, this indenture witnesseth, that for good and valuable consideration, the receipt of which is hereby acknowledged;

We hereby assign, sell and transfer our above-identified rights, title and interest in said invention, said application(s) as identified above, including any divisions, continuations, and continuations-in-part thereof, and in and to any and all Letters Patent of the United States, and countries foreign thereto, which may be granted or have granted for said invention, and in and to any and all reissues and reexaminations thereof, and in and to any and all priority rights, Convention rights, treaty rights, and other benefits accruing or to accrue to us with respect to the filing of applications for patents or securing of patents in the United States and countries foreign thereto, unto said Assignee;

We hereby covenant that the rights and property conveyed by this Assignment are free and clear of any encumbrance, and that we have full right to convey the rights and property as expressed herein;

And we hereby authorize and request the Commissioner of Patents and Trademarks to issue any United States Letters Patent which may issue for said invention, and any other patent-issuing authority to issue any such Letters Patent which may issue for said invention, directly to said Assignee, as assignee of the whole right, title and interest thereto;

KG

17

And we further agree to sign and execute all necessary and lawful future documents, including applications for foreign patents, for filing divisions, continuations and continuations-in-part of said application for patent, and/or, for obtaining any reissues or reexaminations of any Letters Patent which may be granted for the aforesaid Invention, as the Assignee or its Designee(s) may from time to time require and prepare at its own expense.

And we further agree, when requested, without further charge to Assignee but at its expense, to communicate to Assignee or its representatives all facts known to us regarding the aforesaid Invention and improvements, testify in any legal proceeding, sign all papers, make all rightful oaths or declarations, and generally perform all acts, which may be necessary, desirable or convenient, to aid Assignee in securing, maintaining and enforcing patents for the aforesaid inventions and improvements in the aforesaid countries, and for vesting title thereto in Assignee.

Inventors' Signatures

Name	Signature	Date
Mohammad SALMAN	<u>Mohammad Salman</u>	June 11, 2004
Jitendra SATTIGERI	<u>Jitendra Sattigeri</u>	Jun 3, 2004
Yatendra KUMAR	<u>Yatendra Kumar</u>	June 3, 2004
Ram Chander ARYAN	<u>Ram Chander Aryan</u>	June 10, 2004
Vikram Krishna RAMANATHAN	<u>Vikram Krishna Ramanathan</u>	June 11, 2004
Anita CHUGH	<u>Anita Chugh</u>	June 3, 2004

17

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
9 December 2004 (09.12.2004)

PCT

(10) International Publication Number
WO 2004/106299 A2

(51) International Patent Classification²: **C07D 207/00**

Apartments, NH-8, Gurgaon, Haryana 122001 (IN).
CHUGH, Anita [IN/IN]; RA-36, Inderpuri, New Delhi
110012 (IN).

(21) International Application Number:
PCT/IB2004/001761

(22) International Filing Date: 28 May 2004 (28.05.2004)

(74) Common Representative: RANBAXY LABORATO-
RIES LIMITED; c/o DESHMUKH, Jay R., 600 College
Road East, Suite 2100, Princeton, New Jersey 08540 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/449,418 30 May 2003 (30.05.2003) US

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AI, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US 10/449,418 (CIP)
Filed on 30 May 2003 (30.05.2003)

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): RAN-
BAXY LABORATORIES LIMITED [IN/IN]; 19, Nehru
Place, New Delhi, Delhi 110 019 (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SALMAN, Moham-
med [IN/US]; 13 Hampshire Drive, Plainboro, NJ 08536
(US). SATTIGERI, Jitendra [IN/IN]; N-323, Vijay Rat-
tan Vihar, Sector-15-II, Gurgaon, Haryana 122001 (IN).
KUMAR, Yalendra [IN/IN]; U-26/5, Phase - III, DLF
Qutab Enclave, Gurgaon, Haryana 122001 (IN). ARYAN,
Ram, Chander [IN/IN]; 1066, Sector-A, Pocket-A,
Vasant Kunj, New Delhi 110070 (IN). RAMANATHAN,
Vikram, Krishna [IN/IN]; C-103, Ambience Island

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED PYRROLE DERIVATIVES

(57) Abstract: The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.

WO 2004/106299 A2

A

SUBSTITUTED PYRROLE DERIVATIVES**Field of the Invention**

The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors.

5 Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms.

10 **Background of the Invention**

Cardiovascular disease and its associated maladies, dysfunctions and complications are a principal cause of disability and the chief cause of death. One specific factor significantly contributing to this pathophysiologic process is atherosclerosis, which has been generally recognized as the leading health care problem both with respect to

15 mortality and health care costs.

Atherosclerosis is characterized by the deposition of fatty substances, primarily cholesterol, resulting in plaque formation on the inner surface of the arterial wall and degenerative change to the arteries.

It is now well established that cardiovascular disorders including myocardial

20 infarction, coronary heart disease, hypertension and hypotension, cerebrovascular disorders including stroke, cerebral thrombosis and memory loss due to stroke; peripheral vascular disease and intestinal infarction are caused by blockage of arteries and arterioles by atherosclerotic plaque. Atherosclerotic plaque formation is multi-factorial in its production. Hypercholesterolemia, especially elevated levels of low-density lipoprotein

25 cholesterol (LDL), is an important risk factor for atherosclerosis and arteriosclerosis and associated diseases.

The HMG-CoA reductase inhibitors (statins) have been used in reducing blood levels of LDL cholesterol. Cholesterol is produced via the mevalonic acid pathway. Reducing the formation of mevalonic acid, a precursor to cholesterol, leads to a

30 corresponding decrease in hepatic cholesterol biosynthesis with a reduction in the cellular pool of cholesterol.

K9

U. S. Patent No. 4,681,893 assigned to Warner-Lambert, discloses certain trans-6-[2-(3-,or 4-carboxamido-substituted pyrrole-1-yl)alkyl]-4-hydroxypyran-2-ones and the corresponding ring-opened hydroxy acids derived therefrom, including trans($\pm$)-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide, which are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA), an important coenzyme catalyzing the intracellular synthesis of cholesterol.

U. S. Patent No. 5,273,995 assigned to Warner Lambert, relates to the optically pure (R, R) form of the ring-opened acid of trans-5-(4-fluorophenyl)-2-(1-methylethyl-N,4-diphenyl-1-[2-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide that is [R-(R*, R*)]-2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, pharmaceutically acceptable salts thereof, specifically its calcium salt (Atorvastatin, Lipitor[®]), which is currently being used for the treatment of hypercholesterolemia.

U. S. Patent No. 5,385,929 discloses certain phenyl hydroxy derivatives of the compounds disclosed in U. S. 5,273,995, and that such phenyl hydroxy derivatives are also active as the inhibitors of the biosynthesis of cholesterol.

Summary of the Invention

The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, and processes for the synthesis of these compounds. These compounds show utility in inhibiting HMG-CoA reductase, among the key rate limiting steps in the biosynthetic pathway of cholesterol formation. Therefore, these compounds hold promise for the treatment of hypercholesterolemia and hyperlipidemia

Pharmaceutically acceptable salts, pharmaceutically acceptable solvates, tautomers, racemates, polymorphs, pure enantiomers, diastereoisomers, metabolites, prodrugs or N-oxides of these compounds having the same type of activity are also provided.


Pharmaceutical composition containing the compounds, and which may also contain pharmaceutically acceptable carriers or diluents, which can be used for the treatment of cholesterol-related disease or related symptoms thereof are also provided.

Other aspects will be set forth in the accompanying description which follows and in the part will be apparent from the description or may be learnt by the practice of the invention.

In accordance with another aspect, there is provided a method for treating a mammal suffering from cholesterol related disease, diabetes and related disease, cerebrovascular disease or cardiovascular disease, comprising administering to a mammal a therapeutically effective amount of compounds disclosed herein.


The compounds of the present invention can be used for treating arteriosclerosis, atherosclerosis, hypercholesterolemia, hyperlipidemia, hyperlipoproteinemia, hypertriglyceridemia, hypertension, stroke, ischemia, endothelium dysfunction, peripheral vascular disease, peripheral arterial disease, coronary heart disease, myocardial infarction, cerebral infarction, myocardial microvascular disease, dementia, Alzheimer's disease, osteoporosis and/or osteopenia, angina or restenosis.

In accordance with one aspect, there is provided a compound having the structure of Formula I,



Formula I

its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, prodrugs, metabolites, polymorphs, tautomers, racemates, pure enantiomers, diastereoisomers or N-oxides wherein




R₁ can be C₁-C₆, C₃-C₆, or optionally substituted phenyl (wherein up to three substituents are independently selected from halogens, C₁-C₆ alkyl, cyano, or C₁-C₃ perfluoroalkyl);

R_2 can be optionally substituted phenyl (wherein up to three substituents are independently selected from cyano, acetyl, or optionally substituted amino, wherein up to two amino substituents are independently selected from C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, acetyl, or sulfonamide);

- 5 R_3 can be optionally substituted C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl (wherein substituents are independently selected from halogens, hydroxyl, C_1 - C_3 alkoxy and protected hydroxyl);

R_3 can also be $-NR_8R_9$, wherein R_8 and R_9 are optionally substituted C_1 - C_6 alkyl (wherein the optional substituent(s) is/are selected from halogens, hydroxy, C_1 - C_3 alkoxy and protected hydroxyl);

- 10 R_4 can be




wherein R_5 and R_6 are independently hydrogen, C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl,

- 15 optionally substituted aryl or aralkyl, wherein the substituents are selected from halogens, cyano, optionally substituted C_1 - C_6 alkyl (wherein up to two substituents are independently selected from hydroxyl, protected hydroxyl, and halogen(s)), optionally substituted amino (wherein up to two substituents are independently selected from SO_2R_7 , COR_7 , or $CONHR_7$, wherein R_7 is C_1 - C_6 alkyl or aryl), or acetyl, trifluoromethyl, or C_1 - C_6 alkoxy, or R_5 and R_6 together form a 5-7 membered ring with one or more optional heteroatoms wherein the hetero atom(s) are independently selected from nitrogen, oxygen and sulfur,
- 20 or R_4 can be an optionally substituted mono-, bi- or tricyclic heterocycle having one or more hetero atom(s) wherein said hetero atom(s) is/are independently selected from
- 25 oxygen, nitrogen and sulfur, and the optional substituents are independently selected from halogens, hydroxy, protected hydroxyl, C_1 - C_3 alkoxy, cyano, C_1 - C_3 perfluoroalkyl, C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl, aryl or optionally substituted aralkyl wherein the substituents are independently selected from halogens, hydroxy, protected hydroxyl, C_1 - C_3 alkoxy, cyano, or C_1 - C_3 perfluoroalkyl,


- 30 and the pharmaceutically acceptable salts, tautomers, racemates, pure enantiomers or diastereoisomers, and solvates of the compounds of Formula I,

- with the proviso that R_2 is phenyl only when (1) R_3 or R_4 is C_3 - C_6 cycloalkyl or phenyl substituted with acetyl, alkyl, cycloalkyl, hydroxyalkyl, alkylsulfonamido, acetamido or (2) when R_3 and R_4 together form a 5-7 membered ring with or without one or more heteroatoms wherein the hetero atom(s) are selected from nitrogen, oxygen and sulfur or
- (3) when R_3 or R_4 is aralkyl optionally substituted with halogens, cyano, C_1 - C_6 alkyl, C_1 - C_6 halogenated alkyl or (4) when R_4 is optionally substituted mono-, bi- or tricyclic heterocycle having one or more hetero atom(s) (wherein the optional substituents are independently selected from halogens, hydroxy, protected hydroxyl, C_1 - C_3 alkoxy, cyano, perfluoroalkyl of one to three carbon atoms, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, aryl, or optionally substituted aralkyl (wherein the aralkyl substituents are independently selected from halogens, hydroxy, protected hydroxyl, C_1 - C_3 alkoxy, cyano, or C_1 - C_3 perfluoroalkyl)).

In accordance with another aspect, there are provided compounds having the structure of Formula Ib,



- their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, tautomers, racemates, polymorphs, pure enantiomers, diastereoisomers, metabolites, prodrugs or N-oxides wherein




- R_1 can be C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, or optionally substituted phenyl (wherein the substituent(s) is/are selected from halogens, C_1 - C_6 alkyl, cyano and C_1 - C_3 perfluoroalkyl);
- R_2 can be optionally substituted phenyl (wherein the substituent(s) is/are selected from cyano, acetyl and optionally substituted amino);

R_3 can be optionally substituted C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl (wherein the substituent(s) is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and protected hydroxyl); R_3 can also be $-NR_6R_7$ wherein R_6 and R_7 are optionally substituted C_1 - C_6 alkyl (wherein the optional substituent(s) is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and protected hydroxyl);


R_4 can be acetyl, C_1 - C_2 alkoxy carbonyl, optionally substituted C_1 - C_6 alkyl (wherein the substituent is hydroxy or protected hydroxyl), NHR_8 [wherein R_8 is selected from alkyl, aralkyl, SO_2R_9 , COR_9 or $CONHR_9$, $CSNHR_9$ (wherein R_9 is C_1 - C_6 alkyl, aryl or aralkyl)]; R_4 can also be $-COR_{10}$ (wherein R_{10} is selected from hydroxyl and $-NR_{11}R_{12}$ (wherein R_{11} and R_{12} are independently selected from hydrogen, alkyl, aryl, C_3 - C_7 cycloalkyl, heterocyclyl, aralkyl and R_{11} and R_{12} together form 5-7 membered ring with one or more optional heteroatom(s) wherein the heteroatom(s) is/are independently selected from nitrogen, oxygen and sulphur);

R_5 can be hydrogen, C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl, optionally substituted aryl or aralkyl [wherein the substituents are selected from halogens, cyano, optionally substituted C_1 - C_6 alkyl (wherein the substituents are independently selected from hydroxyl, protected hydroxyl, and halogen(s)), optionally substituted amino, acetyl, trifluoromethyl and C_1 - C_6 alkoxy carbonyl.

In one particular embodiment, there are provided compounds of Formula Ib,




their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, tautomers, racemates, polymorphs, pure enantiomers, diastereoisomers, metabolites, prodrugs or N-oxides wherein




R_1 , R_2 , R_3 and R_5 are as defined earlier;

R_4 can be NHR_6 [wherein R_6 is selected from aralkyl, $CONHR_9$ (wherein R_9 is aralkyl); $CSNHR_9$ (wherein R_9 is C_1 - C_6 alkyl, aryl or aralkyl)]; $-COR_{10}$ (wherein R_{10} is selected from hydroxyl and $-NR_{11}R_{12}$ (wherein R_{11} and R_{12} are independently selected from hydrogen, alkyl, aryl, C_3 - C_7 cycloalkyl, aralkyl and R_{11} and R_{12} together form 5-7 membered ring with one or more optional heteroatom(s) wherein the heteroatom(s) is/are independently selected from nitrogen, oxygen and sulphur);

In yet another particular embodiment, there are provided compounds of Formula Ib,




15 their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, tautomers, racemates, polymorphs, pure enantiomers, diastereoisomers, metabolites, prodrugs or N-oxides wherein



R_1 , R_2 , R_3 and R_5 can be 4-fluorophenyl, phenyl, isopropyl and hydrogen, respectively;

R_4 can be C_1 - C_2 alkoxycarbonyl, optionally substituted C_1 - C_6 alkyl (wherein the substituent is hydroxy or protected hydroxyl), NHR_6 [wherein R_6 is selected from SO_2R_9 , COR_9 or $CONHR_9$ (wherein R_9 is methyl or phenyl)]

In accordance with further aspect, there are provided intermediates having the structure of Formula XIX,




wherein

R_3 can be optionally substituted phenyl (wherein the substituent(s) is/are selected from cyano, acetyl and optionally substituted amino;

- 10 R_3 can be optionally substituted C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl (wherein the substituent(s) is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and protected hydroxyl); R_3 can also be $-NR_6R_7$ wherein R_6 and R_7 are optionally substituted C_1 - C_6 alkyl (wherein the optional substituent(s) is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and protected hydroxyl).

- 15 In accordance with third aspect, there are provided intermediates having the structure of Formula XX,



wherein


R_1 can be C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, or optionally substituted phenyl (wherein the substituent(s) is/are selected from halogens, C_1 - C_6 alkyl, cyano and C_1 - C_3 perfluoroalkyl);

- 25 R_3 can be optionally substituted phenyl (wherein the substituent(s) is/are selected from cyano, acetyl and optionally substituted amino;

R_3 can be optionally substituted C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl (wherein the substituent(s) is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and protected hydroxyl); R_3 can also be $-NR_6R_7$ wherein R_6 and R_7 are optionally substituted C_1 - C_6 alkyl

(wherein the optional substituent(s) is/are selected from halogens, hydroxyl, C₁-C₃ alkoxy, and protected hydroxyl).

In accordance with fourth aspect, there are provided intermediates having the structure of Formula XXI,




10 wherein

R₁ can be C₁-C₆ alkyl, C₃-C₆ cycloalkyl, or optionally substituted phenyl (wherein the substituent(s) is/are selected from halogens, C₁-C₆ alkyl, cyano and C₁-C₃ perfluoroalkyl);

R₂ can be optionally substituted phenyl (wherein the substituent(s) is/are selected from cyano, acetyl and optionally substituted amino;

15 R₃ can be optionally substituted C₁-C₆ alkyl or C₃-C₆ cycloalkyl (wherein the substituent(s) is/are selected from halogens, hydroxyl, C₁-C₃ alkoxy, and protected hydroxyl); R₃ can also be -NR₆R₇ wherein R₆ and R₇ are optionally substituted C₁-C₆ alkyl (wherein the optional substituent(s) is/are selected from halogens, hydroxyl, C₁-C₃ alkoxy, and protected hydroxyl).

20 In accordance with fifth aspect, there are provided intermediates having the structure of Formula XXII,



wherein

R₁ can be C₁-C₆ alkyl, C₃-C₆ cycloalkyl, or optionally substituted phenyl (wherein the substituent(s) is/are selected from halogens, C₁-C₆ alkyl, cyano and C₁-C₃ perfluoroalkyl);

27

R_2 can be optionally substituted phenyl (wherein the substituent(s) is/are selected from cyano, acetyl and optionally substituted amino;

R_3 can be optionally substituted C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl (wherein the substituent(s) is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and protected hydroxyl); R_3 can also be $-NR_6R_7$ wherein R_6 and R_7 are optionally substituted C_1 - C_6 alkyl (wherein the optional substituent(s) is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and protected hydroxyl).

As used herein the term "alkyl", unless otherwise defined, refers to straight or branched chain hydrocarbon of from 1 to 10 carbon atom(s). Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, octyl, and the like.

Alkyl may optionally be substituted with halogen, hydroxy, protected hydroxyl, C_1 - C_3 alkoxy, optionally substituted amino and C_1 - C_6 alkoxycarbonyl.

As used herein the term "optionally substituted amino", unless otherwise defined, refers to $NR_{14}R_{15}$ wherein R_{14} and R_{15} are independently selected from hydrogen, alkyl, aryl, aralkyl, C_3 - C_7 cycloalkyl, SO_2R_{16} , COR_{16} , $CONHR_{16}$ and $CSNHR_{16}$ (wherein R_{16} is C_1 - C_6 alkyl, aryl or aralkyl).

As used herein the term "protected hydroxyl" refers to a hydroxy moiety protected by a group R_{17} wherein R_{17} is selected from alkyl, cycloalkyl, aralkyl, aryl, $-(CH_2)_nOR_{18}$ (wherein R_{18} is selected from alkyl, cycloalkyl, aralkyl, aryl and n represents an integer from 1 to 6), COR_{19} , CSR_{19} , $CONHR_{19}$ and $CSNHR_{19}$ (wherein R_{19} is selected from alkyl, aryl, aralkyl and heterocyclyl). Examples of protected hydroxyl include, but are not limited to, $-OCH_3$, $-OC_2H_5$, $-O$ -n-propyl, $-O$ -i-propyl, $-O$ -cyclopropyl, $-OCH_2OCH_3$, $-O$ -cyclopentyl, $-O$ -cyclohexyl, $-O$ -benzyl, $-O$ -chlorobenzyl, $-O$ -methoxybenzyl, $-O$ -phenyl, $-O$ -chlorophenyl, $-O-COCH_3$, $-O-COC_2H_5$, $-O-CO$ benzyl, $-O-CO$ phenyl, $-O-CO$ pyridinyl, $-O-CONH$ phenyl, $-O-CONH$ pyridinyl, $-O-CONH$ -octyl, $-O-CSNH$ phenyl, and the like.

As used herein the term "aralkyl" refers to $(CH_2)_n$ aryl wherein n is an integer from 1 to 6.

As used herein the term "aryl", unless otherwise defined, refers to an aromatic radical having 6 to 14 carbon atoms. Examples of aryl include, but are not limited to, phenyl, naphthyl, anthryl and biphenyl, and the like.

As used herein the term "heterocyclyl" refers to non-aromatic, aromatic or aromatic fused with non-aromatic ring system having one or more heteroatom (s) in either the aromatic or the non-aromatic part wherein the said hetero atom (s) is/ are selected from the group comprising of nitrogen, sulphur and oxygen and the ring system includes mono, bi or tricyclic. Examples of heterocycles include, but not limited to, benzoxazinyl, benzthiazinyl, benzimidazolyl, benzofuranyl, carbazolyl, Indolyl, indoliny, oxazolyl, phenoxazinyl, pyridyl and phenothiazinyl, and the like.

The said aryl or heterocyclyl may optionally be substituted with one or more substituent(s) independently selected from halogen, hydroxy, nitro, cyano, alkyl, aryl, alkoxy, thioalkyl, cycloalkoxy, optionally substituted amino.

In accordance with yet another aspect, there are provided processes for the preparation of the compounds described herein.

In accordance with another aspect, there is provided a method for treating a mammal suffering from cholesterol related disease, diabetes and related disease, cerebrovascular disease or cardiovascular disease, comprising administering to a mammal a therapeutically effective amount of compounds disclosed herein.

The compounds of the present invention can be used for treating arteriosclerosis, atherosclerosis, hypercholesterolemia, hyperlipidemia, hyperlipoproteinemia, hypertriglyceridemia, hypertension, stroke, ischemia, endothelium dysfunction, peripheral vascular disease, peripheral arterial disease, coronary heart disease, myocardial infarction, cerebral infarction, myocardial microvascular disease, dementia, Alzheimer's disease, osteoporosis and/or osteopenia, angina or restenosis.

Detailed Description of the Invention

The compounds described herein may be prepared by techniques well known in the art and familiar to the average synthetic organic chemist. In addition, the compounds of the present invention may be prepared by the following reaction sequences as depicted in Schemes I, Ia, Ib, II, IIa, III, IIIa, and IV. Further compounds which can be useful for treatment of these diseases, and methods for making such compounds, are disclosed in copending United States Patent Application Serial No. 10/448,770 filed 30 May, 2003, entitled "Substituted Pyrrole Derivatives," and PCT Application No. PCT/IB2004/____ filed _____ entitled "Substituted Pyrrole Derivatives," which applications are incorporated herein in their entirety.

SCHEME I

The compound of Formula XII can be prepared according to Scheme I. Accordingly, a compound of Formula II is reacted with a compound of Formula III, wherein R_3 , R_5 and R_6 are as defined earlier, to give a compound of Formula IV which on
5 reaction with a compound of Formula V (wherein R_2 is as defined earlier) gives a compound of Formula VI, which on treatment with a compound of Formula VII (wherein R_1 is as defined earlier) yields a compound of Formula VIII, which on further reaction with a compound of Formula IX gives a compound of Formula X, which on hydrolysis gives a compound of Formula XI, which can then be further converted to hemicalcium
10 salt.


The reaction of a compound of Formula II with a compound of Formula III to give a compound of Formula IV can be carried out in a nonpolar solvent, such as xylene or toluene. The reaction of a compound of Formula II with a compound of Formula III can be carried out in the presence of an organic base, such as triethylamine, pyridine or 1,2-
15 ethylenediamine. The reaction of a compound of Formula IV with an aldehyde of Formula V to give a compound of Formula VI can be carried out in a nonpolar solvent such as hexane, heptane, dichloromethane or toluene or mixture(s) thereof. The reaction of a compound of Formula IV with an aldehyde of Formula V can be carried out in the presence of an organic base such as piperidine, pyridine or β -alanine and an organic acid
20 such as glacial acetic acid or benzoic acid. The reaction of a compound of Formula VI with an aldehyde of Formula VII to give a compound of Formula VIII can be carried out in the presence of a suitable catalyst, such as sodium cyanide, 3-ethyl-5- (2-hydroxyethyl)-4-methyl thiazolium bromide or 3-benzyl-5- (2-hydroxyethyl)-4-methyl thiazolium chloride, in a solvent free condition or in an alcoholic solvent, such as methanol, ethanol,
25 propanol or isopropanol. The reaction of a compound of Formula VI with an aldehyde of Formula VII can be carried out in the presence of an organic base, such as triethylamine or pyridine.

The reaction of a compound of Formula VIII with a compound of Formula IX to give a compound of Formula X can be carried out in a nonpolar solvent, such as xylene, toluene hexane, heptane, tetrahydrofuran, or a mixture thereof in a suitable ratio. The
30 reaction of a compound of Formula VIII with a compound of Formula IX can be carried out in the presence of an organic acid, such as pivalic acid or p-toluene sulfonic acid.


The conversion of a compound of Formula X to a compound of Formula XI can be carried out in a two-step manner, involving an initial acid-catalysed cleavage of ketal, followed by base-catalysed hydrolysis of the tert-butyl ester. The acid can be a mineral acid, such as hydrochloric acid. The cleavage of ketal can be carried out by any other
5 cleavage method known in the prior art. The base can be an organic base, such as lithium hydroxide, sodium hydroxide or potassium hydroxide.

The compound of Formula XI can be converted into its corresponding hemi calcium salt by following procedures well-known to a person ordinary skilled in the art. The hemi calcium salts of compound of Formula XI can also be prepared from the
10 corresponding lactones form of Formula XI by following procedures well-known in the art.

Scheme Ia



SCHEME Ia


The compound of Formula XVII can be prepared according to Scheme Ia. Accordingly, a compound of Formula XIII (that is, Formula X wherein $R_5=H$ and $R_6=$ ) prepared according to Scheme I) is hydrolyzed to give a compound of Formula XIV which, on reduction, gives a compound of Formula XV, which on hydrolysis gives a compound of Formula XVI, which can then be further converted to hemi calcium salt.

The hydrolysis of a compound of Formula XIII to give a compound of Formula XIV can be carried out in a polar solvent, such as tetrahydrofuran, dioxane, methanol, ethanol or mixture(s) thereof. The hydrolysis of a compound of Formula XIII can be carried out in the presence of an inorganic base such as lithium hydroxide, sodium hydroxide or potassium hydroxide.

The reduction of a compound of Formula XIV to give a compound of Formula XV can be carried out in the presence of iodine and a reducing agent, such as sodium borohydride or borane dimethylsulphide in an organic solvent, such as tetrahydrofuran, dioxane or diethylether.

The conversion of a compound of Formula XV to a compound of Formula XVI is carried out in a two-step manner, involving an initial acid-catalyzed cleavage of ketal, followed by base-catalyzed hydrolysis of the tert-butyl ester. The acid can be a mineral acid, such as hydrochloric acid. The cleavage of ketal can be carried out by any other cleavage method known in the prior art. The base can be an inorganic base, such as lithium hydroxide, sodium hydroxide or potassium hydroxide.

The compound of Formula XVI can be converted into its corresponding hemi calcium salt by following procedures well-known to a person ordinary skilled in the art. The hemi calcium salts of compound of Formula XVI can also be prepared from the corresponding lactone form of Formula XVI by following procedures well-known in the art.



SCHEME Ib

The compound of Formula XIIb can be prepared according to Scheme Ib. Accordingly, a compound of Formula II is reacted with a compound of Formula IIIb, wherein R₃, R₄ and R₅ are as defined earlier, to give a compound of Formula IVb which on
5 reaction with a compound of Formula V (wherein R₂ is as defined earlier) gives a compound of Formula VIb, which on treatment with a compound of Formula VII (wherein R₁ is as defined earlier) yields a compound of Formula VIIIb, which on further reaction with a compound of Formula IX gives a compound of Formula Xb, which on hydrolysis gives a compound of Formula XIb, which can then be further converted to
10 hemicalcium salt.

The reaction of a compound of Formula II with a compound of Formula IIIb to give a compound of Formula IVb can be carried out in an aromatic solvent, such as xylene or toluene. The reaction of a compound of Formula II with a compound of Formula IIIb can be carried out in the presence of an organic base, such as triethylamine, pyridine or
15 1,2-ethylenediamine.

The reaction of a compound of Formula IVb with an aldehyde of Formula V to give a compound of Formula VIb can be carried out in a hydrocarbon solvent, such as hexane, heptane, or halogenated solvent, such as dichloromethane, or aromatic solvent, such as toluene, or mixture thereof. The reaction of a compound of Formula IVb with an
20 aldehyde of Formula V can be carried out in the presence of an organic base such as piperidine, pyridine or β -alanine and an organic acid such as glacial acetic acid or benzoic acid.

The reaction of a compound of Formula VIb with an aldehyde of Formula VII to give a compound of Formula VIIIb can be carried out in the presence of a suitable catalyst, such as sodium cyanide, 3-ethyl-5- (2-hydroxyethyl)-4-methyl thiazolium bromide or 3-
25 benzyl-5- (2-hydroxyethyl)-4-methyl thiazolium chloride, in a solvent free condition or in an alcoholic solvent, such as methanol, ethanol, propanol or isopropanol or ethers, such as dioxan or tetrahydrofuran. The reaction of a compound of Formula VIb with an aldehyde of Formula VII can be carried out in the presence of an organic base, such as triethylamine
30 or pyridine.

The reaction of a compound of Formula VIIIb with a compound of Formula IX to give a compound of Formula Xb can be carried out in a solvent, such as xylene, toluene, hexane, heptane, tetrahydrofuran, or a mixture thereof in a suitable ratio. The reaction of a compound of Formula VIIIb with a compound of Formula IX can be carried out in the presence of an organic acid, such as pivalic acid or p-toluene sulfonic acid.

The conversion of a compound of Formula Xb to a compound of Formula XIb can be carried out in a two-step manner, involving an initial acid-catalysed cleavage of ketal, followed by base-catalysed hydrolysis of the tert-butyl ester. The acid can be a mineral acid, such as hydrochloric acid. The cleavage of ketal can be carried out by any other cleavage method known in the prior art. The base can be an inorganic base, such as lithium hydroxide, sodium hydroxide or potassium hydroxide.

The compound of Formula XIb can be converted into its corresponding hemi calcium salt by following procedures well-known to a person ordinary skilled in the art. The hemi calcium salts of compound of Formula XIb can also be prepared from the corresponding lactones form of Formula XIb by following procedures well-known in the art.

SCHEME II

The compound of Formula XII can also be prepared according to Scheme II. Accordingly, a compound of Formula XVIII is reacted with a compound of Formula V to give a compound of Formula XIX (wherein R₂ and R₃ are as defined earlier in Scheme I) which on reaction with a compound of Formula VII (wherein R₁ is as defined earlier) gives a compound of Formula XX, which on treatment with a compound of Formula IX yields a compound of Formula XXI, which on debenzylation gives a compound of Formula XXII, which on

(a) conversion to corresponding acid chloride followed by reaction with an amine of Formula III (Path a) or

(b) reaction with an amine of Formula III in the presence of a coupling agent (Path b), gives a compound of Formula X, which on hydrolysis gives a compound of Formula XI, which can be further converted to hemicalcium salt of Formula XI by following the procedure well known in the art.

The reaction of a compound of Formula XVIII with an aldehyde of Formula V to give a compound of Formula XIX can be carried out in a nonpolar solvent, such as xylene, toluene, heptane, hexane or dichloromethane or mixture thereof. The reaction of a compound of Formula XVIII with a compound of Formula V can be carried out in the presence of an organic base, such as triethylamine, pyridine, piperidine or β -alanine and an organic acid such as glacial acetic acid or benzoic acid.

The reaction of a compound of Formula XIX with an aldehyde of Formula VII to give a compound of Formula XX can be carried out in a polar solvent, such as an alcoholic solvent, for example, methanol, ethanol, propanol or isopropanol. The reaction of a compound of Formula XIX with an aldehyde of Formula VII can be carried out in the presence of an organic base, such as triethylamine or pyridine. The reaction of a compound of Formula XIX with an aldehyde of Formula VII to give a compound of Formula XX can be carried out in the presence of a catalyst, such as sodium cyanide, 3-ethyl-5-(2-hydroxyethyl)-4-methyl thiazolium bromide or 3-benzyl-5-(2-hydroxyethyl)-4-methyl thiazolium chloride.

The reaction of a compound of Formula XX with an amine of Formula IX to give a compound of Formula XXI can be carried out in the presence of an acid, such as pivalic

35

acid and p-toluene sulfonic acid in a nonpolar solvent such as hexane, heptane, toluene or tetrahydrofuran.

The debenzoylation of a compound of Formula XXI to give a compound of Formula XXII can be carried out in the presence of a catalyst, such as palladium on carbon and
5 hydrogen, in a polar solvent, such as methanol, ethanol, propanol or dioxane.


The conversion of compound of Formula XXII to its corresponding acid chloride (Path a) can be carried out with any suitable chlorinating agent, such as oxalyl chloride, in a nonpolar solvent, such as benzene, dichloromethane, tetrahydrofuran, toluene or xylene, followed by reaction with an amine of Formula III to give a compound of Formula X, in a
10 nonpolar solvent, such as benzene, and in the presence of an organic base, such as triethylamine or pyridine.

Reaction of compound of Formula XXII with an amine of Formula III to give a compound of Formula X can be carried out in the presence of a coupling agent (Path b), such as O-benzotriazol-1-yl-N,N,N',N'-tetramethyl uronium hexafluorophosphate (HBTU), bis(2-oxo-3-oxazolidinyl)phosphine (BOP), 1,3-dicyclohexycarbodiimide (DCC), 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU),
15 benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP) or carbonyldiimidazole (CDI) in a polar solvent, such as dimethylformamide, and an organic base, such as diisopropylethyl
20 amine.

The conversion of a compound of Formula X to a compound of Formula XI can be carried out in a two-step manner, involving an initial acid-catalysed cleavage of ketal, followed by base-catalysed hydrolysis of the tert-butyl ester. The acid can be a mineral acid, such as hydrochloric acid. The cleavage of ketal can be carried out by any other
25 cleavage method known in the prior art. The base can be an inorganic base, for example, lithium hydroxide, sodium hydroxide or potassium hydroxide.

The compound of Formula XI can be converted into its corresponding hemi calcium salt by following procedures well-known to a person ordinary skilled in the art. The hemi calcium salts of compound of Formula XI can also be prepared from the
30 corresponding lactone form of Formula XI by following procedures well-known in the art.

Scheme IIa



SCHEME IIa

The compound of Formula XVIa can be prepared according to Scheme IIa.


Accordingly, a compound of Formula XIIIa (that is, Formula Xa wherein $R_5=H$ and $R_4=-COOCH_3$, prepared according to Scheme I) is hydrolyzed to give a compound of Formula
5 XIVa, which on further hydrolysis gives a compound of Formula XVa, which can then be converted to disodium salt.

The conversion of compounds of Formula XIIIa to compounds of Formula XVa
can be carried out in a two-step manner, involving an initial acid-catalyzed cleavage of
ketal, followed by base-catalyzed hydrolysis of the methyl and tert-butyl ester. The acid
10 can be a mineral acid, such as hydrochloric acid. The cleavage of ketal can be carried out
by any other cleavage method known in the prior art. The base can be an inorganic base,
such as lithium hydroxide, sodium hydroxide or potassium hydroxide.

The compound of Formula XVa can be converted into its corresponding disodium
salt by following procedures well-known to a person ordinary skilled in the art.

42

Scheme III



2
1

SCHEME III

The compound of Formula XXVII can be prepared according to Scheme III. Amidoxime (prepared as per procedure described in *J. Med. Chem.*, 45:944 (2002) and *J. Med. Chem.*, 29:2174 (1986)) of Formula XXIII on coupling with a compound of Formula XXII (prepared following the steps of Scheme II) gives a compound of Formula XXIV, which on cyclisation in diglyme gives a compound of Formula XXV, which on hydrolysis gives a compound of Formula XXVI, which can be further converted to its hemi calcium salt.


The coupling of compound of Formula XXIII with a compound of Formula XXII can be carried out in the presence of *N, N'*-carbonyldiimidazole in an organic solvent, such as tetrahydrofuran, dioxane or ether.

The cyclisation of compound of Formula XXIV can be carried out in diglyme to give a compound of Formula XXV.

The conversion of a compound of Formula XXV to a compound of Formula XXVI can be carried out in a two-step manner, involving an initial acid-catalyzed cleavage of ketal, followed by base-catalyzed hydrolysis of the tert-butyl ester. The acid can be a mineral acid, such as hydrochloric acid. The cleavage of ketal can be carried out by any other cleavage method known in the prior art. The base can be an inorganic base, for example, lithium hydroxide, sodium hydroxide or potassium hydroxide.

The compound of Formula XXVI can be converted into its corresponding hemi calcium salt by following procedures well-known to a person ordinary skilled in the art. The hemi calcium salts of compound of Formula XXVI can also be prepared from the corresponding lactone form of Formula XXVI by following procedures well-known in the art.

Scheme IIIa



SCHEME IIIa

The compound of Formula XIIa can also be prepared according to Scheme IIIa. Accordingly, a compound of Formula XVIII is reacted with a compound of Formula V to give a compound of Formula XIX (wherein R₂ and R₃ are as defined earlier) which on
5 reaction with a compound of Formula VII (wherein R₁ is as defined earlier) gives a compound of Formula XX, which on treatment with a compound of Formula IX yields a compound of Formula XXI, which on debenzylolation gives a compound of Formula XXII, which on

(a) conversion to corresponding acid chloride followed by reaction with an amine
10 of Formula IIIa (Path a) or

(b) reaction with an amine of Formula IIIa in the presence of a coupling agent (Path b) gives a compound of Formula Xa, which on hydrolysis gives a compound of Formula XIa, which can be further converted to hemi calcium salt of Formula XIa by following the procedure well known in the art.

15 The reaction of a compound of Formula XVIII with an aldehyde of Formula V to give a compound of Formula XIX can be carried out in a hydrocarbon solvent, such as hexane or heptane, or halogenated solvent, such as dichloromethane, or aromatic solvent, such as toluene or xylene, or mixture thereof. The reaction of a compound of Formula XVIII with a compound of Formula V can be carried out in the presence of an organic
20 base, such as triethylamine, pyridine, piperidine or β -alanine and an organic acid such as glacial acetic acid or benzoic acid.

The reaction of a compound of Formula XIX with an aldehyde of Formula VII to give a compound of Formula XX can be carried out in a polar solvent, such as an alcoholic solvent, for example, methanol, ethanol, propanol or isopropanol. The reaction of a
25 compound of Formula XIX with an aldehyde of Formula VII can be carried out in the presence of an organic base, such as triethylamine or pyridine. The reaction of a compound of Formula XIX with an aldehyde of Formula VII to give a compound of Formula XX can be carried out in the presence of a catalyst, such as sodium cyanide, 3-ethyl-5- (2-hydroxyethyl)-4-methyl thiazolium bromide or 3-benzyl-5- (2-hydroxyethyl)-
30 4-methyl thiazolium chloride.

The reaction of a compound of Formula XX with an amine of Formula IX to give a compound of Formula XXI can be carried out in the presence of an acid, such as pivalic

acid and p-toluene sulfonic acid in a hydrocarbon solvent, such as hexane or heptane, or aromatic solvent, such as toluene, or ether, such as tetrahydrofuran or mixture thereof.

The debenzoylation of a compound of Formula XXI to give a compound of Formula XXII can be carried out in the presence of a catalyst, such as palladium on carbon and
5 hydrogen, in a polar solvent, such as alcoholic solvent, for example, methanol, ethanol or propanol, or ether solvent, for example, dioxane.

The conversion of compound of Formula XXII to its corresponding acid chloride (Path a) can be carried out with any suitable chlorinating agent, such as oxalyl chloride or thionyl chloride, in an aromatic solvent, such as benzene, toluene or xylene, or
10 halogenated solvent, such as dichloromethane, or ether, such as tetrahydrofuran, followed by reaction with an amine of Formula IIIa to give a compound of Formula Xa, in an aromatic solvent, such as benzene, and in the presence of an organic base, such as triethylamine or pyridine.


Reaction of compound of Formula XXII with an amine of Formula IIIa to give a
15 compound of Formula Xa (path b) can be carried out in the presence of a coupling agent, such as O-benzotriazol-1-yl-N,N,N',N'-tetramethyl uronium hexafluorophosphate (HBTU), bis(2-oxo-3-oxazolidinyl)phosphine (BOP), 1,3-dicyclohexycarbodiimide (DCC), 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU), benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP) or
20 carbonyldiimidazole (CDI) in a polar solvent, such as dimethylformamide, and an organic base, such as diisopropylethylamine.

The conversion of a compound of Formula Xa to a compound of Formula XIa can be carried out in a two-step manner, involving an initial acid-catalysed cleavage of ketal, followed by base-catalysed hydrolysis of the tert-butyl ester. The acid can be a mineral
25 acid, such as hydrochloric acid. The cleavage of ketal can be carried out by any other cleavage method known in the prior art. The base can be an inorganic base, for example, lithium hydroxide, sodium hydroxide or potassium hydroxide.


The compound of Formula XIa can be converted into its corresponding hemi calcium salt by following procedures well-known to a person ordinary skilled in the art.

30 The hemi calcium salts of compound of Formula XIa can also be prepared from the corresponding lactones form of Formula XIa by following procedures well-known in the art.


Scheme IV




Formula XII




Formula XXVIII



Formula XXIX



Formula XXX



Formula XXXI
[Hemil calcium salt]

SCHEME IV

The compound of Formula XXXI can be prepared according to Scheme IV. Accordingly, treating acid chloride of compound of Formula XXII with ammonia affords a compound of Formula XXVIII, which on condensation with N,N-dimethylbenzamide dimethylketal followed by treatment with hydrazine hydrate gives a compound of Formula XXIX, which on hydrolysis gives a compound of Formula XXX, which can be further converted to its hemi calcium salt.

The reaction of compound of Formula XXII to give compound of Formula XXVIII can be carried out in presence of a chlorinating agent, such as oxalyl chloride or thionyl chloride followed by reaction with ammonia.

The condensation of a compound of Formula XXVIII with N, N-dimethylbenzamide dimethylacetal followed by treatment with hydrazine hydrate affords compound of Formula XXIX.

The conversion of a compound of Formula XXIX to a compound of Formula XXX can be carried out in a two-step manner, involving an initial acid-catalyzed cleavage of ketal, followed by base-catalyzed hydrolysis of the tert-butyl ester. The acid can be a mineral acid, such as hydrochloric acid. The cleavage of ketal can be carried out by any other cleavage method known in the prior art. The base can be an inorganic base, for example, lithium hydroxide, sodium hydroxide or potassium hydroxide.

The compound of Formula XXX can be converted into its corresponding hemi calcium salt by following procedures well-known to a person ordinary skilled in the art. The calcium salts of compound of Formula XXX can also be prepared from the corresponding lactone form of Formula XXX by following procedures well-known in the art.

In the above schemes, where specific reagents, such as particular bases, reducing agents, solvents, etc., are mentioned, it is to be understood that other bases, reducing agents, solvents, etc., known to those skilled in the art may be used. Similarly, the reaction temperature and duration may be adjusted according to the desired needs.

An illustrative list of particular compounds disclosed herein is given below (also shown in Table I):

(3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(2-acetylphenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 1)

- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(3-acetylphenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 2)
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-acetylphenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 3)
- 5 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(2,4-dimethylphenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 4)
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(cyclohexylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 5)
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-trifluoromethylbenzylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 6)
- 10 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(morpholine-4-carbonyl)-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 7)
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(piperidine-1-carbonyl)-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 8)
- 15 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 11)
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-methanesulfonylaminophenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 12)
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-acetylaminophenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 13)
- 20 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-(4-cyanophenyl)-4-[(phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 14)
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-carboxyphenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 1a),
- 25 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-acetoxymethylphenyl) amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 2a),
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-phenylthiocarbamoyl oxymethylphenyl)amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 3a),
- 30 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-propionyloxymethyl phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 4a),
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-octylcarbamoxyloxymethyl phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 5a),
- 35 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-phenylacetoxymethyl phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 6a),
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-phenylcarbamoxyloxymethyl phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 7a),
- 40

- (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-benzoyloxymethyl phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 8a),
- 5 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-isonicotinoyloxymethyl phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 9a),
- (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-pyridin-4-ylcarbamoyloxymethyl phenyl) amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 10a),
- 10 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-phenylcarbamoyl phenyl) amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 11a),
- (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-cyclohexylcarbamoyl-phenyl) amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 12a),
- 15 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-methylcarbamoyl)-phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 13a),
- (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-benzylcarbamoyl)-phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 14a),
- 20 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(morpholine-4-carbonyl)-phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 15),
- 25 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(piperidine-1-carbonyl)-phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 16),
- (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-benzylamino phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 17),
- 30 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(1-hydroxyethyl)phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 18),
- (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(2-hydroxyethyl) phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 19),
- 35 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(3-hydroxypropyl phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 20),
- 40 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(4-methoxymethyl phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 21),

- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-ethoxymethyl phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 22),
- 5 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-isopropoxymethyl phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 23),
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-propoxymethyl phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 24),
- 10 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-methoxymethoxymethylphenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 25),
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-cyclohexyloxymethyl phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 26),
- 15 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-cyclopentyloxymethyl phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 27),
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-benzyloxymethyl phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 28)
- 20 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-chlorobenzyloxymethyl phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 29),
- 25 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-methoxybenzyloxymethyl phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 30),
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-phenoxyethylphenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 31),
- 30 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-chlorophenoxyethyl phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 32),
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-acetylaminophenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 33),
- 35 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-benzoylamino phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 34),
- 40 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-benzenesulfonylamino phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 36)


- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(3-phenyl-ureido)-phenylamino] carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 37),
- 5 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(3-methyl-ureido)-phenylamino] carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 38),
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(3-benzyl-ureido)-phenylamino] carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 39),
- 10 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(3-benzyl-thioureido)-phenylamino] carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 40),
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(3-phenyl-thioureido)-phenylamino] carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 41),
- 15 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(3-methyl-thioureido)-phenylamino] carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 42),
- 20 and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, tautomers, racemates, polymorphs, pure enantiomers, diastereoisomers, metabolites, prodrugs or N-oxides.

An illustrative list of compounds, which can be prepared by following Schemes III and IV is given below (also shown in Table I):

- 25 (3R,5R)-7-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(3-phenyl-[1,2,4]oxadiazol-5-yl)-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 9)
- (3R,5R)-7-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(5-phenyl-2H-[1,2,4]triazol-3-yl)-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 10)

In Tables I and Ia, R₄ is the indicated structure, unless otherwise noted.

Table I




C. No.	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆
1	4-Fluorophenyl	Phenyl	Isopropyl	-	Hydrogen	2-Acetylphenyl
2	4-Fluorophenyl	Phenyl	Isopropyl	-	Hydrogen	3-Acetylphenyl
3	4-Fluorophenyl	Phenyl	Isopropyl	-	Hydrogen	4-Acetylphenyl
4	4-Fluorophenyl	Phenyl	Isopropyl	-	Hydrogen	2,4-Dimethylphenyl
5	4-Fluorophenyl	Phenyl	Isopropyl	-	Hydrogen	Cyclohexyl
6	4-Fluorophenyl	Phenyl	Isopropyl	-	Hydrogen	4-trifluoromethyl benzyl
7	4-Fluorophenyl	Phenyl	Isopropyl	-	-(CH ₂) ₂ O-(CH ₂) ₂	
8	4-Fluorophenyl	Phenyl	Isopropyl	-	-(CH ₂) ₄	
9*	4-Fluorophenyl	Phenyl	Isopropyl	1,2,4-Oxadiazinylphenyl	--	
10*	4-Fluorophenyl	Phenyl	Isopropyl	1,2,4-Triazolylphenyl	--	
11	4-Fluorophenyl	Phenyl	Isopropyl	-	Hydrogen	4-(Hydroxymethyl)phenyl
12	4-Fluorophenyl	Phenyl	Isopropyl	-	Hydrogen	4-(Methylsulfonylamido)-phenyl
13	4-Fluorophenyl	Phenyl	Isopropyl	-	Hydrogen	4-(Acetamido)phenyl
14	4-Fluorophenyl	4-cyanoPhenyl	Isopropyl	-	Hydrogen	Phenyl

5 * Hypothetical examples

53


Table Ia

5



Formula I

wherein



10

R₁=4-fluorophenyl, R₂=phenyl, R₃=isopropyl, R₄=hydrogen

Compound No.	R ₄
1a	COOH
2a	acetoxymethyl
3a	phenylthiocarbamoyloxymethyl
4a	propionyloxymethyl
5a	octylcarbamoyloxymethyl
6a	phenylacetoxymethyl
7a	phenylcarbamoyloxymethyl
8a	benzoyloxymethyl
9a	isonicotinoyloxymethyl
10a	pyridin-4-ylcarbamoyloxymethyl
11a	phenylcarbamoyl
12a	cyclohexylcarbamoyl
13a	methylcarbamoyl
14a	benzylcarbamoyl
15	morpholine-4-carbonyl
16	piperidine-1-carbonyl
17	benzylamino
18	(1-hydroxyethyl)
19	(2-hydroxyethyl)
20	(3-hydroxypropyl)
21	methoxymethyl
22	ethoxymethyl
23	isopropoxymethyl
24	propoxymethyl
25	methoxymethoxymethyl
26	cyclohexyloxymethyl
27	cyclopentyloxymethyl
28	benzyloxymethyl

54

Compound No.	R ₄
29	4-chlorobenzylloxymethyl
30	4-methoxybenzylloxymethyl
31	phenoxymethyl
32	4-chlorophenoxymethyl
33	acetylamino
34	Benzoylamino
36	benzenesulfonylamino
37	3-phenyl-ureido
38	3-methyl-ureido
39	3-benzyl-ureido
40	3-benzyl-thioureido
41	3-phenyl-thioureido
42	3-methyl-thioureido

The term "pharmaceutically acceptable" means approved by regulatory agency of the federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.

5 The term "pharmaceutically acceptable salts" refer to a salt prepared from pharmaceutically acceptable monovalent, divalent or trivalent non-toxic metal or organic base. Examples of such metal salts include, but are not limited to, lithium, sodium, potassium, calcium, magnesium, zinc, aluminum, and the like. Examples of such organic bases include, but are not limited to, amino acid, ammonia, mono-alkyl ammonium, 10 dialkyl ammonium, trialkyl ammonium and N-methyl glucamine and the like. The free acid forms of compounds of the present invention may be prepared from the salt forms, if desired, by contacting the salt with dilute aqueous solution of an acid such as hydrochloric acid. The base addition salts may differ from the free acid forms of the compounds of this invention in such physical characteristics as solubility and melting point.

15 The term "pharmaceutically acceptable solvates" refers to solvates with water (i.e. hydrates) or pharmaceutically acceptable solvents, for example solvates with ethanol and the like. Such solvates are also encompassed within the scope of the disclosure.

Furthermore, some of the crystalline forms for compounds described herein may exist as polymorphs and as such are intended to be included in the scope of the disclosure.

20 The present invention also includes within its scope prodrugs of these agents. In general, such prodrugs will be functional derivatives of these compounds, which are readily convertible *in vivo* into the required compound. Conventional procedure for the

selection and preparation of suitable prodrug derivatives are described, for example, in "design of prodrugs", ed. H Bundgaard and, Elsevier, 1985.

The present invention also includes metabolites, which become active upon introduction into the biological system.

5 The compounds of the invention possess two chiral centers, they may, therefore, exist as enantiomers and diastereomers. It is to be understood that all such isomers and racemic mixtures therefore are encompassed within the scope of the present invention. Preferably, this invention contemplates compounds only with 3R and 5R configuration.

10 The crystalline or amorphous forms of compounds disclosed herein may exist as polymorphs and as such are intended to be included in the present invention.

Pharmaceutical compositions comprising compounds disclosed herein, their pharmaceutically acceptable salt, pharmaceutically acceptable solvates, or polymorphs, and pharmaceutically acceptable carrier or excipient are also disclosed herein.

15 The compositions provided herein, both those containing one disclosed compound and those containing two or more compounds, may be suitable for oral or parenteral administration. The compositions may be formulated to provide immediate or sustained release of the therapeutic compounds. The compounds described herein can be administered alone but will generally be administered as an admixture with a suitable pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" is
20 intended to include non-toxic, inert solid, semi-solid, liquid filter, diluent, encapsulating materials or formulation auxiliaries of any type.

25 Solid form preparations for oral administration may include capsules, tablets, pills, powder, granules or suppositories. For solid form preparations, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier, for example, sodium citrate, dicalcium phosphate and/or a filler, an extender, for example, starch, lactose, sucrose, glucose, mannitol or silicic acid; binders, for example, carboxymethyl cellulose, alginates, gelatins, polyvinylpyrrolidone, sucrose, or acacia; disintegrating agents, for example, agar-agar, calcium carbonate, potato starch, aliginic acid, certain silicates or sodium carbonate; absorption accelerators, for example,
30 quaternary ammonium compounds; wetting agents, for example, cetyl alcohol, glycerol, or mono stearate adsorbents, for example, Kaolin; lubricants, for example, talc, calcium

stearate, magnesium stearate, solid polyethyleneglycol, or sodium lauryl sulphate, and mixtures thereof.

In case of capsules, tablets, and pills, the dosage form may also comprise buffering agents.

5 The solid preparation of tablets, capsules, pills, or granules can be accomplished with coatings and/or shells, for example, enteric coatings and other coatings well known in the pharmaceutical formulating art.

 Liquid form preparations for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. For liquid form
10 preparations, the active compound can be mixed with water or other solvent, solubilizing agents and emulsifiers, for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (for example, cottonseed, ground corn, germ, live, castor and sesame oil), glycerol and fatty acid ester of sorbitan and mixture thereof.

15 Besides inert diluents, the oral compositions can also include adjuvants, for example, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents and perfuming agents.

 The formulations as described herein may be formulated so as to provide quick, sustained, or delayed release of the active compound after administration to the patient by
20 employing procedures well-known to the art. The term "patient" as used herein refers to a human or non-human mammal, which is the object of treatment, observation or experiment.

 The pharmaceutical preparations can be in unit dosage forms, and in such forms, the preparations are subdivided into unit doses containing appropriate quantities of an
25 active compound.

 The amount of a compound disclosed herein that will be effective in the treatment of a particular disorder or condition can be determined by standard clinical techniques. In addition, *in vitro* or *in vivo* assays may optionally be employed to help identify optimal dosage ranges.

30 Examples set forth below demonstrate general synthetic procedures for preparation of particular representative compounds. The examples are provided to

illustrate particular aspects of the disclosure, and do not constrain the scope of the present invention as defined by the claims.

EXAMPLES

General Procedure

5 Schemes I and Ib

Step 1: Preparation of β -ketoamide-1 (Formula IV and IVb)

A mixture of β ketoester (Formula II, 1 equiv.), amine (Formula III, 1 equiv) 1,2-ethylene diamine (0.01 equiv) in xylene was refluxed with the azeotropic removal of water. After the completion of reaction, solvent was evaporated & the residue purified on
10 column (silica gel; 100-200 mesh). Compounds of Formula IVb can be prepared analogously. The following intermediates were prepared following above general procedure

4-Methyl-3-oxo-pentanoic acid (3-acetylphenyl)-amide

¹H NMR(CDCl₃): δ 1.19 (d, J=6.9Hz, 6H), 2.61 (s, 3H), 2.75 (sep, J=6.9Hz, 1H), 3.64 (s,
15 2H), 7.43 (t, J=7.8Hz, 1H), 7.71 (d, J=7.8Hz, 1H), 7.87 (d, J=8.1Hz, 1H), 8.08 (s, 1H), 9.44 (brs, 1H); MS (positive ion mode): m/z 248 [M+1]; Yield: 49%

4-Methyl-3-oxo-pentanoic acid (4-acetylphenyl)-amide

¹H NMR(CDCl₃): δ 1.19 (d, J=6Hz, 6H), 2.58 (s, 3H), 2.75 (sep, J=6Hz, 1H), 3.65 (s, 2H),
20 7.67 (d, J=6Hz, 2H), 7.95 (d, J=6Hz, 2H), 9.60 (s, 1H), MS (positive ion mode): m/z 248 [M+1]; Yield 54%

4-Methyl-3-oxo-pentanoic acid (2,4-dimethylphenyl)-amide

¹H NMR(CDCl₃): δ 1.18 (d, J=6Hz, 6H), 2.29 (s, 6H), 2.73 (Sep, J=6Hz, 1H), 3.64 (s, 2H),
25 7.00 (s, 2H), 7.76 (d, J=6Hz, 1H), 9.11 (brs, 1H); MS (positive ion mode): m/z 234 [M+1]
Yield 72%

4-Methyl-3-oxo-pentanoic acid 4-trifluoromethylbenzyl amide

¹H NMR(CDCl₃): δ 1.14 (d, J=6Hz, 6H), 2.70 (sept, J=6Hz, 1H), 3.53 (s, 2H), 4.53 (d,
30 J=6Hz, 2H), 7.40 (d, J=6Hz, 2H), 7.59 (d, J=6Hz, 2H); MS (positive ion mode): m/z 287

4-Methyl-1-piperidin-1-yl-pentane-1,3-dione

¹H NMR(CDCl₃, 300MHz): δ 1.14 (d, J=6Hz, 6H), 1.57-1.65 (m, 6H), 2.76 (brs, 1H), 3.20-3.75 (m, 6H);

5 *4-Methyl-3-oxo-pentanoic acid phenylamide*

Step 2: Preparation of β-ketoamide-2 (Formula VI and VIb)

To β-ketoamide-1 (Formula IV, 1 equiv) in hexane was added to β-alanine (0.18 equiv), aldehyde (Formula V, 1.1 equiv) and glacial acetic acid (0.16 % w/w of β-ketoamide-1). The resulting suspension was heated under reflux with the azeotropic
10 removal of water. The reaction mixture was cooled and product was isolated by filtration. The product was purified by washing the precipitate with hot hexane, water and dried in vacuo to afford β-ketoamide-2. Compounds of Formula VIb can be prepared analogously. The following intermediates were prepared following above general procedure

2-Benzylidene-4-methyl-3-oxo-pentanoic acid (3-acetylphenyl)-amide; Isomer-1

15 ¹H NMR(CDCl₃): δ 1.1 (d, J=6.9Hz, 6H), 2.50-2.70 (m, 4H), 7.28-7.52 (m, 6H), 7.73 (d, J=7.2Hz, 1H), 7.93 (d, J=8.1Hz, 1H), 8.19 (d, J=9.9Hz, 2H), 9.23 (s, 1H); MS (positive ion mode): m/z 336 [M+1]; Yield: 13%

2-Benzylidene-4-methyl-3-oxo-pentanoic acid (3-acetylphenyl)-amide; Isomer-2

20 ¹H NMR(CDCl₃): δ 1.24 (d, J=9Hz, 6H), 2.60 (s, 3H), 3.39 (sep, J=6Hz, 1H), 7.33-7.98 (m, 11H); MS (positive ion mode): m/z 336 [M+1]; Yield: 32%

2-Benzylidene-4-methyl-3-oxo-pentanoic acid (4-acetylphenyl)-amide

25 ¹H NMR(CDCl₃): δ 1.23 (d, J=6.6Hz, 6H), 2.58 (s, 3H), 3.37 (Sep, J=6.6Hz, 1H), 7.27-7.42 (m, 3H), 7.49-7.73 (m, 5H), 7.95 (d, J=8.7Hz, 2H); MS (positive ion mode): m/z 336 [M+1]
Yield 48%

2-Benzylidene-4-methyl-3-oxo-pentanoic acid (2,4-dimethylphenyl)-amide

30 ¹H NMR(CDCl₃): δ 1.23 (d, J=6Hz, 6H), 1.99 (s, 1H), 2.29 (s, 1H), 3.38 (Sep, J=6Hz, 1H), 6.97 (s, 1H), 7.04 (d, J=6Hz, 1H), 7.30 (s, 1H), 7.35-7.45 (m, 3H), 7.53-7.72 (m, 7H)
MS (positive ion mode): m/z 323 [M+1]; Yield 50%

59

2-Benzylidene-4-methyl-3-oxo-pentanoic acid 4-trifluoromethylbenzyl amide

¹H NMR(CDCl₃, 300MHz): δ 1.19 (d, J=6.9Hz, 6H), 3.30 (sept, J=6.9Hz, 1H), 6.16 (brs, 1H), 7.26-7.60 (m, 10H)

5 2-Benzylidene-4-methyl-1-piperidin-1-yl-pentane-1,3-dione

¹H NMR(CDCl₃, 300 MHz): δ 0.88-0.97 (m, 2H), 1.15-1.35 (m, 8H), 1.43-1.62 (m, 4H), 3.13-3.30 (m, 3H), 3.61 (brs, 1H), 3.78 (brs, 1H), 7.38 (brs, 3H), 7.54 (brs, 3H); MS (positive ion mode): m/z 286 (M⁺+1)

10 2-(4-Cyanobenzylidene)-4-methyl-3-oxo-pentanoic acid phenylamide

¹H NMR (CDCl₃): δ 1.23 (d, J=6Hz, 6H), 3.34 (Sep, J=6Hz, 1H), 7.18 (t, J=6Hz, 1H), 7.36 (t, J=6Hz, 2H), 7.48 (d, J=6Hz, 2H), 7.57 (s, 1H), 7.65 (s, 4H), 7.81 (s, 1H); MS (positive ion mode): m/z 319 [M+1]; Yield: 67%

15 Step 3: Preparation of Diketone (Formula VIII and VIIIb)

β-ketoamide-2 (Formula VI, 1 equiv), aldehyde (Formula VII, 1.1 equiv), triethylamine (1 equiv) ethanol and 3-ethyl-5- (2-hydroxyethyl)-4-methyl thiazolium bromide (0.2 equiv) were placed in a vial. The contents were flushed with N₂ and the vial was capped immediately and was heated to 78°C. After the completion of reaction,

20 contents were cooled and triturated with ethyl acetate. The organic layer was washed with 6N hydrochloric acid, water, dried over anhydrous sodium sulphate, concentrated on rotary evaporator and residue was purified on a chromatographic column (silica gel, 100-200 mesh). Compounds of Formula VIIIb can be prepared analogously. The following intermediates were prepared following above general procedure

25 2-[2-(Fluorophenyl)-2-oxo-1-phenyl-ethyl]-4-methyl-3-oxo-pentanoic acid (3-acetylphenyl)-amide

¹H NMR(CDCl₃): δ 1.15 (d, J=6Hz, 3H), 1.20 (d, J=6Hz, 3H), 2.58 (s, 3H), 2.99 (sep, J=6Hz, 1H), 4.61 (d, J=12Hz, 1H), 5.38 (d, J=12Hz, 1H), 7.05 (t, J=9Hz, 2H), 7.15-7.44 (m, 6H), 7.54-7.72 (m, 4H), 7.94-8.05 (m, 2H); MS (positive ion mode): m/z 460 [M+1];

30 Yield: 55%

60

2-[2-(4-Fluorophenyl)-2-oxo-1-phenylethyl]-4-methyl-3-oxo-pentanoic acid (4-acetylphenyl)-amide

- ¹H NMR(CDCl₃): δ 1.16 (d, J=6.9Hz, 3H), 1.23 (d, J=6.9Hz, 3H), 2.55 (s, 3H), 2.99 (Sep, J=6.6Hz, 1H), 4.56 (d, J=10.5Hz, 1H), 5.35 (d, J=10.8Hz, 1H), 7.04 (t, J=8.7Hz, 3H), 7.18-7.37 (brn, 6H), 7.48 (s, 1H), 7.86 (d, J=8.4Hz, 2H), 7.87-8.03 (m, 2H); MS (positive ion mode): m/z 460 [M+1]; Yield 64%

2-[2-(4-Fluorophenyl)-2-oxo-1-phenylethyl]-4-methyl-3-oxo-pentanoic acid (2,4-dimethylphenyl)-amide

- ¹H NMR(DMSO-d₆): δ 0.99 (d, J=6.6Hz, 3H), 1.19 (d, J=6.9Hz, 3H), 1.67 (s, 3H), 2.18 (s, 3H), 3.00 (Sep, J=6.9Hz, 1H), 4.94 (d, J=11.1Hz, 1H), 5.36 (d, J=10.8Hz, 1H), 6.68 (d, J=8.1Hz, 1H), 6.82-6.93 (m, 2H), 7.17-7.45 (m, 7H), 8.08-8.24 (m, 2H), 9.60 (brs, 1H) MS (positive ion mode): m/z 446 [M+1]; Yield 66%

2-[2-(4-Fluorophenyl)-2-oxo-1-phenyl-ethyl]-4-methyl-3-oxo-pentanoic acid 4-trifluoromethylbenzyl amide

- ¹H NMR(CDCl₃, 300MHz): δ 1.10 (d, J=6.6Hz, 3H), 1.16 (d, J=7.2Hz, 3H), 2.88 (sept, J=6.9Hz, 1H), 4.15 (dd, J=15 & 4.8Hz, 1H), 4.40 (dd, J=15.9 & 6.6Hz, 1H), 4.46 (d, J=11.1Hz, 1H), 5.32 (d, J=10.8Hz, 1H), 5.80 (brs, 1H), 6.89 (d, J=7.8Hz, 2H), 6.97 (t, J=8.4Hz, 1H), 7.45 (d, J=7.5Hz, 2H), 7.94-7.98 (m, 2H); MS (positive ion mode): m/z 500 (M⁺+1)

1-(4-Fluorophenyl)-5-methyl-2-pentyl-3-(piperidine-1-carbonyl-hexane-1,4-dione

- ¹H NMR(CDCl₃, 300MHz): δ 1.05 (d, J=6.9Hz, 3H), 1.19 (d, J=7.1Hz, 4H), 1.45 (brs, 5H), 2.62 (sept, J=6.8Hz, 1H), 2.95-3.15 (m, 1H), 3.20-3.40 (m, 2H), 3.45-3.60 (m, 1H), 4.99 (d, J=10.5Hz, 1H), 5.34 (d, J=10.6Hz, 1H), 7.03 (t, J=8.5Hz, 2H), 7.24 (brs, 5H), 7.97-8.07 (m, 2H); MS (positive ion mode): m/z 493 (M⁺+1)

2-[1-(4-Cyanophenyl)-2-(4-fluorophenyl)-2-oxo-ethyl]-4-methyl-3-oxo-pentanoic acid phenylamide

- MS (positive ion mode): m/z 443 [M+1]

Step 4: Preparation of Pyrrole (Formula X and Xb)

- A mixture of diketone (Formula VIII, 1 equiv), amine (Formula IX, 1.00, equiv) and pivalic acid (1.03 equiv) in heptane:toluene:tetrahydrofuran (4:1:1) was refluxed and water was removed using Dean Stark trap. After the completion of reaction, solvents were removed and the residue was dissolved in ethyl acetate. The organic layer was washed in

saturated sodium bicarbonate, water, dried over anhydrous sodium sulphate, concentrated on rotary evaporator and the residue was purified on a chromatographic column (silica gel, 100-200 mesh). Compounds of Formula Xb can be prepared analogously. The following intermediates were prepared following above general procedure

- 5 *(6-{2-[3-(3-Acetylphenylcarbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-pyrrol-1-yl]-ethyl}-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid tert-butyl ester*

¹H NMR(CDCl₃): δ 1.30 (s, 3H), 1.36 (s, 3H), 1.43 (s, 9H), 1.53 (d, J=6Hz, 6H), 1.67 (brs, 2H), 2.20-2.43 (m, 2H), 2.52 (s, 3H), 3.52-3.75 (m, 2H), 3.76-3.88 (m, 1H), 4.00-4.22 (m, 2H), 6.85-7.05 (m, 3H), 7.10-7.51 (m, 10H), 7.58 (d, J=9Hz, 1H); MS (positive ion mode):

10 m/z 697 [M+1]; Yield: 23%

- (6-{2-[3-(4-Acetylphenylcarbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-pyrrol-1-yl]-ethyl}-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid tert-butyl ester*

¹H NMR(CDCl₃): δ 1.31 (s, 3H), 1.38 (s, 3H), 1.44 (s, 9H), 1.53 (d, J=9Hz, 6H), 1.66 (brs, 2H), 2.22-2.49 (m, 2H), 2.54 (s, 3H), 3.49-3.75 (m, 2H), 4.00-4.25 (m, 2H), 7.01 (t,

15 J=6Hz, 2H), 7.06-7.26 (m, 10H), 7.81 (d, J=9Hz, 2H); MS (positive ion mode): m/z 698 [M+1]; Yield: 14%

- (6-{2-[3-(2,4-Dimethylphenylcarbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-pyrrol-1-yl]-ethyl}-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid tert-butyl ester*

¹H NMR(CDCl₃): δ 1.30 (s, 3H), 1.36 (s, 3H), 1.43 (s, 9H), 1.52 (d, J=6Hz, 6H), 1.65-1.76 (m, 2H), 2.18-2.32 (m, 4H), 2.33-2.47 (m, 1H), 3.48 (Sep, J=6Hz, 1H), 3.63-3.90 (m, 2H), 4.0-4.25 m, 2H), 6.72 (s, 1H), 6.81 (s, 1H), 6.99 (t, S=6Hz, 3H), 7.07-7.25 (m, 7H), 7.88 (d, J=6Hz, 1H); MS (positive ion mode): m/z 684 [M+1]; Yield 21%

- (6-{2-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(4-trifluoromethylbenzylcarbamoyl)-pyrrol-1-yl]-ethyl}-2,2-dimethyl-[1,3]dioxan-4-yl) acetic acid tert-butyl ester*

25 ¹H NMR(CDCl₃, 300MHz): δ 0.8-1.2 (m, 2H), 1.29 (s, 3H), 1.35 (s, 3H), 1.43 (s, 9H), 1.63 (brs, 2H), 2.22-2.27 (m, 1H), 2.38 (dd, J=15.0 & 6.0Hz, 1H), 9.36-3.50 (m, 1H), 3.6-3.7 (m, 1H), 3.71-3.85 (m, 1H), 4.1-4.25 (m, 2H), 4.38 (d, J=6.0Hz, 2H), 7.02-7.16 (m, 12H), 7.41 (d, J=9.0Hz, 2H); MS (positive ion): m/z 737.4 [M+1]⁺

- 30 *6-{2-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(piperidine-1-carbonyl)-pyrrol-1-yl]-ethyl}-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid tert-butyl ester*

¹H NMR(CDCl₃, 300MHz): δ 0.99-1.60 (m, 29H), 2.17-2.52 (m, 2H), 2.80-3.25 m, 3H), 3.35-3.50 (m, 1H), 3.65-3.90 (m, 3H), 3.90-4.25 (m, 3H), 6.91-7.19 (m, 9H); MS (positive ion mode): m/z 646 (M⁺+1)

(6-{2-[3-(4-cyanophenyl)-5-isopropyl-2-(4-fluorophenyl)-4-(phenylamino) carbonyl-pyrrol-1-yl]-ethyl}-2,2-dimethyl-[1,3]dioxan-4-yl) acetic acid tert-butyl ester

¹H NMR (CDCl₃): δ 1.30 (s, 3H), 1.36 (s, 3H), 1.44 (s, 9H), 1.50 (d, J=6.9Hz, 6H), 1.67 (brs, 3H), 1.55-1.75 (brm, 3H), 2.20-2.40 (m, 2H), 3.38 (sep, J=6.6Hz, 1H), 3.63-3.88 (m, 2H), 3.97-4.24 (m, 2H), 6.85 (s, 1H), 6.96-7.48 (m, 12H); MS (positive ion mode): m/z 680 [M+1]; Yield: 20%

Step 5: Preparation of hemi calcium salt of compound of Formula XI and XIb

(a) To a solution of a compound of Formula X in methanol and tetrahydrofuran (1:1) was added 1N hydrochloric acid (3 equiv) and the mixture was stirred at ambient temperature. After the complete hydrolysis of the ketal, the reaction mixture was cooled to 0°C and sodium hydroxide pellets (6 equiv) were added. The reaction was then stirred at ambient temperature. At the end of ester hydrolysis, solvents were removed and the residue was dissolved in water; aqueous layer was washed with ether, and was neutralized with 1N hydrochloric acid. The organic phase was extracted into ethyl acetate, and concentrated. The residue was then purified on a chromatographic column (silica gel 100-200 mesh).

(b) To an aqueous solution of sodium salt of acid (is prepared by adding 1 equivalent 1N sodium hydroxide solution) was added dropwise an aqueous solution (1M) of calcium acetate (0.55 equiv). White precipitate was obtained, which was filtered off, washed with copious amount of water, and dried *in vacuo*.

Compounds of Formula XIb and XIIb can be formed analogously. The following compounds were prepared following above general procedure

Hemi calcium salt of (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(3-acetylphenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid

¹H NMR(DMSO-d₆): δ 1.23 (brs, 2H), 1.38 (d, J=6Hz, 6H), 1.63 (brs, 2H), 1.90-2.15 (m, 2H), 3.52 (brs, 1H), 3.76 (brs, 2H), 3.99 (brs, 1H), 6.95-7.45 (m, 10H), 7.60 (d, J=7.5Hz, 1H), 7.71 (d, J=7.5Hz, 1H), 8.15 (s, 1H), 9.98 (s, 1H, D₂O exchanged); MS (positive ion mode): m/z 601 [Acid+1]; Yield: 21.35; m.pt: 167.5-204°C

Hemi calcium salt of (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-acetylphenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid

¹H NMR(DMSO-d₆): δ 1.24 (brs, 2H), 1.37 (d, 3=6Hz, 6H), 1.58 (brs, 2H), 1.88-1.99 (m, 1H), 2.00-2.12 (m, 1H), 3.53 (brs, 1H), 3.73 (brs, 2H), 3.96 (brs, 1H), 7.09 (brs, 5H), 7.14-7.37 (m, 4H), 7.66 (d, J=9 Hz, 2H), 7.85 (d, J=9 Hz, 2H), 10.21 (s, 1H, D₂O exchanged); MS (positive ion mode): m/z 601 [Acid+1]; Yield 23%; m.pt 188.9-216.5°C

5

Hemi calcium salt of (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(2,4-dimethylphenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid

¹H NMR(DMSO): δ 1.29 (brs, 2H), 1.31-1.76 (m, 11H), 1.87-2.01 (dd, J=15 & 6Hz, 1H), 2.02-2.15 (dd, J=15 & 3Hz, 1H), 2.19 (s, 3H), 3.59 (brs, 1H), 3.76 (brs, 2H), 3.95 (brs, 1H), 6.85-6.95 (m, 2H), 7.05-7.33 (m, 10H), 8.78 (s, 1H, D₂O exchanged); MS (positive ion mode): m/z 587 [Acid+1]; Yield 45%; m.p 172.6-198.9°C

10

Hemi calcium salt of (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-trifluoromethylbenzylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid

¹H NMR(DMSO-d₆, 300MHz): δ 1.15-1.24 (m, 2H), 1.31 (d, J=6Hz, 6H), 1.48-1.56 (m, 2H), 1.84 (dd, J=15.8, 7.8Hz, 1H), 2.01 (dd, J=15 & 4.2Hz, 1H), 3.15-3.33 (m, 1H), 3.42 (brs, 1H), 3.50 (brs, 1H), 3.68-3.73 (m, 2H), 3.80-4.02 (m, 1H), 4.29 d, J=5.4Hz, 1H), 6.99 (brs, 2H), 7.05 (brs, 3H), 7.12-7.23 (m, 6H), 7.50 (d, J=8.1Hz, 2H), 8.24 (t, J=5.4Hz, 1H); MS (positive ion mode): m/z 641 (acid+1)

20

Hemi calcium salt of (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(piperidine-1-carbonyl)-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid

¹H NMR(DMSO-d₆, 300MHz, D₂O exchanged): δ 1.08-1.13 (m, 2H), 1.24 (brs, 7H), 1.27 (d, J=9Hz, 6H), 1.43 (brs, 2H), 2.02 (dd, J=15 & 6Hz, 1H), 2.15-2.19 (m, 1H), 2.88-2.95 (m, 2H), 3.12-3.24 m, 2H), 3.64-3.69 (m, 3H), 6.95 (d, J=6Hz, 2H), 7.05-7.15 (m, 5H), 7.25 (brs, 2H), 8.08 (s, 1H).

25

Hemi calcium salt of (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-(4-cyanophenyl)-4-[(phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid

¹H NMR (DMSO-d₆): δ 1.24 (brs, 2H), 1.37 (d, J=6Hz, 6H), 1.45-1.73 (m, 2H), 1.87-2.15 (m, 2H), 3.10-3.60 (m, 2H), 3.70-3.90 (brm, 2H), 3.91-4.08 (brm, 1H), 7.01 (t, J=6Hz, 1H), 7.13-7.35 (m, 8H), 7.45-7.63 (m, 4H), 10.02 (s, 1H, D₂O exchanged); MS (positive ion mode): m/z 584 [Acid+1]; Yield: 87%; m.pt. 197.7-222.1°C

30

SCHEME Ia

Step 1: Preparation of compound of Formula XIV

- Compound XIII (prepared following the appropriate steps of Scheme I to produce a compound of Formula X with appropriate substitution) was dissolved in tetrahydrofuran: methanol (1:2) mixture and 1N lithium hydroxide (equiv) was added. The reaction mixture was stirred at 0 °C for 12 to 15 hours. After completion of reaction, reaction mixture was acidified and the solvent was evaporated under reduced pressure to get crude product. The crude product was purified by column chromatography (silica gel –100-200 mesh) using 50% ethyl acetate in hexane. The following intermediates were prepared in this fashion.
- 10 4-([1-[2-(6-*tert*-butoxycarbonylmethyl-2,2-dimethyl-[1,3]dioxan-4-yl)-ethyl]-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-3-carbonyl]-amino)-benzoic acid
- ¹H NMR(CDCl₃): δ 1.03-1.11 (m, 1H), 1.26 (s, 3H), 1.30 (s, 3H), 1.43 (s, 9H), 1.53 (d, J=7.2Hz, 3H), 1.65-1.69 (m, 2H), 2.23 (dd, J=15.6 & 6.3Hz, 1H), 2.40 (dd, J=15.6 & 6.3Hz, 1H), 3.63-3.71 (m, 2H), 3.75-3.8 (m, 1H), 4.05-4.20 (m, 2H), 6.96-7.20 (m, 12H), 7.90 (d, J=8.4Hz, 2H); MS (positive ion mode): m/z 698 (M⁺+1); Yield = 51%
- 15

Step 2: Preparation of compound of Formula XV

- Method A: Compound XIV (1 equiv) was dissolved in dry tetrahydrofuran and sodium borohydride (2 equiv) was added slowly in two to three fractions. The resulting suspension was stirred for 5 minutes at 0 °C. A solution of iodine (1 equiv) in tetrahydrofuran was added slowly at 0 °C and reaction mixture was stirred for 24 to 30 hours at an ambient temperature. At the end of reaction, solvent was evaporated to get crude product. The crude product was purified by column chromatography (silica gel, 100-200 mesh) using 25% ethyl acetate in hexane.
- 20
- ¹H NMR(CDCl₃, 300MHz): δ 1.02-1.06 (m, 1H), 1.26 (s, 3H), 1.33 (s, 3H), 1.43 (s, 9H), 1.55 (d, J=6Hz, 6H), 2.21 (dd, J=15 & 6Hz, 1H), 2.38 (dd, J=15 & 6Hz, 1H), 2.40-4.17 (m, 5H), 4.58 (s, 2H), 6.87-7.19 (m, 13H); MS (+ve ion mode): m/z 685 (M⁺+1); Yield = 87%
- 25

- 30 Method B: A mixture of compound of Formula XIV (1 equiv.) and tetrahydrofuran (4 mL, Dry) was placed in a 3 neck round bottom flask equipped with a reflux condenser, nitrogen was purged. The reaction mixture was heated at about 50 °C and borane

CS

dimethylsulphide (2 equiv.) was added dropwise over 1 hour. Water (6 mL) was added to the reaction mixture, solvent was evaporated. Solid residue was dissolved in ethyl acetate, washed with water and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulphate, concentrated. The crude product was purified by silica gel column chromatography using ethyl acetate and hexane as eluant.

Yield: 2.16 g (73.72%)

Step 3: Preparation of hemi calcium salt of Formula XVI

(a) To a solution of XV in methanol and tetrahydrofuran (1:1) was added 1N hydrochloric acid (3 equiv) and the mixture stirred at an ambient temperature. After the complete hydrolysis of ketal, the reaction mixture was cooled to 0°C and sodium hydroxide pellets (6 equiv) were added. The reaction was then allowed to stir at ambient temperature. At the end of ester hydrolysis, solvents were removed and the residue was dissolved in water; the aqueous layer was washed with ether, and neutralized with 1N hydrochloric acid. The organic phase was extracted into ethyl acetate, and concentrated. The residue was then purified on column (silica gel 100-200 mesh).

(b) To an aqueous solution of the sodium salt of the acid (prepared by adding 1 equivalent 1N sodium hydroxide solution) was added dropwise an aqueous solution (1M) of calcium acetate (0.55 equiv). White precipitate was obtained, which was filtered off and washed with copious amount of water, and dried in vacuo.

The following compound was prepared similarly.

Hemi calcium salt of (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid

¹H NMR(DMSO-d₆): δ 1.22-1.62 (M, 11H), 1.98 (dd, J=15 & 8.1Hz, 1H), 2.06-2.16 (m, 1H), 3.25-3.37 (m, 2H), 3.57 (brs, 2H), 3.80 (brs, 1H), 4.43 (s, 2H), 7.03-7.28 (m, 12H), 7.50 (d, J=6H, 2H), 9.80 (s, 1H); MS (positive ion mode): m/z 589 (Acid+1); Yield = 31%; m.p. = 189-204°C

Scheme IIa**Step I: Preparation of compound of Formula XVa**

A compound of Formula XIIIa (1 equiv.) and a mixture of 1N hydrochloric acid:methanol:tetrahydrofuran (2:5:5) were stirred at room temperature for about 7 hours.

- 5 At the end of reaction, sodium hydroxide pellets (7 equiv.) were added and the reaction mixture was further stirred at room temperature for about 5 hours. Reaction mixture was concentrated and the residue was dissolved in distilled water and acidified to ~1pH with 1N hydrochloric acid. The aqueous layer was extracted with ethyl acetate, washed with water, brine and dried over anhydrous sodium sulphate. Organic layer was concentrated
- 10 and adsorbed over silica gel (5% methanol-dichloromethane). The following compound was prepared by following above procedures

(3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-carboxyphenyl]amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid

Yield : 5g (84.6%)

15 **Step II: Preparation of disodium salt of compound of Formula XVa**

A compound of XVa (1 equiv.), tetrahydrofuran:methanol (1:1) and sodium hydroxide (1N, 2 equiv.) solution were stirred at ambient temperature for about 2 hours. Disodium salt of compound of Formula XVa was isolated by evaporating solvent under reduced pressure. The residue was washed with diethylether, dried *in vacuo* to afford the

20 pure compound in a yield of 4.5g (84.9%). The following compound was prepared by following above procedures.

Disodium salt of (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-carboxyphenyl]amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid

- ¹H NMR (DMSO, 300 MHz): δ 1.135-1.179 (m, 2H), 1.365 (d, J=6.3Hz, 6H), 1.752 (brs, 4H), 1.752-1.779 (m, 1H), 1.950-1.998 (m, 1H), 2.733 (s, 1H), 2.89 (s, 1H), 3.607-3.75 (m, 3H), 3.924-4.004 (m, 2H), 6.99-7.07 (m, 5H), 7.155-7.247 (m, 4H), 7.4 (d, J=6Hz, 2H), 7.70 (d, J=9Hz, 2H), 9.827 (s, 1H); MS (positive ion mode): m/z 603.13 (Acid⁺ +1);
- 25 Yield : 4.5g (84.9%).

SCHEME II**Preparation of Compound of Formula XIX**

To a solution of a compound of Formula XVIII (4.5 mmoles; prepared according to procedure as described in *Tet. Let.*, 43:1161 (2002) and *J. Org. Chem.*, 50:438 (1985), in toluene (15 ml) was added a compound of Formula V (4.9 mmoles), piperidine (0.02 ml) and acetic acid (0.054 ml). The mixture was heated at reflux with azeotropic removal of water for about 4 to 6 hours. The reaction mixture was concentrated and the residue was extracted in dichloromethane. The organic layer was washed with 1N hydrochloric acid solution, sodium bicarbonate solution, brine, dried over anhydrous sodium sulphate, and concentrated. The crude product was purified on a chromatographic column (silica gel, 100-200 mesh, 2% EtOAc-hexane).

Preparation of compound of Formula XX

A compound of Formula XIX (6.49 mmoles), a compound of Formula VII (7.14 mmoles), 3-ethyl-5- (2-hydroxyethyl)-4-methyl thiazolium bromide (1.298 mmoles), triethylamine (6.49 mmoles), and ethanol (0.6 ml) were placed in a 30 ml vial, flushed with argon and the vial sealed properly. The reaction mixture was stirred at 70°C for about 12 to 15 hours. To the reaction mixture was added ethyl acetate, the mixture was washed with water, 6N hydrochloric acid, again with water and brine, dried over anhydrous sodium sulphate, and concentrated to give crude product. The crude product was purified on a chromatographic column (silica gel 100-200 mesh) using 7% ethyl acetate in hexane.

Preparation of compound of Formula XXI

To a solution of Formula XX (4.62 mmoles) in heptane: toluene: tetrahydrofuran (4:1:1) was added a compound of Formula IX (6.99 mmoles) and pivalic acid (4.768 mmoles). The mixture was refluxed with azeotropic removal of water for about 22 to 25 hours. The reaction mixture was concentrated, ethyl acetate was added, the reaction mixture was washed with sodium bicarbonate solution and brine, dried over anhydrous sodium sulphate and concentrated to give the crude product. The crude product was purified on column (silica gel, 100-200 mesh) using 7% ethyl acetate in hexane.

Preparation of compound of Formula XXII

To a solution of a compound of Formula XXI (0.8g) in methanol: dioxan (2:8) mixture was added 10% palladium carbon (50% wet, 60% w/w). The resulting reaction mixture was hydrogenated at 40 psi for about 2.5 hours. After the reaction was over, the reaction mixture was passed through celite and the resulting solution was concentrated under vacuum to give the required product, which was further used as such for next step.

Preparation of compound of Formula X : path a

To a solution of a compound of Formula XXII (1 equiv) in benzene at 0°C under argon, oxalyl chloride (2.0 equiv) was added dropwise. After the evolution of gas had ceased, the reaction mixture was heated on oil bath at 70°C for 2 hours. The reaction mixture was evaporated to dryness. The residue was dissolved in benzene (dry) and added at ambient temperature to a solution of amine of formula III (1.1 equiv.) in benzene. The reaction mixture was then heated to 70°C until completion of reaction. Volatiles were removed in vacuo and the residue was purified on a chromatographic column (silica gel, 100-200 mesh). The following compound was prepared following above general procedure

(6-{2-[3-(2-Acetylphenylcarbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-pyrrol-1-yl]-ethyl}-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid tert-butyl ester

¹H NMR(CDCl₃, 300MHz): δ 1.0-1.15 (m, 1H), 1.30 (s, 1H), 1.33 (s, 3H), 1.44 (s, 9H), 1.48 (d, J=6.0Hz, 6H), 2.23 (dd, J=15.0 & 6.0Hz, 1H), 2.35-2.5 (m, 4H), 3.35 (sept, J=6.0Hz, 1H), 3.64-3.89 (m, 2H), 4.0-4.25 (m, 2H), 6.93-7.08 (m, 8H), 7.18-7.22 (m, 2H), 7.50 (d, J=9.0Hz, 1H), 7.69 (d, J=6.0Hz, 1H), 8.82 (d, J=9.0Hz, 1H), 11.02 (brs, 1H); MS (positive ion): m/z 697.500 [M+1]⁺; Yield= 59%

Preparation of compound of Formula X : path b

To a solution of a compound of Formula XXII (1.2 mmole) in dimethylformamide (2.5 ml) was added diisopropylethylamine (2.4 mmole) and O-benzotriazol-1-yl-N,N,N',N'-tetramethyl uronium hexafluorophosphate (HBTU) (1.2 mmole). To the resulting clear solution was then added cyclohexylamine (1.2 mmole) in dimethylformamide (0.5 ml). The reaction mixture was stirred at 50°C to 60°C overnight. To the reaction mixture was added water and the mixture was extracted with dichloromethane, the organic layer was washed with water, brine, dried over anhydrous sodium sulphate and concentrated to get the crude product. The crude product was purified

by column chromatography (silica gel, 100-200 mesh) using 10 % ethyl acetate in hexane. The following compound was prepared as per this protocol.

(6-[2-[3-Cyclohexylcarbamoyl]-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-pyrrol-1-yl]-ethyl)-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid tert-butyl ester

- 5 ¹H NMR(CDCl₃, 300 MHz): δ 0.7-0.88 (m, 2H), 0.97-1.05 (m, 2H), 1.20-1.30 (m, 4H), 1.30-1.34 (s, 3H), 1.43 (s, 9H), 1.47 (d, J=6.9Hz, 6H), 1.43-1.48 (m, 2H), 1.63 (brs, 3H), 2.25 (dd, J=15 & 6Hz, 1H), 2.35 (dd, J=15 & 6.9Hz, 1H), 3.35 (sept, J=6.9Hz, 1H), 3.69-3.81 (m, 3H), 3.85-4.15 (m, 1H), 4.15-4.25 (m, 1H), 6.91-6.99 (m, 3H), 7.07-7.15 (m, 6H); MS (positive ion mode): m/z 661 (M⁺+1)

10

Preparation of hemi calcium salt of Formula XI

- (a) To a solution of a compound of Formula X in methanol and tetrahydrofuran (1:1) was added 1N hydrochloric acid (3 equiv) and the mixture stirred at ambient temperature. After the complete hydrolysis of ketal, the reaction mixture was cooled to 0°C and sodium hydroxide pellets (6 equiv) were added. The reaction was then stirred at ambient temperature. At the end of ester hydrolysis, solvents were removed and the residue was dissolved in water, the aqueous layer was washed with ether, and neutralized with 1N hydrochloric acid. The organic phase was extracted into ethyl acetate, and concentrated. The residue was then purified on a chromatographic column (silica gel 100-200 mesh).

- (b) To an aqueous solution of the sodium salt of the acid (prepared by adding 1 equivalent 1N sodium hydroxide solution) was added dropwise an aqueous solution (1M) of calcium acetate (0.55 equiv). White precipitate was obtained, which was filtered, washed with copious amount of water, and dried in vacuo.

- 25 The following compounds were prepared following above general procedure

Hemi calcium salt of (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(cyclohexylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid

- 30 ¹H NMR(DMSO-d₆, D₂O exchanged, 300MHz): δ 0.99 (brs, 2H), 1.2-1.35 (m, 5H), 1.35-1.50 (m, 7H), 1.55 (m, 4H), 1.90-2.1 (m, 1H), 2.10-2.20 (m, 1H), 3.17-3.20 (m, 1H), 3.51 (brs, 1H), 3.73 (brs, 1H), 7.02-7.36 (m, 9H); MS (positive ion mode): m/z 565 (acid+1).

Hemi calcium salt of (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(2-acetylphenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid

¹H NMR(DMSO-d₆, 300MHz): δ 1.10-1.25 (m, 2H), 1.39 (d, J=6.0Hz, 6H), 1.5-1.7 (m, 2H), 1.77 (dd, J=15.0 & 6.0Hz, 1H), 1.97 (dd, J=15.0 & 3.0Hz, 1H), 2.38 (s, 3H), 6.94-7.01 (m, 5H), 7.08-7.20 (m, 3H), 7.29-7.34 (m, 2H), 7.56 (t, J=9.0Hz, 1H), 7.87 (d, J=6.0Hz, 1H), 8.58 (d, 9.0Hz, 1H), 10.98 (s, 1H); MS (positive ion): m/z 601.300

5 [Acid+1]⁺; Yield= 28%; m. pt: 202.6-208.7°C.

Scheme IIIa

Preparation of Compound of Formula XIX

To a solution of a compound of Formula XVIII (4.5 mmoles; prepared according to procedure as described in *Tet. Let.*, 43:1161 (2002) and *J. Org. Chem.*, 50:438 (1985))
10 in toluene (15 ml) was added a compound of Formula V (4.9 mmoles), piperidine (0.02 ml) and acetic acid (0.054 ml). The mixture was heated at reflux with azeotropic removal of water for about 4 to 6 hours. The reaction mixture was concentrated and the residue was extracted in dichloromethane. The organic layer was washed with 1N hydrochloric acid solution, sodium bicarbonate solution, brine, dried over anhydrous sodium sulphate, and
15 was concentrated. The crude product was purified on a chromatographic column (silica gel, 100-200 mesh, 2% EtOAc-hexane).

¹H NMR(CDCl₃, 300MHz): δ 1.02 (d, J=6.9Hz, 6H), 2.65 (sept, J=7.2Hz, 1H), 5.26 (s, 2H), 7.25 (s, 2H), 7.25 (brs, 10H), 7.81 (s, 1H).). isomer 2 : ¹H NMR(CDCl₃, 300MHz): δ 1.02 (d, J = 6.9 Hz, 6H), 2.65 (sept, J = 6.9 Hz, 1H), 5.27 (s, 2H), 7.36 (brs, 10H), 7.82 (s,
20 1H).MS (+ ve ion mode): m/z 309 (M⁺+1); Yield: 70%

Preparation of compound of Formula XX

A compound of Formula XIX (6.49 mmoles), a compound of Formula VII (7.14 mmoles), 3-ethyl-5- (2-hydroxyethyl)-4-methyl thiazolium bromide (1.298 mmoles), triethylamine (6.49 mmoles), and ethanol (0.6 ml) were placed in a 30 ml vial, the reaction
25 was flushed with argon and the vial was sealed properly. The reaction mixture was stirred at 70°C for about 12 to 15 hours. To the reaction mixture was added ethyl acetate, the mixture was washed with water, 6N hydrochloric acid, again with water and brine, was dried over anhydrous sodium sulphate, and was concentrated to give crude product. The crude product was purified on a chromatographic column (silica gel 100-200 mesh) using
30 7% ethyl acetate in hexane.

¹H NMR(CDCl₃, 300MHz): (1:1 mixture of diastereomers) δ 0.48 (d, J=6.9Hz, 3H), 0.91 (d, J=6.6Hz, 3H), 1.07 (d, J=6.6Hz, 3H), 1.21 (d, J=6.9Hz, 3H), 2.30 (sept, J=6.6Hz, 1H), 2.82 (sept, 6.6Hz, 1H), 4.76 (d, J=14Hz, 1H), 4.77 (d, J=12.3Hz, 1H), 5.33 (d, J=11.1Hz, 1H), 5.35 (d, J=11.1Hz, 1H), 7.02 (t, J=8.4Hz, 6H), 7.22-7.29 (m, 8H), 7.75-7.99 (m, 4H);

5 MS (+ ve ion mode): m/z 433 (M⁺+1). Yield: 72%

Preparation of compound of Formula XXI

To a solution of Formula XX (4.62 mmoles) in heptane:toluene:tetrahydrofuran (4:1:1) was added a compound of Formula IX (6.99 mmoles) and pivalic acid (4.768 mmoles). The mixture was refluxed with azeotropic removal of water for about 22 to 25
10 hours. The reaction mixture was concentrated, ethyl acetate was added, and the reaction mixture was washed with sodium bicarbonate solution and brine, was dried over anhydrous sodium sulphate and was concentrated to give the crude product. The crude product was purified on column (silica gel, 100-200 mesh) using 7% ethyl acetate in hexane.

15 ¹H NMR(CDCl₃, 300MHz): δ 0.99-1.08 (m, 2H), 1.25 (s, 3H), 1.34 (s), 1.43 (s, 9H), 1.96 (d, J=6Hz, 6H), 1.58-1.63 (m, 2H), 2.21 (dd, J=158.6Hz, 1H), 2.37 (dd, J=15 & 9Hz, 1H), 3.51 (sept, J=6Hz), 3.65 (brs, 1H), 3.75-3.85 (m, 1H), 4.00-4.25 (m, 2H), 5.03 (s, 2H), 6.83-7.25 (m, 14H). MS (+ ve ion mode): m/z 670 (M⁺+1). yield 74%

Preparation of compound of Formula XXII

20 To a solution of a compound of Formula XXI (0.8g) in methanol:dioxan (2:8) mixture was added 10% palladium carbon (50% wet, 60% w/w). The resulting reaction mixture was hydrogenated at 40 psi for about 2.5 hours. After the reaction was over, the reaction mixture was passed through celite and the resulting solution was concentrated under vacuum to give the required product, which was further used as such for next step.

25 ¹H NMR(CDCl₃, 300MHz): δ 0.95-1.05 (m, 1H), 1.21-1.28 (m, 1H), 1.28 (s, 3H), 1.34 (s, 3H), 1.43 (s, 9H), 1.47 (d, J=7.1Hz), 1.59-1.65 (m, 2H), 2.22 (dd, J=15.2 & 6.1Hz, 1H), 2.35 (dd, J=15.2 & 6.1Hz, 1H), 3.61-3.66 (m, 2H), 3.67-3.86 (m, 1H), 4.00-4.15 (m, 2H), 6.95 (t, J=9Hz, 2H), 7.06-7.15 (m, 7H) MS (+ ve ion mode): m/z 586 (M⁺+1) Yield 76%

Preparation of compound of Formula Xa: path a

30 To a solution of a compound of Formula XXII (1 equiv) in benzene at 0°C under argon, oxalyl chloride (2.0 equiv) is added dropwise. After the evolution of gas ceases,

73

the reaction mixture is heated on oil bath at 70°C for 2 hours. The reaction mixture is evaporated to dryness. The residue is dissolved in benzene (dry) and is added at ambient temperature to a solution of amine of Formula IIIa (1.1 equiv.) in presence of triethylamine, in benzene. The reaction mixture is then heated to 70°C until completion of reaction. Volatiles are removed *in vacuo* and the residue is purified on a chromatographic column (silica gel, 100-200 mesh).

Preparation of compound of Formula Xa: path b

To a solution of a compound of Formula XXII (1.2 mmole) in dimethylformamide (2.5 ml) is added diisopropylethylamine (2.4 mmole) and O-benzotriazol-1-yl-N,N,N',N'-tetramethyl uronium hexafluorophosphate (HBTU) (1.2 mmoles). To the resulting clear solution is then added cyclohexylamine (1.2 mmoles) in dimethylformamide (0.5 ml). The reaction mixture is stirred at 50°C to 60°C overnight. To the reaction mixture is added water and the mixture is extracted with dichloromethane, the organic layer is washed with water, brine, is dried over anhydrous sodium sulphate and is concentrated to get the crude product. The crude product is purified by column chromatography (silica gel, 100-200 mesh) using 10 % ethyl acetate in hexane.

Preparation of hemi calcium salt of Formula XIa

(a) To a solution of a compound of Formula Xa in methanol and tetrahydrofuran (1:1) is added 1N hydrochloric acid (3 equiv) and the mixture is stirred at ambient temperature. After the complete hydrolysis of ketal, the reaction mixture is cooled to 0°C and sodium hydroxide pellets (6 equiv) are added. The reaction is then stirred at ambient temperature. At the end of ester hydrolysis, solvents are removed and the residue is dissolved in water; the aqueous layer is washed with ether, and is neutralized with 1N hydrochloric acid. The organics phase is extracted into ethyl acetate, and concentrated. The residue is then purified on a chromatographic column (silica gel 100-200 mesh).

(b) To an aqueous solution of the sodium salt of the acid (is prepared by adding 1 equivalent 1N sodium hydroxide solution) is added dropwise an aqueous solution (1M) of calcium acetate (0.55 equiv). White precipitate is obtained, which is filtered, is washed with copious amount of water, and is dried in *vacuo*. The following compounds can be prepared following scheme Ib or IIIa or both.

- 94
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-acetoxymethylphenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 2a) and its hemicalcium salt,
- 5 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-phenylthiocarbamoyloxymethylphenyl)amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 3a) and its hemicalcium salt,
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-propionyloxymethylphenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 4a) and its hemicalcium salt,
- 10 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-octylcarbamoyloxymethyl phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 5a) and its hemicalcium salt,
- (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-phenylacetoxymethyl phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound
- 15 No. 6a) and its hemicalcium salt,
- (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-phenylcarbamoyloxymethyl phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 7a) and its hemicalcium salt,
- 20 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-benzoyloxymethyl phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 8a) and its hemicalcium salt,
- (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-isonicotinoyloxymethyl phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound
- 25 No. 9a) and its hemicalcium salt,
- (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-pyridin-4-ylcarbamoyloxymethyl phenyl) amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 10a) and its hemicalcium salt,
- (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-phenylcarbamoyl phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound
- 30 No. 11a) and its hemicalcium salt,
- (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-cyclohexylcarbamoyl-phenyl) amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 12a) and its hemicalcium salt,
- (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-methylcarbamoyl)-phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound
- 35 No. 13a) and its hemicalcium salt,
- (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-benzylcarbamoyl)-phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 14a) and its hemicalcium salt,
- 40 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(morpholine-4-carbonyl)-phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 15) and its hemicalcium salt,

24

- (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(piperidine-1-carbonyl)-phenylamino]carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 16) and its hemicalcium salt,
- 5 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-benzylamino phenylamino]carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 17) and its hemicalcium salt,
- (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(1-hydroxyethyl)phenylamino]carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 18) and its hemicalcium salt,
- 10 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(2-hydroxyethyl) phenylamino]carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 19) and its hemicalcium salt,
- (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(3-hydroxypropyl phenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 20) and its hemicalcium salt,
- 15 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(4-methoxymethyl phenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 21) and its hemicalcium salt,
- (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(4-ethoxymethyl phenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 22) and its hemicalcium salt,
- 20 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(4-isopropoxymethyl phenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 23) and its hemicalcium salt,
- 25 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(4-propoxymethyl phenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 24) and its hemicalcium salt,
- (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(4-methoxymethoxymethylphenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 25) and its hemicalcium salt,
- 30 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(4-cyclohexyloxymethyl phenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 26) and its hemicalcium salt,
- (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(4-cyclopentyloxymethyl phenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 27) and its hemicalcium salt,
- 35 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(4-benzyloxymethyl phenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 28) and its hemicalcium salt,
- 40 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(4-chlorobenzyloxymethyl phenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 29) and its hemicalcium salt,

- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-methoxybenzyloxymethyl phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 30) and its hemicalcium salt,
- 5 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-phenoxyethylphenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 31) and its hemicalcium salt,
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-chlorophenoxyethyl phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 32) and its hemicalcium salt,
- 10 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-acetylaminophenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 33) and its hemicalcium salt,
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-benzoylamino phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 34) and its hemicalcium salt,
- 15 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-benzenesulfonylamino phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 36) and its hemicalcium salt,
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(3-phenyl-ureido)-phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 37) and its hemicalcium salt,
- 20 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(3-methyl-ureido)-phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 38) and its hemicalcium salt,
- 25 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(3-benzyl-ureido)-phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 39) and its hemicalcium salt,
- (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(3-benzyl-thioureido)-phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 40) and its hemicalcium salt,
- 30 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(3-phenyl-thioureido)-phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 41) and its hemicalcium salt,
- 35 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(3-methyl-thioureido)-phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 42) and its hemicalcium salt.

Pharmacological activity

- The compounds disclosed herein have activity as inhibitors of 3-hydroxy-3-methyl-glutanyl coenzyme A (HMG-CoA) reductase, and thus are useful in inhibiting
- 40 cholesterol biosynthesis and/or in lowering triglycerides.

The compounds described herein are screened in an *in-vitro* HMG-CoA reductase enzyme assay as described by Kubo et al., *Endocrinology* 120:214 (1987) and Hellar et al., *Biochem and Biophys. Res. Comm.* 50:859 (1973).

5 HMG-CoA reductase is a rate-limiting enzyme in the cholesterol biosynthesis, catalyzing the following reaction.


[¹⁴C] HMG-CoA + 2NADPH + 2H⁺ → [¹⁴C] mevalonate + CoA + 2NADP⁺ microsomes, utilizing 2.5 μM [¹⁴C] HMG-CoA as a substrate. The reaction is carried out in presence of 100 mM KH₂PO₄, 20 mM G-6-P, 2.5 mM NADP, 10 mM EDTA, 5 mM DTT and 1.4 G-6-P dehydrogenase, at 37 °C for 15 minutes and quantitating [¹⁴C] mevalonate as an end
10 product. For IC₅₀ determination, the compounds dissolved in 1% dimethylsulfoxide are preincubated with liver microsomes at 37°C for 30 minutes.

The IC₅₀ for HMG-CoA reductase inhibition in rat liver microsome ranged from 0.1 to 0.96 nM. The compounds disclosed herein ranged from being equipotent to 4 fold more potent than atorvastatin. Some of the compounds disclosed herein were potent than
15 atorvastatin in inhibiting cholesterol synthesis *in vivo* rat model. Some of the compounds disclosed herein have intrinsic clearance in human liver microsome significantly less than atorvastatin and are not major substrate for CYP3A4 (cytochrome p450 3A4). Some of the compounds exhibit potency and selectivity greater than atorvastatin in inhibition of cholesterol synthesis in rat primary hepatocytes over inhibition of cholesterol synthesis in
20 extra hepatic cells/cell lines [e.g. NRK-49F (Fibroblast) and L6 (Myoblast)].

While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention:


We Claim:

1. A compound having the structure of Formula I,



Formula I

its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, tautomers, racemates, pure enantiomers, prodrugs, metabolites, polymorphs, diastereoisomers or N-oxides, wherein



R_1 can be C_1-C_6 , C_3-C_6 , or optionally substituted phenyl (wherein up to three substituents are independently selected from halogens, C_1-C_6 alkyl, cyano, or C_1-C_3 perfluoroalkyl);

R_2 can be optionally substituted phenyl (wherein up to three substituents are independently selected from cyano, acetyl, or optionally substituted amino, wherein up to two amino substituents are independently selected from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, acetyl, or sulfonamide);

R_3 can be optionally substituted C_1-C_6 alkyl or C_3-C_6 cycloalkyl (wherein substituents are independently selected from halogens, hydroxyl, C_1-C_3 alkoxy and protected hydroxyl);


R_3 can also be $-NR_4R_5$, wherein R_4 and R_5 are optionally substituted C_1-C_6 alkyl (wherein the optional substituent(s) is/are selected from halogens, hydroxy, C_1-C_3 alkoxy and protected hydroxyl);

26 R_4 can be

27

28

29



30 wherein R_5 and R_6 are independently hydrogen, C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl,
 31 optionally substituted aryl or aralkyl, wherein the substituents are selected from
 32 halogens, cyano, optionally substituted C_1 - C_6 alkyl (wherein up to two substituents
 33 are independently selected from hydroxyl, protected hydroxyl, and halogen(s)),
 34 optionally substituted amino (wherein up to two substituents are independently
 35 selected from SO_2R_7 , COR_7 , or $CONHR_7$, wherein R_7 is C_1 - C_6 alkyl or aryl), or
 36 acetyl, trifluoromethyl, or C_1 - C_6 alkoxycarbonyl, or R_5 and R_6 together form a 5-7
 37 membered ring with one or more optional heteroatoms wherein the hetero atom(s)
 38 are independently selected from nitrogen, oxygen and sulfur,


39 or R_4 can be an optionally substituted mono-, bi- or tricyclic heterocycle having
 40 one or more hetero atom(s) wherein said hetero atom(s) is/are independently
 41 selected from oxygen, nitrogen and sulfur, and the optional substituents are
 42 independently selected from halogens, hydroxy, protected hydroxyl, C_1 - C_3 alkoxy,
 43 cyano, C_1 - C_3 perfluoroalkyl, C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl, aryl or optionally
 44 substituted aralkyl wherein the substituents are independently selected from
 45 halogens, hydroxy, protected hydroxyl, C_1 - C_3 alkoxy, cyano, or C_1 - C_3
 46 perfluoroalkyl,

47 and the pharmaceutically acceptable salts, tautomers, racemates, pure enantiomers
 48 or diastereoisomers, and solvates of the compounds of Formula I,

49 with the proviso that R_4 is phenyl only when (1) R_5 or R_6 is C_3 - C_6 cycloalkyl or
 50 phenyl substituted with acetyl, alkyl, cycloalkyl, hydroxyalkyl, alkylsulfonamido,
 51 acetamido or (2) when R_5 and R_6 together form a 5-7 membered ring with or
 52 without one or more heteroatoms wherein the hetero atom(s) are selected from
 53 nitrogen, oxygen and sulfur or (3) when R_5 or R_6 is aralkyl optionally substituted
 54 with halogens, cyano, C_1 - C_6 alkyl, C_1 - C_6 halogenated alkyl or (4) when R_4 is
 55 optionally substituted mono-, bi- or tricyclic heterocycle having one or more hetero
 56 atom(s) (wherein the optional substituents are independently selected from


57 halogens, hydroxy, protected hydroxyl, C₁-C₃ alkoxy, cyano, perfluoroalkyl of one
 58 to three carbon atoms, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, aryl, or optionally substituted
 59 aralkyl (wherein the aralkyl substituents are independently selected from halogens
 60 hydroxy, protected hydroxyl, C₁-C₃ alkoxy, cyano, or C₁-C₃ perfluoroalkyl)).

1 2. A compound having the structure of Formula Ib,



Formula Ib

6 its pharmaceutically acceptable salts, pharmaceutically acceptable solvates,
 7 tautomers, racemates, polymorphs, pure enantiomers, diastereoisomers,
 8 metabolites, prodrugs or N-oxides wherein



11 R₁ is C₁-C₆ alkyl, C₃-C₆ cycloalkyl, or optionally substituted phenyl (wherein the
 12 substituent(s) is/are selected from halogens, C₁-C₆ alkyl, cyano and C₁-C₃
 13 perfluoroalkyl);

14 R₂ is optionally substituted phenyl (wherein the substituent(s) is/are selected from
 15 cyano, acetyl and optionally substituted amino;

16 R₃ is optionally substituted C₁-C₆ alkyl or C₃-C₆ cycloalkyl (wherein the
 17 substituent(s) is/are selected from halogens, hydroxyl, C₁-C₃ alkoxy, and protected
 18 hydroxyl); R₃ can also be -NR₆R₇ wherein R₆ and R₇ are optionally substituted C₁-
 19 C₆ alkyl (wherein the optional substituent(s) is/are selected from halogens,
 20 hydroxyl, C₁-C₃ alkoxy, and protected hydroxyl);

21 R₄ is NHR₈ [wherein R₈ is selected from aralkyl, CONHR₉ (wherein R₉ is aralkyl),
 22 CSNHR₉ (wherein R₉ is C₁-C₆ alkyl, aryl or aralkyl)]; -COR₁₀ (wherein R₁₀ is
 23 selected from hydroxyl and -NR₁₁R₁₂ (wherein R₁₁ and R₁₂ are independently
 24 selected from hydrogen, alkyl, aryl, C₃-C₇ cycloalkyl, aralkyl and R₁₁ and R₁₂

25 together form 5-7 membered ring with one or more optional heteroatom(s) wherein
 26 the heteroatom(s) is/are independently selected from nitrogen, oxygen and
 27 sulphur); and

28 R₅ is hydrogen, C₁-C₆ alkyl or C₃-C₆ cycloalkyl, optionally substituted aryl or
 29 aralkyl [wherein the substituents are selected from halogens, cyano, optionally
 30 substituted C₁-C₆ alkyl (wherein the substituents are independently selected from
 31 hydroxyl, protected hydroxyl, and halogen(s)), optionally substituted amino,
 32 acetyl, trifluoromethyl and C₁-C₆ alkoxy carbonyl.

1 3. A compound according to claim 1 wherein R₁ is phenyl substituted with one or
 2 more halogens.

1 4. A compound according to claim 1 wherein R₁ is phenyl substituted with one or
 2 more fluorine atoms.

1 5. A compound according to claim 1 wherein R₁ is 4-fluorophenyl.

1 6. A compound according to claim 1 wherein R₂ is phenyl, R₅ and R₆ are
 2 respectively, hydrogen and phenyl substituted with acetyl.

1 7. A compound according to claim 1 wherein R₆ is 2-acetylphenyl.

1 8. A compound according to claim 1 wherein R₆ is 3-acetylphenyl.

1 9. A compound according to claim 1 wherein R₆ is 4-acetylphenyl.

1 10. A compound according to claim 1 wherein R₂ is phenyl, R₅ and R₆ are
 2 respectively, hydrogen and phenyl substituted with one or more alkyl of from one
 3 to six carbon atoms.

1 11. A compound according to claim 1 wherein R₆ is 2,4-dimethylphenyl.

1 12. A compound according to claim 1 wherein R₂ is phenyl, R₅ and R₆ are
 2 respectively, hydrogen and cycloalkyl of from three to six carbon atoms.

1 13. A compound according to claim 1 wherein R₆ is cyclohexyl.

1 14. A compound according to claim 1 wherein R₂ is phenyl, R₅ and R₆ are
 2 respectively, hydrogen and benzyl substituted with halogenated alkyl of from one
 3 to six carbon atoms.

1 15. A compound according to claim 1 wherein R₆ is 4-trifluoromethyl benzyl.


- 1 16. A compound according to claim 1 wherein R₂ is phenyl, R₅ and R₆ together form
2 5-7 membered ring with or without one or more heteroatoms wherein heteroatoms
3 are selected from the group consisting of nitrogen, oxygen and sulphur.
- 1 17. A compound of claim 1 wherein R₅ and R₆ together form piperidine.
- 1 18. A compound according to claim 1 wherein R₅ and R₆ together form morpholine.
- 1 19. A compound according to claim 1 wherein R₂ is phenyl, R₅ and R₆ are
2 respectively, hydrogen and phenyl substituted with hydroxylated alkyl of from one
3 or six carbon atoms.
- 1 20. A compound according to claim 1 wherein R₆ is 4-hydroxymethyl phenyl.
- 1 21. A compound according to claim 1 wherein R₂ is phenyl, R₅ and R₆ are
2 respectively, hydrogen and 4-(methylsulfonamido)phenyl.
- 1 22. A compound according to claim 1 wherein R₂ is phenyl, R₅ and R₆ are
2 respectively, hydrogen and 4-(acetamido)phenyl.
- 1 23. A compound according to claim 1 wherein R₂ is phenyl and R₄ is 1,2,4-oxadiazinyl
2 phenyl.
- 1 24. A compound according to claim 1 wherein R₂ is phenyl and R₄ is 1,2,4-
2 triazolylphenyl.
- 1 25. A compound according to claim 1 wherein R₂ is 4-cyanophenyl, R₅ and R₆ are
2 respectively, hydrogen and phenyl.

82


1 26. A compound according to claim 1 wherein R_3 is alkyl of from one to six or cycloalkyl
2 of from three to six carbon atoms.

1 27. A compound according to claim 1 wherein R_3 is isopropyl.

1 28. A compound having the structure of Formula Ib,



6 its pharmaceutically acceptable salts, pharmaceutically acceptable solvates,
7 tautomers, racemates, polymorphs, pure enantiomers, diastereoisomers, metabolites,
8 prodrugs or N-oxides wherein



12 R_1 , R_2 , R_3 and R_5 can be 4-fluorophenyl, phenyl, isopropyl and hydrogen,
13 respectively;

14 R_4 is C_1 - C_2 alkoxycarbonyl, optionally substituted C_1 - C_6 alkyl (wherein the
15 substituent is hydroxy or protected hydroxyl), NHR_8 [wherein R_8 is selected from
16 SO_2R_9 , COR_9 or $CONHR_9$ (wherein R_9 is methyl or phenyl)].

1 29. The compound according to claim 2, wherein R_1 is phenyl substituted with one or
2 more halogen.

1 30. The compound according to claim 29, wherein R_1 is phenyl substituted with one or
2 more fluorine.

1 31. The compound according to claim 30, wherein R_1 is 4-fluorophenyl.

85

- 1 32. The compound according to claim 28, wherein R₂ and R₃ are phenyl and hydrogen,
2 respectively.
- 1 33. The compound according to claim 2, wherein R₃ is C₁-C₆ alkyl.
- 1 34. The compound according to claim 33, wherein R₃ is isopropyl.
- 1 35. The compound according to claim 2, wherein R₄ is -COR₁₀ wherein R₁₀ is hydroxy.
- 1 36. The compound according to claim 2, wherein R₄ is -COR₁₀ wherein R₁₀ is NR₁₁R₁₂
2 (wherein R₁₁ and R₁₂ together form 5-7 membered ring with one or more optional
3 heteroatom(s) wherein the heteroatom(s) is/are independently selected from nitrogen,
4 oxygen and sulphur).
- 1 37. The compound according to claim 2, wherein R₄ is -COR₁₀ wherein R₁₀ is NR₁₁R₁₂
2 wherein R₁₁ and R₁₂ together form morpholinyl.
- 1 38. The compound according to claim 2, wherein R₄ is -COR₁₀ wherein R₁₀ is NR₁₁R₁₂
2 wherein R₁₁ and R₁₂ together form piperidinyl.
- 1 39. The compound according to claim 2, wherein R₄ is -COR₁₀ wherein R₁₀ is NR₁₁R₁₂
2 wherein R₁₁ and R₁₂ are respectively, hydrogen and C₁-C₁₀ alkyl.
- 1 40. The compound according to claim 39, wherein R₄ is -COR₁₀ wherein R₁₀ is NR₁₁R₁₂
2 wherein R₁₁ and R₁₂ are respectively, hydrogen and methyl.
- 1 41. The compound according to claim 2, wherein R₄ is -COR₁₀ wherein R₁₀ is NR₁₁R₁₂
2 wherein R₁₁ and R₁₂ are respectively, hydrogen and aryl.
- 1 42. The compound according to claim 41, wherein R₄ is -COR₁₀ wherein R₁₀ is NR₁₁R₁₂
2 wherein R₁₁ and R₁₂ are respectively, hydrogen and phenyl.
- 1 43. The compound according to claim 2, wherein R₄ is -COR₁₀ wherein R₁₀ is NR₁₁R₁₂
2 wherein R₁₁ and R₁₂ are respectively, hydrogen and aralkyl.
- 1 44. The compound according to claim 43, wherein R₄ is -COR₁₀ wherein R₁₀ is NR₁₁R₁₂
2 wherein R₁₁ and R₁₂ are respectively, hydrogen and benzyl.
- 1 45. The compound according to claim 2, wherein R₄ is -COR₁₀ wherein R₁₀ is NR₁₁R₁₂
2 wherein R₁₁ and R₁₂ are respectively, hydrogen and C₃-C₇ cycloalkyl.

- 1 46. The compound according to claim 45, wherein R_4 is $-\text{COR}_{10}$ wherein R_{10} is $\text{NR}_{11}\text{R}_{12}$
2 wherein R_{11} and R_{12} are respectively, hydrogen and cyclohexyl.
- 1 47. The compound according to claim 2, wherein R_4 is NHR_8 wherein R_8 is aralkyl.
- 1 48. The compound according to claim 47, wherein R_4 is NHR_8 wherein R_8 is benzyl.
- 1 49. The compound according to claim 2, wherein R_4 is NHR_8 wherein R_8 is CONHR_9
2 wherein R_9 is aralkyl.
- 1 50. The compound according to claim 49, wherein R_4 is NHR_8 wherein R_8 is CONHR_9
2 wherein R_9 is benzyl.
- 1 51. The compound according to claim 2, wherein R_4 is NHR_8 wherein R_8 is CSNHR_9
2 wherein R_9 is selected from $\text{C}_1\text{-C}_6$ alkyl, aryl and aralkyl.
- 1 52. The compound according to claim 51, wherein R_4 is NHR_8 wherein R_8 is CSNHR_9
2 wherein R_9 is selected from methyl, phenyl and benzyl.
- 1 53. The compound according to claim 28, wherein R_4 is $\text{C}_1\text{-C}_2$ alkoxy carbonyl.
- 1 54. The compound according to claim 53, wherein R_4 is methoxy carbonyl.
- 1 55. The compound according to claim 53, wherein R_4 is ethoxy carbonyl.
- 1 56. The compound according to claim 28, wherein R_4 is optionally substituted $\text{C}_1\text{-C}_6$ alkyl
2 wherein optional substituent is hydroxy.
- 1 57. The compound according to claim 56, wherein R_4 is 1-hydroxyethyl.
- 1 58. The compound according to claim 56, wherein R_4 is 2-hydroxyethyl.
- 1 59. The compound according to claim 56, wherein R_4 is 3-hydroxypropyl.
- 1 60. The compound according to claim 28, wherein R_4 is NHR_8 wherein R_8 is selected
2 from COCH_3 , COPh , SO_2CH_3 , SO_2Ph , CONHCH_3 and CONHPh .
- 1 61. The compound according to claim 28, wherein R_4 is optionally substituted $\text{C}_1\text{-C}_6$ alkyl
2 wherein optional substituent is protected hydroxyl selected from the group consisting
3 of $-\text{OCH}_3$, $-\text{OC}_2\text{H}_5$, $-\text{O-n-propyl}$, $-\text{O-i-propyl}$, $-\text{O-cyclopropyl}$, $-\text{O-CH}_2\text{OCH}_3$, $-\text{O-}$
4 cyclopentyl , $-\text{O-cyclohexyl}$, $-\text{O-benzyl}$, $-\text{O-chlorobenzyl}$, $-\text{O-methoxybenzyl}$, $-\text{O-}$
5 phenyl , $-\text{O-chlorophenyl}$, $-\text{O-COCH}_3$, $-\text{O-COC}_2\text{H}_5$, $-\text{O-CO-benzyl}$, $-\text{O-CO-phenyl}$, $-\text{O-}$

6 CO-pyridinyl, -O-CONH-phenyl, -O-CONH-octyl, -O-CONH-pyridinyl and -O-
7 CSNH-phenyl.

1 62. A compound, which is:

2 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(2-acetylphenylamino)
3 carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 1),

4 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(3-acetylphenylamino)
5 carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 2),

6 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-acetylphenylamino)
7 carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 3),

8 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(2,4-dimethylphenylamino)
9 carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 4),

10 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(cyclohexylamino)
11 carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 5),

12 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-
13 trifluoromethylbenzylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid
14 (Compound No. 6),

15 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(morpholine-4-carbonyl)-
16 pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 7),

17 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(piperidine-1-carbonyl)-
18 pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 8),

19 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-
20 hydroxymethylphenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid
21 (Compound No. 11),

22 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-
23 methanesulfonylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic
24 acid (Compound No. 12),

25 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-acetylaminophenylamino)
26 carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 13),

27 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-(4-cyanophenyl)-4-[(phenylamino)
28 carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 14),

29 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-carboxyphenylamino]
30 carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 1a),

31 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-
32 acetoxymethylphenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid
33 (Compound No. 2a),

34 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-
35 phenylthiocarbamoyloxymethylphenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-
36 heptanoic acid (Compound No. 3a),

- 37 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-
38 propionyloxymethylphenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic
39 acid (Compound No. 4a),
40 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-octylcarbamoyloxymethyl
41 phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
42 5a),
43 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-phenylacetoxymethyl
44 phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
45 6a),
46 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-
47 phenylcarbamoyloxymethyl phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-
48 heptanoic acid (Compound No. 7a),
49 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-benzoyloxymethyl
50 phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
51 8a),
52 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-isonicotinoyloxymethyl
53 phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
54 9a),
55 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-pyridin-4-
56 ylcarmoyloxymethyl phenyl) amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-
57 heptanoic acid (Compound No. 10a),
58 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-phenylcarbamoyl
59 phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
60 11a),
61 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-cyclohexylcarbamoyl-
62 phenyl) amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
63 12a),
64 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-methylcarbamoyl]-
65 phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
66 13a),
67 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-benzylcarbamoyl]-
68 phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
69 14a),
70 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(morpholine-4-carbonyl)-
71 phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
72 15),
73 (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(piperidine-1-carbonyl)-
74 phenyl)amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
75 16),

87

- 76 (3R, 5R)-7-[2-(4-fluorophenyl)-5- isopropyl-3-phenyl-4-[4-benzylamino
77 phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
78 17),
- 79 (3R,5R)-7-[2-(4-fluorophenyl)-5- isopropyl-3-phenyl-4-[4-(1-
80 hydroxyethyl)phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid
81 (Compound No. 18),
- 82 (3R,5R)-7-[2-(4-fluorophenyl)-5- isopropyl-3-phenyl-4-[4-(2-hydroxyethyl)
83 phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
84 19),
- 85 (3R,5R)-7-[2-(4-fluorophenyl)-5- isopropyl-3-phenyl-4-[4-(3-hydroxypropyl
86 phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
87 20),
- 88 (3R,5R)-7-[2-(4-fluorophenyl)-5- isopropyl-3-phenyl-4-[(4-methoxymethyl
89 phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
90 21),
- 91 (3R,5R)-7-[2-(4-fluorophenyl)-5- isopropyl-3-phenyl-4-[(4-ethoxymethyl
92 phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
93 22),
- 94 (3R,5R)-7-[2-(4-fluorophenyl)-5- isopropyl-3-phenyl-4-[(4-isopropoxymethyl
95 phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
96 23),
- 97 (3R,5R)-7-[2-(4-fluorophenyl)-5- isopropyl-3-phenyl-4-[(4-propoxymethyl
98 phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
99 24),
- 100 (3R,5R)-7-[2-(4-fluorophenyl)-5- isopropyl-3-phenyl-4-[(4-
101 methoxymethoxymethylphenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic
102 acid (Compound No. 25),
- 103 (3R,5R)-7-[2-(4-fluorophenyl)-5- isopropyl-3-phenyl-4-[(4-cyclohexyloxymethyl
104 phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
105 26),
- 106 (3R,5R)-7-[2-(4-fluorophenyl)-5- isopropyl-3-phenyl-4-[(4-cyclopentyloxymethyl
107 phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
108 27),
- 109 (3R,5R)-7-[2-(4-fluorophenyl)-5- isopropyl-3-phenyl-4-[(4-benzyloxymethyl
110 phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
111 28),
- 112 (3R,5R)-7-[2-(4-fluorophenyl)-5- isopropyl-3-phenyl-4-[(4-chlorobenzyloxymethyl
113 phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
114 29),

- 115 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-methoxybenzyloxymethyl
116 phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
117 30),
- 118 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-
119 phenoxymethylphenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid
120 (Compound No. 31),
- 121 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-chlorophenoxymethyl
122 phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
123 32),
- 124 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-acetylamino)phenylamino]
125 carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No. 33),
- 126 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-benzoylamino
127 phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
128 34),
- 129 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-benzenesulfonylamino
130 phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
131 36)
- 132 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(3-phenyl-ureido)-
133 phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
134 37),
- 135 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(3-methyl-ureido)-
136 phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
137 38),
- 138 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(3-benzyl-ureido)-
139 phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
140 39),
- 141 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(3-benzyl-thioureido)-
142 phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
143 40),
- 144 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(3-phenyl-thioureido)-
145 phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
146 41),
- 147 (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[4-(3-methyl-thioureido)-
148 phenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid (Compound No.
149 42),
- 150 and their lactone forms, pharmaceutically acceptable solvates, pharmaceutically
151 acceptable salts, tautomers, racemates, pure enantiomers, diastereoisomers,
152 metabolites, prodrugs, polymorphs, or N-oxides.

- 1 63. A pharmaceutically acceptable salt of a compound of claim 1, wherein the salt is
2 selected from lithium, sodium, potassium, calcium, magnesium, zinc, aluminium,
3 amino acid, ammonium, mono-alkyl ammonium, dialkyl ammonium, trialkyl
4 ammonium and N-methyl glucamine.
- 1 64. The pharmaceutically acceptable salt of claim 63, wherein the salt is sodium salt.
- 1 65. The pharmaceutically acceptable salt of claim 63, wherein the salt is potassium salt.
- 1 66. The pharmaceutically acceptable salt of claim 63, wherein the salt is hemicalcium salt.
- 1 67. The pharmaceutically acceptable salt of claim 63, wherein the salt is hemimagnesium
2 salt.
- 1 68. The pharmaceutically acceptable salt of claim 63, wherein the salt is hemizinc salt.
- 1 69. The pharmaceutically acceptable salt of claim 63, wherein the salt is N-methyl
2 glucamine salt.
- 1 70. A pharmaceutical composition comprising a therapeutically effective amount of a
2 compound of claim 1 together with a pharmaceutically acceptable carrier, excipient or
3 diluent.
- 1 71. A method for treating or preventing a mammal suffering from cholesterol-related
2 disease, diabetes and related disease, cerebrovascular disease or cardiovascular
3 disease, comprising administering to the said mammal, a therapeutically effective
4 amount of a compound of claim 1.
- 1 72. A method for treating or preventing a mammal suffering from cholesterol-related
2 disease, diabetes and related disease, cerebrovascular disease or cardiovascular
3 disease, comprising administering to the said mammal, a therapeutically effective
4 amount of a composition according to claim 70.
- 1 73. The method according to claim 72, wherein the disease is selected from the group
2 comprising of arteriosclerosis, atherosclerosis, hyperlipidemia, hyperlipoproteinemia,
3 hypercholesterolemia, hypertriglyceridemia, hypertension, stroke, ischemia,
4 endothellium dysfunctions, peripheral vascular disease, peripheral arterial disease,
5 coronary heart disease, myocardial infarction, cerebral infarction, myocardial

microvascular disease, dementia, Alzheimer's disease, osteoporosis and/or osteopenia, angina or restenosis.

74. The method according to claim 73 wherein the disease is hyperlipidemia.


75. The method according to claim 73 wherein the disease is hypercholesterolemia.

76. The method according to claim 73 wherein the disease is hyperlipoproteinemia.

77. The method according to claim 73 wherein the disease is hypertriglyceridemia.

78. The method according to claim 73 wherein the disease is hypertension.

79. A process for the preparation of compound of Formula XIb,



their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, tautomers, racemates, polymorphs, pure enantiomers, diastereoisomers, metabolites, prodrugs or N-oxides wherein

R₁ is C₁-C₆ alkyl, C₃-C₆ cycloalkyl, or optionally substituted phenyl (wherein the substituent(s) is/are selected from halogens, C₁-C₄ alkyl, cyano and C₁-C₃ perfluoroalkyl);

R₂ is optionally substituted phenyl (wherein the substituent(s) is/are selected from cyano, acetyl and optionally substituted amino;


R₃ is optionally substituted C₁-C₆ alkyl or C₃-C₆ cycloalkyl (wherein the substituent(s) is/are selected from halogens, hydroxyl, C₁-C₃ alkoxy, and protected hydroxyl); R₃ can also be -NR₆R₇ wherein R₆ and R₇ are optionally substituted C₁-C₆ alkyl (wherein the optional substituent(s) is/are selected from halogens, hydroxyl, C₁-C₃ alkoxy, and protected hydroxyl);

20 R_4 is acetyl, C_1 - C_2 alkoxy carbonyl, optionally substituted C_1 - C_6 alkyl (wherein the
21 substituent is hydroxy or protected hydroxyl), NHR_8 [wherein R_8 is selected from
22 alkyl, aralkyl, SO_2R_9 , COR_9 or $CONHR_9$, $CSNHR_9$ (wherein R_9 is C_1 - C_6 alkyl, aryl or
23 aralkyl)]; R_4 can also be $-COR_{10}$ (wherein R_{10} is selected from hydroxyl and $-$
24 $NR_{11}R_{12}$ (wherein R_{11} and R_{12} are independently selected from hydrogen, alkyl, aryl,
25 C_3 - C_7 cycloalkyl, heterocyclyl, aralkyl and R_{11} and R_{12} together form 5-7 membered
26 ring with one or more optional heteroatom(s) wherein the heteroatom(s) is/are
27 independently selected from nitrogen, oxygen and sulphur); and


28 R_5 is hydrogen, C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl, optionally substituted aryl or aralkyl
29 [wherein the substituents are selected from halogens, cyano, optionally substituted C_1 -
30 C_6 alkyl (wherein the substituents are independently selected from hydroxyl, protected
31 hydroxyl, and halogen(s)), optionally substituted amino, acetyl, trifluoromethyl and
32 C_1 - C_6 alkoxy carbonyl,

33 comprising:

34 reacting a compound of Formula II with a compound of Formula IIIb to give a
35 compound of Formula IVb;




40 treating the compound of Formula IVb with an aldehyde of Formula V to give a
41 compound of Formula VIb;



44 treating the compound of Formula VIb with an aldehyde of Formula VII to give a
45 compound of Formula VIIIb;




50 treating the compound of Formula VIIIb with a compound of Formula IX to give a
51 compound of Formula Xb; and



57 hydrolysing the compound of Formula Xb to give a compound of Formula XIb.

1 80. A process for the preparation of compound of Formula XVa,



8 its lactone forms, its pharmaceutically acceptable salts, pharmaceutically acceptable
9 solvates, tautomers, racemates, polymorphs, pure enantiomers, diastereoisomers,
10 metabolites, prodrugs or N-oxides wherein

25

94

R_1 is C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, or optionally substituted phenyl (wherein up to three substituents are independently selected from halogens, C_1 - C_6 alkyl, cyano and C_1 - C_3 perfluoroalkyl);


R_2 is optionally substituted phenyl (wherein up to three substituents are independently selected from cyano, acetyl, or optionally substituted amino, wherein up to two amino substituents are independently selected from C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, acetyl, or sulfonamide); and

R_3 is optionally substituted C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl (wherein the substituents are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and protected hydroxyl); or

R_3 is $-NR_6R_7$ wherein R_6 and R_7 are optionally substituted C_1 - C_6 alkyl (wherein the optional substituent(s) is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and protected hydroxyl);

comprising:

hydrolyzing a compound of Formula XIIIa




Formula Xa wherein $R_5=H$ and $R_4=-COOCH_3$

to give a compound of Formula XIVa, which on further hydrolysis gives a compound of Formula XVa.

CCT

1 81. A process for the preparation of compound of Formula XIa,



7 their pharmaceutically acceptable salts, pharmaceutically acceptable solvates,

8 tautomers, racemates, polymorphs, pure enantiomers, diastereoisomers, metabolites,

9 prodrugs or N-oxides wherein

10 R_1 is C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, or optionally substituted phenyl (wherein the

11 substituent(s) is/are selected from halogens, C_1 - C_6 alkyl, cyano and C_1 - C_3

12 perfluoroalkyl);

13 R_2 is optionally substituted phenyl (wherein the substituent(s) is/are selected from

14 cyano, acetyl and optionally substituted amino;

15 R_3 is optionally substituted C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl (wherein the substituent(s)

16 is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and protected hydroxyl); R_3

17 can also be $-NR_6R_7$ wherein R_6 and R_7 are optionally substituted C_1 - C_6 alkyl (wherein

18 the optional substituent(s) is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and

19 protected hydroxyl);

20 R_4 is acetyl, C_1 - C_2 alkoxy carbonyl, optionally substituted C_1 - C_6 alkyl (wherein the

21 substituent is hydroxy or protected hydroxyl), NHR_8 [wherein R_8 is selected from

22 alkyl, aralkyl, SO_2R_9 , COR_9 or $CONHR_9$, $CSNHR_9$ (wherein R_9 is C_1 - C_6 alkyl, aryl or

23 aralkyl)]; R_4 can also be $-COR_{10}$ (wherein R_{10} is selected from hydroxyl and $-$

24 $NR_{11}R_{12}$ (wherein R_{11} and R_{12} are independently selected from hydrogen, alkyl, aryl,

25 C_3 - C_7 cycloalkyl, heterocyclyl, aralkyl and R_{11} and R_{12} together form 5-7 membered

26 ring with one or more optional heteroatom(s) wherein the heteroatom(s) is/are


27 independently selected from nitrogen, oxygen and sulphur); and

R_3 is hydrogen, C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl, optionally substituted aryl or aralkyl [wherein the substituents are selected from halogens, cyano, optionally substituted C_1 - C_6 alkyl (wherein the substituents are independently selected from hydroxyl, protected hydroxyl, and halogen(s)), optionally substituted amino, acetyl, trifluoromethyl and C_1 - C_6 alkoxy carbonyl, comprising:


reacting a compound of Formula XVIII with a compound of Formula V to give a compound of Formula XIX;



reacting the compound of Formula XIX with a compound of Formula VII to give a compound of Formula XX;




treating the compound of Formula XX with a compound of Formula IX to yield a compound of Formula XXI;



Handwritten signature or mark.

97


debenzylating the compound of Formula XXI to give a compound of Formula XXII;



Formula XXII

converting the compound of Formula XXII to the corresponding acid chloride;


reacting the acid chloride form of the compound of Formula XXII with an amine of Formula IIIa to give a compound of Formula Xa; and



Formula Xa

hydrolyzing the compound of Formula Xa to give a compound of Formula XIa.

82. A compound having the structure of Formula XIX,



Formula XIX

wherein


R_2 is optionally substituted phenyl (wherein the substituent(s) is/are selected from cyano, acetyl and optionally substituted amino; and

R_3 is optionally substituted C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl (wherein the substituent(s) is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and protected hydroxyl); R_3 can also be $-\text{NR}_6\text{R}_7$ wherein R_6 and R_7 are optionally substituted C_1 - C_6 alkyl (wherein

97

the optional substituent(s) is/are selected from halogens, hydroxyl, C₁-C₃ alkoxy, and protected hydroxyl).

83. A compound having the structure of Formula XX,



Formula XX


wherein

R₁ is C₁-C₆ alkyl, C₃-C₆ cycloalkyl, or optionally substituted phenyl (wherein the substituent(s) is/are selected from halogens, C₁-C₆ alkyl, cyano and C₁-C₃ perfluoroalkyl);

R₂ is optionally substituted phenyl (wherein the substituent(s) is/are selected from cyano, acetyl and optionally substituted amino; and

R₃ is optionally substituted C₁-C₆ alkyl or C₃-C₆ cycloalkyl (wherein the substituent(s) is/are selected from halogens, hydroxyl, C₁-C₃ alkoxy, and protected hydroxyl); R₃ can also be -NR₆R₇ wherein R₆ and R₇ are optionally substituted C₁-C₆ alkyl (wherein the optional substituent(s) is/are selected from halogens, hydroxyl, C₁-C₃ alkoxy, and protected hydroxyl).

84. A compound having the structure of Formula XXI,




Formula XXI

wherein

R₁ is C₁-C₆ alkyl, C₃-C₆ cycloalkyl, or optionally substituted phenyl (wherein the substituent(s) is/are selected from halogens, C₁-C₆ alkyl, cyano and C₁-C₃ perfluoroalkyl);

- 10 R_2 is optionally substituted phenyl (wherein the substituent(s) is/are selected from
 11 cyano, acetyl and optionally substituted amino; and
 12 R_3 is optionally substituted C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl (wherein the substituent(s)
 13 is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and protected hydroxyl); R_3
 14 can also be $-NR_6R_7$ wherein R_6 and R_7 are optionally substituted C_1 - C_6 alkyl (wherein
 15 the optional substituent(s) is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and
 16 protected hydroxyl).

- 1 85. A compound having the structure of Formula XXII,




- 7 wherein
 8 R_1 is C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, or optionally substituted phenyl (wherein the
 9 substituent(s) is/are selected from halogens, C_1 - C_6 alkyl, cyano and C_1 - C_3
 10 perfluoroalkyl);
 11 R_2 is optionally substituted phenyl (wherein the substituent(s) is/are selected from
 12 cyano, acetyl and optionally substituted amino; and
 13 R_3 is optionally substituted C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl (wherein the substituent(s)
 14 is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and protected hydroxyl); R_3
 15 can also be $-NR_6R_7$ wherein R_6 and R_7 are optionally substituted C_1 - C_6 alkyl (wherein
 16 the optional substituent(s) is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and
 17 protected hydroxyl).

1 86. A process for the preparation of a compound of Formula XIX,

2

3

4



Formula XIX

5

wherein

6

R_1 is optionally substituted phenyl (wherein the substituent(s) is/are selected from cyano, acetyl and optionally substituted amino; and

7

8

R_3 is optionally substituted C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl (wherein the substituent(s) is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and protected hydroxyl); R_3 can also be $-NR_6R_7$ wherein R_6 and R_7 are optionally substituted C_1 - C_6 alkyl (wherein the optional substituent(s) is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and protected hydroxyl),

9

10

11

12

13


comprising:

14

reacting a compound of Formula XVIII with a compound of Formula V;

15

16



Formula XVIII

17

18

R_2CHO
Formula V

19

to give a compound of Formula XIX (wherein R_2 and R_3 are as defined).

1

87. A process for the preparation of a compound of Formula XX,


2

3

4

5

6



Formula XX

wherein

R_1 is C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, or optionally substituted phenyl (wherein the substituent(s) is/are selected from halogens, C_1 - C_6 alkyl, cyano and C_1 - C_3 perfluoroalkyl);


R_2 is optionally substituted phenyl (wherein the substituent(s) is/are selected from cyano, acetyl and optionally substituted amino; and

R_3 is optionally substituted C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl (wherein the substituent(s) is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and protected hydroxyl); R_3 can also be $-NR_6R_7$ wherein R_6 and R_7 are optionally substituted C_1 - C_6 alkyl (wherein the optional substituent(s) is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and protected hydroxyl),

comprising:

reacting a compound of Formula XIX with a compound of Formula VII


R_1CHO
Formula VII



Formula XIX

to give a compound of Formula XX.

88. A process for the preparation of a compound of Formula XXI,



Formula XXI

wherein



R_1 is C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, or optionally substituted phenyl (wherein the substituent(s) is/are selected from halogens, C_1 - C_6 alkyl, cyano and C_1 - C_3 perfluoroalkyl);

R_4 is optionally substituted phenyl (wherein the substituent(s) is/are selected from cyano, acetyl and optionally substituted amino; and

R_3 is optionally substituted C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl (wherein the substituent(s) is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and protected hydroxyl); R_3 can also be $-NR_6R_7$ wherein R_6 and R_7 are optionally substituted C_1 - C_6 alkyl (wherein the optional substituent(s) is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and protected hydroxyl),

comprising:

treating a compound of Formula XX with a compound of Formula IX



to yield a compound of Formula XXI.


KE

1 89. A process for the preparation of a compound of Formula XXII,

2

3

4



Formula XXII

5

wherein

6

R_1 is C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, or optionally substituted phenyl (wherein the substituent(s) is/are selected from halogens, C_1 - C_6 alkyl, cyano and C_1 - C_3 perfluoroalkyl);

7

8

R_2 is optionally substituted phenyl (wherein the substituent(s) is/are selected from cyano, acetyl and optionally substituted amino; and

9

10

R_3 is optionally substituted C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl (wherein the substituent(s) is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and protected hydroxyl); R_3 can also be $-NR_6R_7$ wherein R_6 and R_7 are optionally substituted C_1 - C_6 alkyl (wherein the optional substituent(s) is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and protected hydroxyl),

11

12


comprising:

13

debenzylating the compound of Formula XXI

14

15



Formula XXI


16

17


to give a compound of Formula XXII.

103

1 90. A process for the preparation of a compound of Formula XI,



6 Formula XI



8 its lactone forms, pharmaceutically acceptable salts, pharmaceutically acceptable
9 solvates, prodrugs, metabolites, polymorphs, tautomers, racemates, pure enantiomers,
10 diastereoisomers or N-oxides wherein


11 R_1 can be C_1 - C_6 , C_3 - C_6 , or optionally substituted phenyl (wherein up to three
12 substituents are independently selected from halogens, C_1 - C_6 alkyl, cyano, or C_1 - C_3
13 perfluoroalkyl);

14 R_2 can be optionally substituted phenyl (wherein up to three substituents are
15 independently selected from cyano, acetyl, or optionally substituted amino, wherein up
16 to two amino substituents are independently selected from C_1 - C_6 alkyl, C_3 - C_6
17 cycloalkyl, acetyl, or sulfonamide);

18 R_3 can be optionally substituted C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl (wherein substituents
19 are independently selected from halogens, hydroxyl, C_1 - C_3 alkoxy and protected
20 hydroxyl);

21 R_3 can also be $-NR_8R_9$, wherein R_8 and R_9 are optionally substituted C_1 - C_6 alkyl
22 (wherein the optional substituent(s) is/are selected from halogens, hydroxy, C_1 - C_3
23 alkoxy and protected hydroxyl);

24 R_4 can be




27 wherein R_5 and R_6 are independently hydrogen, C_1-C_6 alkyl or C_3-C_6 cycloalkyl,
28 optionally substituted aryl or aralkyl, wherein the substituents are selected from
29 halogens, cyano, optionally substituted C_1-C_6 alkyl (wherein up to two substituents are
30 independently selected from hydroxyl, protected hydroxyl, and halogen(s)), optionally
31 substituted amino (wherein up to two substituents are independently selected from
32 SO_2R_7 , COR_7 , or $CONHR_7$, wherein R_7 is C_1-C_6 alkyl or aryl), or acetyl,
33 trifluoromethyl, or C_1-C_6 alkoxy, or R_5 and R_6 together form a 5-7 membered
34 ring with one or more optional heteroatoms wherein the hetero atom(s) are
35 independently selected from nitrogen, oxygen and sulfur,
36 or R_4 can be an optionally substituted mono-, bi- or tricyclic heterocycle having one or
37 more hetero atom(s) wherein said hetero atom(s) is/are independently selected from
38 oxygen, nitrogen and sulfur, and the optional substituents are independently selected
39 from halogens, hydroxy, protected hydroxyl, C_1-C_3 alkoxy, cyano, C_1-C_3
40 perfluoroalkyl, C_1-C_6 alkyl or C_3-C_6 cycloalkyl, aryl or optionally substituted aralkyl
41 wherein the substituents are independently selected from halogens, hydroxy, protected
42 hydroxyl, C_1-C_3 alkoxy, cyano, or C_1-C_3 perfluoroalkyl,
43 and the pharmaceutically acceptable salts, tautomers, racemates, pure enantiomers or
44 diastereoisomers, and solvates of the compounds of Formula I,
45 with the proviso that R_2 is phenyl only when (1) R_5 or R_6 is C_3-C_6 cycloalkyl or
46 phenyl substituted with acetyl, alkyl, cycloalkyl, hydroxyalkyl, alkylsulfonamido,
47 acetamido or (2) when R_5 and R_6 together form a 5-7 membered ring with or without
48 one or more heteroatoms wherein the hetero atom(s) are selected from nitrogen,
49 oxygen and sulfur or (3) when R_5 or R_6 is aralkyl optionally substituted with halogens,
50 cyano, C_1-C_6 alkyl, C_1-C_6 halogenated alkyl or (4) when R_4 is optionally substituted
51 mono-, bi- or tricyclic heterocycle having one or more hetero atom(s) (wherein the
52 optional substituents are independently selected from halogens, hydroxy, protected
53 hydroxyl, C_1-C_3 alkoxy, cyano, perfluoroalkyl of one to three carbon atoms, C_1-C_6
54 alkyl, C_3-C_6 cycloalkyl, aryl, or optionally substituted aralkyl (wherein the aralkyl
55 substituents are independently selected from halogens, hydroxy, protected hydroxyl,
56 C_1-C_3 alkoxy, cyano, or C_1-C_3 perfluoroalkyl)).

57 comprising:


58 reacting a compound of Formula II with a compound of Formula III to give a
59 compound of Formula IV;




63 treating the compound of Formula IV with an aldehyde of Formula V to give a
64 compound of Formula VI;



69 treating the compound of Formula VI with an aldehyde of Formula VII to give a
70 compound of Formula VIII;




75 treating the compound of Formula VIII with a compound of Formula IX to give a
76 compound of Formula X; and



81 hydrolysing the compound of Formula X to give a compound of Formula XI.

106

91. A process for the preparation of compound of Formula XVI,



its lactone forms, pharmaceutically acceptable salt, pharmaceutically acceptable solvates, prodrugs, metabolites, polymorphs, tautomers, racemates, pure enantiomers, diastereoisomers or N-oxides wherein

R_1 can be C_1-C_6 , C_3-C_6 , or optionally substituted phenyl (wherein up to three substituents are independently selected from halogens, C_1-C_6 alkyl, cyano, or C_1-C_3 perfluoroalkyl);



R_2 can be optionally substituted phenyl (wherein up to three substituents are independently selected from cyano, acetyl, or optionally substituted amino, wherein up to two amino substituents are independently selected from C_1-C_6 alkyl, C_3-C_6 cycloalkyl, acetyl, or sulfonamide);

R_3 can be optionally substituted C_1-C_6 alkyl or C_3-C_6 cycloalkyl (wherein substituents are independently selected from halogens, hydroxyl, C_1-C_3 alkoxy and protected hydroxyl);

R_3 can also be $-NR_8R_9$, wherein R_8 and R_9 are optionally substituted C_1-C_6 alkyl (wherein the optional substituent(s) is/are selected from halogens, hydroxy, C_1-C_3 alkoxy and protected hydroxyl);


comprising:

25 hydrolysing a compound of Formula XIII to give a compound of Formula XIV;



36


37 reducing the compound of Formula XIV to give a compound of Formula XV; and



43 hydrolysing the compound of Formula XV to give a compound of Formula XVI.

44

1 92. A process for the preparation of compound of Formula XI,



5 Formula XI

6 Formula I wherein, $R_4 =$

7 $Y =$


8 its lactone forms, pharmaceutically acceptable salt, pharmaceutically acceptable
9 solvates, prodrugs, metabolites, polymorphs, tautomers, racemates, pure enantiomers,
10 diastereoisomers or N-oxides wherein

11 R_1 can be C_1-C_6 , C_3-C_6 , or optionally substituted phenyl (wherein up to three
12 substituents are independently selected from halogens, C_1-C_6 alkyl, cyano, or C_1-C_3
13 perfluoroalkyl);

14 R_2 can be optionally substituted phenyl (wherein up to three substituents are
15 independently selected from cyano, acetyl, or optionally substituted amino, wherein up
16 to two amino substituents are independently selected from C_1-C_6 alkyl, C_3-C_6
17 cycloalkyl, acetyl, or sulfonamide);

18 R_3 can be optionally substituted C_1-C_6 alkyl or C_3-C_6 cycloalkyl (wherein substituents
19 are independently selected from halogens, hydroxyl, C_1-C_3 alkoxy and protected
20 hydroxyl);

21 R_5 can also be $-NR_8R_9$, wherein R_8 and R_9 are optionally substituted C_1-C_6 alkyl
22 (wherein the optional substituent(s) is/are selected from halogens, hydroxy, C_1-C_3
23 alkoxy and protected hydroxyl);




26 wherein R₅ and R₆ are independently hydrogen, C₁-C₆ alkyl or C₃-C₆ cycloalkyl,
27 optionally substituted aryl or aralkyl, wherein the substituents are selected from
28 halogens, cyano, optionally substituted C₁-C₆ alkyl (wherein up to two substituents are
29 independently selected from hydroxyl, protected hydroxyl, and halogen(s)), optionally
30 substituted amino (wherein up to two substituents are independently selected from
31 SO₂R₇, COR₇, or CONHR₇, wherein R₇ is C₁-C₆ alkyl or aryl), or acetyl,
32 trifluoromethyl, or C₁-C₆ alkoxy, or R₅ and R₆ together form a 5-7 membered
33 ring with one or more optional heteroatoms wherein the hetero atom(s) are
34 independently selected from nitrogen, oxygen and sulfur,
35 or R₄ can be an optionally substituted mono-, bi- or tricyclic heterocycle having one or
36 more hetero atom(s) wherein said hetero atom(s) is/are independently selected from
37 oxygen, nitrogen and sulfur, and the optional substituents are independently selected
38 from halogens, hydroxy, protected hydroxyl, C₁-C₃ alkoxy, cyano, C₁-C₃
39 perfluoroalkyl, C₁-C₆ alkyl or C₃-C₆ cycloalkyl, aryl or optionally substituted aralkyl
40 wherein the substituents are independently selected from halogens, hydroxy, protected
41 hydroxyl, C₁-C₃ alkoxy, cyano, or C₁-C₃ perfluoroalkyl,
42 and the pharmaceutically acceptable salts, tautomers, racemates, pure enantiomers or
43 diastereoisomers, and solvates of the compounds of Formula I,
44 with the proviso that R₂ is phenyl only when (1) R₅ or R₆ is C₃-C₆ cycloalkyl or
45 phenyl substituted with acetyl, alkyl, cycloalkyl, hydroxyalkyl, alkylsulfonamido,
46 acetamido or (2) when R₅ and R₆ together form a 5-7 membered ring with or without
47 one or more heteroatoms wherein the hetero atom(s) are selected from nitrogen,
48 oxygen and sulfur or (3) when R₅ or R₆ is aralkyl optionally substituted with halogens,
49 cyano, C₁-C₆ alkyl, C₁-C₆ halogenated alkyl or (4) when R₄ is optionally substituted
50 mono-, bi- or tricyclic heterocycle having one or more hetero atom(s) (wherein the
51 optional substituents are independently selected from halogens, hydroxy, protected
52 hydroxyl, C₁-C₃ alkoxy, cyano, perfluoroalkyl of one to three carbon atoms, C₁-C₆
53 alkyl, C₃-C₆ cycloalkyl, aryl, or optionally substituted aralkyl (wherein the aralkyl
54 substituents are independently selected from halogens, hydroxy, protected hydroxyl,
55 C₁-C₃ alkoxy, cyano, or C₁-C₃ perfluoroalkyl)),

comprising:


reacting a compound of Formula XVIII with a compound of Formula V to give a compound of Formula XIX;




reacting the compound of Formula XIX with a compound of Formula VII to give a compound of Formula XX;




treating the compound of Formula XX with a compound of Formula IX to yield a compound of Formula XXI;



debenzylating the compound of Formula XXI to give a compound of Formula XXII;




80 converting the compound of Formula XXII to the corresponding acid chloride;
 81 reacting the acid chloride form of the compound of Formula XXII with an amine of
 82 Formula III to give a compound of Formula X; and



87 hydrolyzing the compound of Formula X to give a compound of Formula XI

1 93. A process for the preparation of compound of Formula XI,




2 its lactone forms, pharmaceutically acceptable salt, pharmaceutically acceptable
 3 solvates, tautomers, racemates, pure enantiomers, diastereoisomers or N-oxides
 4 wherein
 5 R_1 can be C_1-C_6 , C_3-C_6 , or optionally substituted phenyl (wherein up to three
 6 substituents are independently selected from halogens, C_1-C_6 alkyl, cyano, or C_1-C_3
 7 perfluoroalkyl);
 8 R_2 can be optionally substituted phenyl (wherein up to three substituents are
 9 independently selected from cyano, acetyl, or optionally substituted amino, wherein up
 10 to two amino substituents are independently selected from C_1-C_6 alkyl, C_3-C_6
 11 cycloalkyl, acetyl, or sulfonamide);

12 R_3 can be optionally substituted C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl (wherein substituents
13 are independently selected from halogens, hydroxyl, C_1 - C_3 alkoxy and protected
14 hydroxyl);

15 R_3 can also be $-NR_8R_9$, wherein R_8 and R_9 are optionally substituted C_1 - C_6 alkyl
16 (wherein the optional substituent(s) is/are selected from halogens, hydroxy, C_1 - C_3
17 alkoxy and protected hydroxyl);

18 R_4 can be



19
20
21 wherein R_5 and R_6 are independently hydrogen, C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl,
22 optionally substituted aryl or aralkyl, wherein the substituents are selected from
23 halogens, cyano, optionally substituted C_1 - C_6 alkyl (wherein up to two substituents are
24 independently selected from hydroxyl, protected hydroxyl, and halogen(s)), optionally
25 substituted amino (wherein up to two substituents are independently selected from
26 SO_2R_7 , COR_7 , or $CONHR_7$, wherein R_7 is C_1 - C_6 alkyl or aryl), or acetyl,
27 trifluoromethyl, or C_1 - C_6 alkoxy carbonyl, or R_5 and R_6 together form a 5-7 membered
28 ring with one or more optional heteroatoms wherein the hetero atom(s) are
29 independently selected from nitrogen, oxygen and sulfur,

30 or R_4 can be an optionally substituted mono-, bi- or tricyclic heterocycle having one or
31 more hetero atom(s) wherein said hetero atom(s) is/are independently selected from
32 oxygen, nitrogen and sulfur, and the optional substituents are independently selected
33 from halogens, hydroxy, protected hydroxyl, C_1 - C_3 alkoxy, cyano, C_1 - C_3
34 perfluoroalkyl, C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl, aryl or optionally substituted aralkyl
35 wherein the substituents are independently selected from halogens, hydroxy, protected
36 hydroxyl, C_1 - C_3 alkoxy, cyano, or C_1 - C_3 perfluoroalkyl,

37 and the pharmaceutically acceptable salts, tautomers, racemates, pure enantiomers or
38 diastereoisomers, and solvates of the compounds of Formula I,


39 with the proviso that R_4 is phenyl only when (1) R_3 or R_6 is C_3 - C_6 cycloalkyl or
40 phenyl substituted with acetyl, alkyl, cycloalkyl, hydroxyalkyl, alkylsulfonamido,

115


acetamido or (2) when R_5 and R_6 together form a 5-7 membered ring with or without one or more heteroatoms wherein the hetero atom(s) are selected from nitrogen, oxygen and sulfur or (3) when R_5 or R_6 is aralkyl optionally substituted with halogens, cyano, C_1 - C_6 alkyl, C_1 - C_6 halogenated alkyl or (4) when R_4 is optionally substituted mono-, bi- or tricyclic heterocycle having one or more hetero atom(s) (wherein the optional substituents are independently selected from halogens, hydroxy, protected hydroxyl, C_1 - C_3 alkoxy, cyano, perfluoroalkyl of one to three carbon atoms, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, aryl, or optionally substituted aralkyl (wherein the aralkyl substituents are independently selected from halogens, hydroxy, protected hydroxyl, C_1 - C_3 alkoxy, cyano, or C_1 - C_3 perfluoroalkyl)),

comprising:


reacting a compound of Formula XVIII with a compound of Formula V to give a compound of Formula XIX;




reacting the compound of Formula XIX with a compound of Formula VII to give a compound of Formula XX;




64 treating the compound of Formula XX with a compound of Formula IX to yield a
65 compound of Formula XXI;



71 debenzylating the compound of Formula XXI to give a compound of Formula XXII;




77 reacting the compound of Formula XXII with an amine of Formula III and a coupling
78 agent to give a compound of Formula X,



hydrolyzing the compound of Formula X to give a compound of Formula XI

HS

1 94. A process for the preparation of compound of Formula XIIb,



7 their pharmaceutically acceptable salts, pharmaceutically acceptable solvates,
8 tautomers, racemates, polymorphs, pure enantiomers, diastereoisomers, metabolites,
9 prodrugs or N-oxides wherein

10 R_1 is C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, or optionally substituted phenyl (wherein the
11 substituent(s) is/are selected from halogens, C_1 - C_4 alkyl, cyano and C_1 - C_3
12 perfluoroalkyl);

13 R_2 is optionally substituted phenyl (wherein the substituent(s) is/are selected from
14 cyano, acetyl and optionally substituted amino;


15 R_3 is optionally substituted C_1 - C_4 alkyl or C_3 - C_6 cycloalkyl (wherein the substituent(s)
16 is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and protected hydroxyl); R_3
17 can also be $-NR_6R_7$ wherein R_6 and R_7 are optionally substituted C_1 - C_4 alkyl (wherein
18 the optional substituent(s) is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and
19 protected hydroxyl);

20 R_4 is acetyl, C_1 - C_2 alkoxy carbonyl, optionally substituted C_1 - C_6 alkyl (wherein the
21 substituent is hydroxy or protected hydroxyl), NHR_8 [wherein R_8 is selected from
22 alkyl, aralkyl, SO_2R_9 , COR_9 or $CONHR_9$, $CSNHR_9$ (wherein R_9 is C_1 - C_6 alkyl, aryl or
23 aralkyl)]; R_4 can also be $-COR_{10}$ (wherein R_{10} is selected from hydroxyl and -
24 $NR_{11}R_{12}$ (wherein R_{11} and R_{12} are independently selected from hydrogen, alkyl, aryl,
25 C_3 - C_7 cycloalkyl, heterocyclyl, aralkyl and R_{11} and R_{12} together form 5-7 membered
26 ring with one or more optional heteroatom(s) wherein the heteroatom(s) is/are
27 independently selected from nitrogen, oxygen and sulphur); and

R_5 is hydrogen, C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl, optionally substituted aryl or aralkyl [wherein the substituents are selected from halogens, cyano, optionally substituted C_1 - C_6 alkyl (wherein the substituents are independently selected from hydroxyl, protected hydroxyl, and halogen(s)), optionally substituted amino, acetyl, trifluoromethyl and C_1 - C_6 alkoxy carbonyl,


comprising:

treating the compound of Formula XIb with sodium hydroxide followed by calcium acetate



to give compound of Formula XIIb

95. A process for the preparation of compound of Formula XVIa,



its lactone forms, its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, tautomers, racemates, polymorphs, pure enantiomers, diastereoisomers, metabolites, prodrugs or N-oxides wherein

R_1 is C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, or optionally substituted phenyl (wherein up to three substituents are independently selected from halogens, C_1 - C_6 alkyl, cyano and C_1 - C_3 perfluoroalkyl);

R_2 is optionally substituted phenyl (wherein up to three substituents are independently selected from cyano, acetyl, or optionally substituted amino, wherein up to two amino


15 substituents are independently selected from C₁-C₆ alkyl, C₃-C₆ cycloalkyl, acetyl, or
16 sulfonamide); and

17 R₃ is optionally substituted C₁-C₆ alkyl or C₃-C₆ cycloalkyl (wherein the substituents
18 are selected from halogens, hydroxyl, C₁-C₃ alkoxy, and protected hydroxyl); or

19 R₃ is -NR₆R₇ wherein R₆ and R₇ are optionally substituted C₁-C₆ alkyl (wherein the
20 optional substituent(s) is/are selected from halogens, hydroxyl, C₁-C₃ alkoxy, and
21 protected hydroxyl);


22 comprising:

23 treating the compound of Formula XVa with sodium hydroxide



28 to give a compound of Formula XVIa.

1 96. A process for the preparation of compound of Formula XIIa,




7 their pharmaceutically acceptable salts, pharmaceutically acceptable solvates,
8 tautomers, racemates, polymorphs, pure enantiomers, diastereoisomers, metabolites,
9 prodrugs or N-oxides wherein

26


10 R_1 is C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, or optionally substituted phenyl (wherein the
11 substituent(s) is/are selected from halogens, C_1 - C_6 alkyl, cyano and C_1 - C_3
12 perfluoroalkyl);
13 R_2 is optionally substituted phenyl (wherein the substituent(s) is/are selected from
14 cyano, acetyl and optionally substituted amino;
15 R_3 is optionally substituted C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl (wherein the substituent(s)
16 is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and protected hydroxyl); R_3
17 can also be $-NR_6R_7$ wherein R_6 and R_7 are optionally substituted C_1 - C_6 alkyl (wherein
18 the optional substituent(s) is/are selected from halogens, hydroxyl, C_1 - C_3 alkoxy, and
19 protected hydroxyl);
20 R_4 is acetyl, C_1 - C_2 alkoxy carbonyl, optionally substituted C_1 - C_6 alkyl (wherein the
21 substituent is hydroxy or protected hydroxyl), NHR_8 [wherein R_8 is selected from
22 alkyl, aralkyl, SO_2R_9 , COR_9 or $CONHR_9$, $CSNHR_9$ (wherein R_9 is C_1 - C_6 alkyl, aryl or
23 aralkyl)]; R_4 can also be $-COR_{10}$ (wherein R_{10} is selected from hydroxyl and -
24 $NR_{11}R_{12}$ (wherein R_{11} and R_{12} are independently selected from hydrogen, alkyl, aryl,
25 C_3 - C_7 cycloalkyl, heterocyclyl, aralkyl and R_{11} and R_{12} together form 5-7 membered
26 ring with one or more optional heteroatom(s) wherein the heteroatom(s) is/are
27 independently selected from nitrogen, oxygen and sulphur); and
28 R_5 is hydrogen, C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl, optionally substituted aryl or aralkyl
29 [wherein the substituents are selected from halogens, cyano, optionally substituted C_1 -
30 C_6 alkyl (wherein the substituents are independently selected from hydroxyl, protected
31 hydroxyl, and halogen(s)), optionally substituted amino, acetyl, trifluoromethyl and
32 C_1 - C_6 alkoxy carbonyl,
33 comprising:

treating the compound of Formula XIa with sodium hydroxide followed by calcium acetate



to give a compound of Formula XIIa.

97. A process for the preparation of a compound of Formula XII,



its lactone forms, pharmaceutically acceptable salts, pharmaceutically acceptable solvates, prodrugs, metabolites, polymorphs, tautomers, racemates, pure enantiomers, diastereoisomers or N-oxides wherein


R₁ can be C₁-C₆, C₃-C₆, or optionally substituted phenyl (wherein up to three substituents are independently selected from halogens, C₁-C₆ alkyl, cyano, or C₁-C₃ perfluoroalkyl);

R₂ can be optionally substituted phenyl (wherein up to three substituents are independently selected from cyano, acetyl, or optionally substituted amino, wherein up to two amino substituents are independently selected from C₁-C₆ alkyl, C₃-C₆ cycloalkyl, acetyl, or sulfonamide);

R_3 can be optionally substituted C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl (wherein substituents are independently selected from halogens, hydroxyl, C_1 - C_3 alkoxy and protected hydroxyl);

R_3 can also be $-NR_8R_9$, wherein R_8 and R_9 are optionally substituted C_1 - C_6 alkyl (wherein the optional substituent(s) is/are selected from halogens, hydroxy, C_1 - C_3 alkoxy and protected hydroxyl);

R_4 can be



wherein R_5 and R_6 are independently hydrogen, C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl, optionally substituted aryl or aralkyl, wherein the substituents are selected from halogens, cyano, optionally substituted C_1 - C_6 alkyl (wherein up to two substituents are independently selected from hydroxyl, protected hydroxyl, and halogen(s)), optionally substituted amino (wherein up to two substituents are independently selected from SO_2R_7 , COR_7 , or $CONHR_7$, wherein R_7 is C_1 - C_6 alkyl or aryl), or acetyl, trifluoromethyl, or C_1 - C_6 alkoxycarbonyl, or R_5 and R_6 together form a 5-7 membered ring with one or more optional heteroatoms wherein the hetero atom(s) are independently selected from nitrogen, oxygen and sulfur,

or R_4 can be an optionally substituted mono-, bi- or tricyclic heterocycle having one or more hetero atom(s) wherein said hetero atom(s) is/are independently selected from oxygen, nitrogen and sulfur, and the optional substituents are independently selected from halogens, hydroxy, protected hydroxyl, C_1 - C_3 alkoxy, cyano, C_1 - C_3 perfluoroalkyl, C_1 - C_6 alkyl or C_3 - C_6 cycloalkyl, aryl or optionally substituted aralkyl wherein the substituents are independently selected from halogens, hydroxy, protected hydroxyl, C_1 - C_3 alkoxy, cyano, or C_1 - C_3 perfluoroalkyl,


and the pharmaceutically acceptable salts, tautomers, racemates, pure enantiomers or diastereoisomers, and solvates of the compounds of Formula I,

with the proviso that R_2 is phenyl only when (1) R_5 or R_6 is C_3 - C_6 cycloalkyl or phenyl substituted with acetyl, alkyl, cycloalkyl, hydroxyalkyl, alkylsulfonamido,


acetamido or (2) when R_3 and R_4 together form a 5-7 membered ring with or without one or more heteroatoms wherein the hetero atom(s) are selected from nitrogen, oxygen and sulfur or (3) when R_3 or R_4 is aralkyl optionally substituted with halogens, cyano, C_1 - C_6 alkyl, C_1 - C_6 halogenated alkyl or (4) when R_4 is optionally substituted mono-, bi- or tricyclic heterocycle having one or more hetero atom(s) (wherein the optional substituents are independently selected from halogens, hydroxy, protected hydroxyl, C_1 - C_3 alkoxy, cyano, perfluoroalkyl of one to three carbon atoms, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, aryl, or optionally substituted aralkyl (wherein the aralkyl substituents are independently selected from halogens, hydroxy, protected hydroxyl, C_1 - C_3 alkoxy, cyano, or C_1 - C_3 perfluoroalkyl)),

comprising:

treating the compound of Formula XI with sodium hydroxide followed by calcium acetate




Formula XI



to give a compound of Formula XII.

122

1 98. A process for the preparation of compound of Formula XVI,



8 its lactone forms, pharmaceutically acceptable salt, pharmaceutically acceptable
9 solvates, tautomers, racemates, pure enantiomers, diastereoisomers or N-oxides
10 wherein

11 R_1 can be C_1-C_6 , C_3-C_6 , or optionally substituted phenyl (wherein up to three
12 substituents are independently selected from halogens, C_1-C_6 alkyl, cyano, or C_1-C_3
13 perfluoroalkyl);


14 R_2 can be optionally substituted phenyl (wherein up to three substituents are
15 independently selected from cyano, acetyl, or optionally substituted amino, wherein up
16 to two amino substituents are independently selected from C_1-C_6 alkyl, C_3-C_6
17 cycloalkyl, acetyl, or sulfonamide);

18 R_3 can be optionally substituted C_1-C_6 alkyl or C_3-C_6 cycloalkyl (wherein substituents
19 are independently selected from halogens, hydroxyl, C_1-C_3 alkoxy and protected
20 hydroxyl);


21 R_3 can also be $-NR_8R_9$, wherein R_8 and R_9 are optionally substituted C_1-C_6 alkyl
22 (wherein the optional substituent(s) is/are selected from halogens, hydroxy, C_1-C_3
23 alkoxy and protected hydroxyl),


127

- 24 comprising:
 25 treating the compound of Formula XVI with sodium hydroxide followed by calcium
 26 acetate




Formula XVI

31 Formula I wherein, $R_4 =$ 




- 33 to give a compound of Formula XVII.

- 1 99. A process for the preparation of compound of Formula XII,



Formula XII

6 Formula I wherein, $R_4 =$ 



- 9 its lactone forms, pharmaceutically acceptable salt, pharmaceutically acceptable
 10 solvates, prodrugs, metabolites, polymorphs, tautomers, racemates, pure enantiomers,
 11 diastereoisomers or N-oxides wherein

- 12 R_1 can be C_1-C_6 , C_3-C_6 , or optionally substituted phenyl (wherein up to three
 13 substituents are independently selected from halogens, C_1-C_6 alkyl, cyano, or C_1-C_3
 14 perfluoroalkyl);

- 15 R_2 can be optionally substituted phenyl (wherein up to three substituents are
 16 independently selected from cyano, acetyl, or optionally substituted amino, wherein up

128

17 to two amino substituents are independently selected from C₁-C₆ alkyl, C₃-C₆
 18 cycloalkyl, acetyl, or sulfonamide);
 19 R₃ can be optionally substituted C₁-C₆ alkyl or C₃-C₆ cycloalkyl (wherein substituents
 20 are independently selected from halogens, hydroxyl, C₁-C₃ alkoxy and protected
 21 hydroxyl);
 22 R₃ can also be -NR₈R₉, wherein R₈ and R₉ are optionally substituted C₁-C₆ alkyl
 23 (wherein the optional substituent(s) is/are selected from halogens, hydroxy, C₁-C₃
 24 alkoxy and protected hydroxyl);

25 R₄ can be

$$\begin{array}{c}
 R_5 \\
 | \\
 N - R_6 \\
 | \\
 C \\
 // \quad \backslash \\
 O \quad \quad \cdot
 \end{array}$$


26
27

28 wherein R₅ and R₆ are independently hydrogen, C₁-C₆ alkyl or C₃-C₆ cycloalkyl,
 29 optionally substituted aryl or aralkyl, wherein the substituents are selected from
 30 halogens, cyano, optionally substituted C₁-C₆ alkyl (wherein up to two substituents are
 31 independently selected from hydroxyl, protected hydroxyl, and halogen(s)), optionally
 32 substituted amino (wherein up to two substituents are independently selected from
 33 SO₂R₇, COR₇, or CONHR₇, wherein R₇ is C₁-C₆ alkyl or aryl), or acetyl,
 34 trifluoromethyl, or C₁-C₆ alkoxycarbonyl, or R₅ and R₆ together form a 5-7 membered
 35 ring with one or more optional heteroatoms wherein the hetero atom(s) are
 36 independently selected from nitrogen, oxygen and sulfur,
 37 or R₄ can be an optionally substituted mono-, bi- or tricyclic heterocycle having one or
 38 more hetero atom(s) wherein said hetero atom(s) is/are independently selected from
 39 oxygen, nitrogen and sulfur, and the optional substituents are independently selected
 40 from halogens, hydroxy, protected hydroxyl, C₁-C₃ alkoxy, cyano, C₁-C₃
 41 perfluoroalkyl, C₁-C₆ alkyl or C₃-C₆ cycloalkyl, aryl or optionally substituted aralkyl
 42 wherein the substituents are independently selected from halogens, hydroxy, protected
 43 hydroxyl, C₁-C₃ alkoxy, cyano, or C₁-C₃ perfluoroalkyl,
 44 and the pharmaceutically acceptable salts, tautomers, racemates, pure enantiomers or
 45 diastereoisomers, and solvates of the compounds of Formula I,

with the proviso that R_2 is phenyl only when (1) R_3 or R_4 is C_3 - C_6 cycloalkyl or phenyl substituted with acetyl, alkyl, cycloalkyl, hydroxyalkyl, alkylsulfonamido, acetamido or (2) when R_3 and R_4 together form a 5-7 membered ring with or without one or more heteroatoms wherein the hetero atom(s) are selected from nitrogen, oxygen and sulfur or (3) when R_3 or R_4 is aralkyl optionally substituted with halogens, cyano, C_1 - C_6 alkyl, C_1 - C_6 halogenated alkyl or (4) when R_4 is optionally substituted mono-, bi- or tricyclic heterocycle having one or more hetero atom(s) (wherein the optional substituents are independently selected from halogens, hydroxy, protected hydroxyl, C_1 - C_3 alkoxy, cyano, perfluoroalkyl of one to three carbon atoms, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, aryl, or optionally substituted aralkyl (wherein the aralkyl substituents are independently selected from halogens, hydroxy, protected hydroxyl, C_1 - C_3 alkoxy, cyano, or C_1 - C_3 perfluoroalkyl)),


comprising:

treating the compound of Formula XI with sodium hydroxide followed by calcium acetate



Formula XI

Formula I wherein, $R_4 =$



to give a compound of Formula XII.

TRADUCCIÓN OFICIAL**TRASPASO DE DERECHOS, NOMBRE E INTERÉS DE UN INVENTO**

Este es un Traspaso de los siguientes derechos, nombre e interés de un invento (marque todo lo que aplica):

- ☒ Derechos sobre el nombre e interés de un invento registrado en los Estados Unidos de América,
- ☒ Derechos sobre el nombre e interés de un invento registrado en la India.
- ☒ Derechos Extranjeros sobre el nombre e interés de un invento (que no han sido registrados ni en la India, ni en los Estados Unidos).
- Solicitud de Registro de Patente en los Estados Unidos, Serie No. _____
Fecha de Ejecución _____ Fecha de Registro _____
- Solicitud provisional para Registro de Patente en los Estados Unidos, Serie No. _____
- Registro de Patente en los Estados Unidos No(s). _____
- ☒ Solicitud de Registro de Patente Internacional (PCT), Serie No. PCT/IB2004/001761
- Otra (especificar) _____

Nombre del Invento:

**SUBSTITUTED PYRROLE DERIVATIVES
DERIVADOS SUSTITUIDOS DEL PIRROL**

f27